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Introduction
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IntrODuCtIOn
Clinical studies with first-generation sirolimus-eluting stents (SES) and pacli-
taxel-eluting stents (PES) have demonstrate a dramatic reduction in resteno-
sis rates compared with bare-metal stents (BMS)1,2, however, reintervention 
rates were still high in patients with complex coronary artery disease3, and an 
ongo ing propensity for stent thrombosis (ST) beyond one year raised further 
concerns regard ing safety issues with these devices4. Furthermore, as both of 
these devices were relatively high-profile stainless steel stents, they were dif-
ficult to deliver in complex anatomy, and the SES in particular was prone to a 
high fracture rate, contributing to late adverse events.
The everolimus-eluting stent (EES), (XIENCE V, Abbott Vascular, CA, USA; also 
distributed as the PROMUS stent by Boston Scientific, MA, USA) is a second-
generation drug-eluting stent (DES) designed to overcome the limitations of 
earlier DES. 
In the EES, everolimus, a rapamycin derivative, is released from a thin layer 
(7.8-μm) of a biocompatible fluoropolymer coated on an open-cell, thin-strut 
(81-μm) flexible and highly deliverable cobalt–chro mium stent. The polymer is 
inert and non- inflammatory5,6, and the stent is extremely resistant to fracture. 
Two moderate-sized trials with the EES demonstrated a sig nificant reduction 
in angiographic in-stent and in-segment late lumen loss compared with the 
first-generation TAXUS Expres (PES, Boston Scientific), and noninferior ity in 
major clinical end points7,8. These findings suggested that, if tested in larger 
populations, the EES might achieve supe rior clinical outcomes compared with 
the earlier predicate devices. However, given the favourable outcomes with 
PES, large studies would be required to elicit small differences in low frequency 
but impor tant clinical end points. Toward this end, a large-scale randomized 
trial was performed, the SPIRIT IV9 trial. SPIRIT IV was a prospective, multi-
center trial that randomized 3690 patients throughout the USA in a 2:1 ratio 
to EES versus the TAXUS Express PES. The primary end point was a composite 
of target lesion failure (defined as cardiac death, tar get vessel myocardial 
infarction (MI) or ischemia-driven target lesion revascular ization (TLR)). The 
trial was large enough to provide data on other secondary end points and im-
portant subgroups, particu larly patients with diabetes mellitus, but excluded 
patients with acute coronary syndromes (ACS) and ST-segment elevation MI 
(STEMI), large bifurcations and other complex lesion subsets. We therefore 
compared the safety and efficacy of the second-generation everolimus-eluting 
and paclitaxel-eluting stents in unselected patients in real-life practice, in one 
other large, prospective and randomized trial: the COMPARE trial10.
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Chapter 2 describes the design as well as the one and two year results of the 
COMPARE trial.  As there was a paucity of data evaluating the performance of 
EES in the high risk population of  patients presenting with MI, we analysed 
the results of this subgroup of patients from the COMPARE trial database. A 
detailed analysis of two year outcomes of EES as compared to PES in all MI 
patients as well as stratified for non-ST elevation myocardial infarction and ST 
elevation myocardial infarction was performed and presented.
In Chapter 3 the major findings of  SPIRIT IV and COMPARE trials are summa-
rized in a overview paper leading further to what is the focus of this chapter: 
the clinical impact of safety outcomes with EES. For this end, as none of these 
trials were adequately powered to examine the incidence and predictors of 
ST and of the combined safety endpoint of cardiac mortally and MI, as well 
as to evaluate the impact of dual antiplatelet therapy (DAPT) permanent 
interruption on ST outcomes in the EES and PES cohorts separately, we pooled 
patient-level data from four randomized trials in which the outcomes of EES 
compared to PES, in 6,789 patients, have been examined.
In Chapter 4 we investigate the performance of the EES in DM patients. 
As known, patients with diabetes mellitus undergoing percutaneous coronary 
intervention with bare metal stents have higher rates of angiographic and 
clinical restenosis than patients without diabetes mellitus.11,12  Compared with 
bare metal stents, drug-eluting stents (DES) have been shown to be safe13 
and to result in greater absolute reductions in target lesion revascularization 
(TLR) and target vessel revascularization in patients with versus those without 
diabetes mellitus.14,15,16 However, whether the presence of diabetes mellitus 
differentially affects the relative clinical outcomes with different types of DES 
is a matter of considerable debate. Most prior studies have shown compa-
rable rates of angiographic in-stent late loss and clinical restenosis with PES 
in patients with versus without diabetes mellitus.17 In contrast, whether the 
relatively greater suppression of neointimal hyperplasia observed from stents 
that elute rapamycin analogs (such as sirolimus or everolimus) is preserved in 
patients with diabetes mellitus is unsettled. In this regard, several studies have 
provided conflicting results.18,19 Moreover, none of these prior trials was pow-
ered to determine whether there are differences in safety outcomes between 
different DES according to the presence of diabetes mellitus.
To this end, we studied the safety and efficacy outcomes of the second gen-
eration EES and the first generation PES in patients with and without DM in 
the above mentioned patient-level pooled database from the  SPIRIT II, III, IV 
and COMPARE trials. We also specifically examined the outcomes with these 
stents after stratifying for insulin dependence in each cohort. 
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To re-evaluate the findings of the previous here above mentioned, device 
comparison , as well as to study the impact of the stent design improvements 
when comparing two rapamycin – analog stents, respectively the second gen-
eration EES and the first generation SES, a second analysis in a much larger 
diabetes mellitus real life population, was performed, using the data of the 
Swedish Coronary Angiography and Angioplasty Register (SCAAR) 
In Chapter 5 the results of the studies presented in thesis are summarised, fo-
cusing particularly in the clinical impact, future perspectives,  as well as in the 
designs of  new trials, particularly the COMPARE-ACUTE20 and DAPT-STEMI21. 
Both trials are designed and  powered  based on the findings and the clinical 
impact of the above mentioned studies, and intend to set a step ahead in the 
treatment approach of STEMI with multivessel disease at presentation as well 
as the duration of DAPT after primary PCI and stenting with modern  DES. 
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AbStrACt
background 
Everolimus-eluting and paclitaxel-eluting stents, compared with bare metal 
stents, reduced the risk of restenosis in clinical trials with strict inclusion and 
exclusion criteria. We compared the safety and efficacy of the second-genera-
tion everolimus-eluting and paclitaxel-eluting stents in real-life practice. 
Methods 
We randomly assigned 1800 consecutive patients (aged 18–85 years) under-
going percutaneous coronary intervention at one centre to treatment with 
everolimus-eluting or paclitaxel-eluting stents. The primary endpoint was a 
composite of safety and efficacy (all-cause mortality, myocardial infarction, 
and target vessel revascularisation) within 12 months. Patients were not told 
which stent they had been allocated. Analysis was by intention to treat. The 
trial is registered with ClinicalTrials.gov, number NCT01016041. 
findings 
Follow-up was completed in 1797 patients. The primary endpoint occurred in 
56 (6%) of 897 patients in the everolimus-eluting stent group versus 82 (9%) of 
903 in the paclitaxel-eluting stent group (relative risk 0,69 [95% CI 0,50–0,95], 
p value for superiority=0,02). The difference was attributable to a lower rate 
of stent thrombosis (6 [<1%] vs 23 [3%], 0,26 [0,11–0,64], p=0,002), myocardial 
infarction (25 [3%] vs 48 [5%], 0,52 [0,33–0,84], p=0,007), and target vessel re-
vascularisation (21 [ 2%] vs 54 [6%], 0,39 [0,24–0,64], p=0,0001). Cardiac death, 
non-fatal myocardial infarction, or target lesion revascularisation occurred in 
44 [5%] patients in the everolimus-eluting stent group versus 74 [8%] patients 
in the paclitaxel-eluting stent group, p value for superiority was 0,005.
Interpretation 
The everolimus-eluting stent is better than the second generation paclitaxel-
eluting stent in unselected patients in terms of safety and efficacy. On the basis 
of our results, we suggest that paclitaxel-eluting stents should no longer be 
used in everyday clinical practice.
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IntroductIon
On the basis of results from randomised trials with strict inclusion and ex-
clusion criteria, first-generation drug-eluting stents, coated with sirolimus 
or paclitaxel, were approved for clinical use in patients with coronary artery 
disease.1–3 Early experience with use of first generation stents in patients in 
real-life practice showed that benefit, in terms of the need for reintervention, 
was most apparent in those with high risk of restenosis.4 Widespread use of 
first-generation drug-eluting stents has drawn attention to several unresolved 
issues that are clinically relevant. First, although the risk is small, stent throm-
bosis is unpredictable, continues to increase with time, and has serious clinical 
consequences.5,6 Second, the deliverability of first generation drug-eluting 
stents could be improved.
Third, although these stents are more effective than are bare metal stents in 
patients at high risk of restenosis, the need for reintervention is still a problem 
in patients with severe coronary disease, as shown in a randomised study in 
which individuals with complex coronary disease were given percutaneous 
treatment with the first-generation paclitaxel-eluting stent or coronary artery 
bypass surgery.7
Compared with the currently available first-generation drug-eluting stents, 
second-generation drug-eluting stents have been designed with the goal of 
improving safety, efficacy, and device performance. Everolimus, a semisyn-
thetic sirolimus analogue, is released from a thin coating of a biocompatible 
fluoropolymer on an open cell, thin-strut, cobalt-chromium frame. A signifi-
cant reduction in serious adverse cardiac events was noted in patients with the 
everolimus-eluting stent compared with those who had the first-generation 
paclitaxel-eluting stent.8 This first-generation stent has been superseded in 
Europe by the new-generation paclitaxel-eluting stent since September, 2005. 
Whether such differences persist with a new-generation paclitaxel-eluting 
stent that consists of the same polymer but has a different stent platform is 
not known. We therefore compared the safety and efficacy of the second-
generation everolimus-eluting and paclitaxel-eluting stents in unselected 
patients in real-life practice.
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Study design and patients
Consecutive patients (aged 18–85 years) referred to the Maasstad Ziekenhuis 
for elective or emergent percutaneous coronary intervention, were eligible to 
participate in the study. There were no limitations about the number of lesions 
or vessels, location of lesions, or their length. Exclusion criteria were contra-
indications or expected non-adherence to dual antiplatelet drugs in the 12 
months after the procedure; planned major surgery within 30 days; inability or 
refusal to comply with follow-up procedures; participation in other coronary-
device trials; and inability to provide informed consent. All patients provided 
written informed consent. The study complied with the Declaration of Helsinki 
for investigation in human beings, and was approved by the institutional eth-
ics committee of the Maasstad Ziekenhuis, Rotterdam, the Netherlands, and 
the Dutch Central Committee on Research Involving Human Subjects.
randomisation and masking
The allocation schedule was based on computer-generated random numbers. 
The statistician involved in the design of the study generated the randomi-
sation list. Patients were assigned in a one-to-one ratio to a polymer based, 
everolimus-eluting stent (Xience V, Abbott Vascular, Santa Clara, CA, USA) 
or a polymer-based, paclitaxel-eluting stent (Taxus Liberte, Boston Scientific, 
Natick, MA, USA), using sealed, opaque, sequentially numbered allocation 
envelopes after passage of the guide wire. The patients knew they had been 
randomly assigned in a trial of drug-eluting stents, but did not know which 
stent they had been allocated.
Procedures
Staged procedures were permitted and the same stent type, allocated at initial 
randomisation, was used. Everolimus-eluting stents were available in diam-
eters of 2,25 mm, 2,50 mm, 3,00 mm, 3,50 mm, and 4,00 mm, and in lengths 
of 8 mm, 12 mm, 15 mm, 18 mm, 23 mm, and 28 mm. Paclitaxel-eluting stents 
were available in diameters of 2,25 mm, 2,50 mm, 3,00 mm, 3,50 mm, and 
4,00 mm, and in lengths of 8 mm, 12 mm, 16 mm, 20 mm, 24 mm, 28 mm, and 
32 mm. Percutaneous coronary intervention was done according to standard 
techniques. Crossover to another stent was allowed in the event of an inability 
to insert the assigned device. Technical details, such as the decision to stent 
without balloon predilatation, use of adjunctive techniques such as rotational 
atherectomy, and decision to postdilate the stent, were at the discretion of 
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the operator. Off -line quantitative coronary angiography analysis for the 
baseline data was done with an automated edge-detection system (CAAS, 
version 1.1, Pie Medical Imaging, Maastricht, Netherlands). The analyses were 
done by experienced technicians. All patients not on dual antiplatelet drugs 
were given aspirin (300 mg) and clopidogrel (300 mg or 600 mg) before the 
procedure. The high dose of clopidogrel was given to patients undergoing 
primary percutaneous intervention for ST-segment elevation myocardial in-
farction. An initial bolus of unfractionated heparin (70–100 IU/kg) was given 
to all patients, and additional boluses were given to achieve and maintain an 
activated clotting time of more than 250 s, which was checked every 30 min. 
The use of bivaluridin or low molecular-weight heparin was not allowed. The 
use of glycoprotein IIb/IIIa antagonists was at the discretion of the operator. A 
12-lead electrocardiograph was done before and after the procedure; before 
discharge; and at 1 month, 6 months, and 12 months follow-up. Postproce-
dural measurements of cardiac biomarkers were obtained systematically only 
in patients in whom procedural complications, such as side-branch closure, 
residual dissection, or no reflow, occurred or when patients had chest pain or 
electrocardiographic changes after the procedure. At the time of discharge, 
all patients were given aspirin (100 mg once a day) for an indefinite period, as 
well as clopidogrel (75 mg per day) for 12 months.
Outcomes and data management
The prespecified primary endpoint was a composite of all-cause mortality, 
non-fatal myocardial infarction, and target vessel revascularisation within 12 
months. The secondary endpoints were a composite of major adverse cardiac 
events (cardiac death, non-fatal myocardial infarction, and clinically justified 
target lesion revascularisation within 12 months of follow-up), and a composite 
of all-cause mortality, non-fatal myocardial infarction, and target vessel revas-
cularisation at 3 years and 5 years. All deaths were regarded as cardiac unless 
an unequivocal non-cardiac cause was established. Periprocedural myocardial 
infarction, in patients without infarction at baseline, was defined as any eleva-
tion in concentrations of creatine kinase to more than double normal value, 
with elevated values of a confirmatory cardiac biomarker (creatine kinase-MB 
fraction or troponin). Spontaneous infarction was defined as a typical rise and 
fall in concentrations of troponin or creatinine kinase-MB with at least one 
of the following: ischaemic symptoms, development of pathological Q waves, 
ischaemic electrocardiographic changes, or pathological findings of an acute 
myocardial infarction.9 Target lesion revascularisation was defined as revascu-
larisation for a stenosis within the stent or within the 5-mm borders adjacent 
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to the stent. Revascularisation of the target lesion and vessel was regarded as 
clinically justified if the stenosis of any target lesion or vessel was at least 50% 
of vessel diameter on the basis of quantitative coronary angiography in the 
presence of objective evidence of ischaemia on non-invasive or invasive testing 
or symptoms, or if the stenosis was at least 70% of vessel diameter even in the 
absence of ischaemic signs or symptoms. Stent thrombosis was defined accord-
ing to the definitions provided by the Academic Research Cnsortium.10 Adverse 
events were assessed in the hospital, and at 1 month and 12 months. Data were 
gathered by study monitors who visited the hospitals in which follow-up was 
undertaken, reviewed the clinical notes, and collected the protocol-mandated 
electrocardiographs. Furthermore, medical questionnaires were posted to all 
patients at 1 month, 6 months, and 12 months to check for adverse events and 
establish current antiplatelet drugs. Data were stored in our institution. Data 
processing and adjudication of adverse events were done by an independent 
contract research organisation and core lab (Cardialysis, Rotterdam, Nether-
lands). An independent data and safety monitoring board reviewed the data 
after interim analyses with formal stopping rules.
Statistical analysis
On the basis of results from the T-SEARCH registry,4 and SIRTAX11 and SPIRIT 
II trials,12 we assumed an incidence of the primary endpoint of 9% in the 
everolimus- eluting stent group and 14% in the paclitaxel-eluting stent group. 
Enrolment of 1800 patients would provide the study with a statistical power 
of 85% to detect this difference with a two-sided significance level of 0,05, 
allowing for 3–4% of patients lost to follow-up. All analyses were done ac-
cording to the intention-to treat principle. Patients were censored from the 
Kaplan-Meier plots when they reached any component of the composite 
endpoint. Categorical variables were assessed with use of χ2 or Fisher’s exact 
tests, whereas continuous variables were assessed with the Wilcoxon rank-sum 
test. The time to the primary endpoint was assessed according to the method 
of Kaplan-Meier, and the log-rank test was applied to compare the incidence 
of the endpoint between groups. Relative risks with 95% CIs, were calculated 
with the log-binomial method.13 The Kaplan-Meier curves were drawn with 
the guidelines provided by Pocock and colleagues.14 All p values were two-
sided, and a p value of less than 0,05 was regarded as significant. Analyses 
were done with SAS (version 8.02).
The trial is registered with ClinicalTrials.gov, number NCT01016041.
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role of the funding source
The sponsors had no involvement in the design, conduct, or analysis of the 
study. The corresponding author had full access to all the data in the study, 
and had full responsibility for the decision to submit for publication.
reSultS
Figure 1 shows the trial profile. 1800 patients were enrolled between February, 
2007, and September, 2008. Five (<1%) were not given the designated stent. 
Staged procedures were done in 191 (21%) patients in the everolimus-eluting 
stent group and in 172 (19%) patients in the paclitaxel-eluting stent group 
(p=0,23). Three were lost to follow-up. The groups had similar baseline clinical 
(table 1), angiographic (table 2), and procedural characteristics (table 3).
Most patients presented with an acute coronary syndrome (table 1); the sub-
type of acute coronary syndrome was equally distributed in the two groups; 
74% of lesions were complex (type B2 or C; table 2). The median total stent 
length per lesion, compared with previous studies, and the number of stents 
per lesion were high; the number of stents was slightly, but significantly, 
higher in the everolimus-eluting stent group because of a shorter available 
maximum stent length (table 3). Postprocedural cardiac biomarkers were as-
sessed in 364 (41%) patients in the everolimus-eluting stent group and in 338 
 
 
 
Figure 1: Trial profile 
 
Figure 1 Trial profile
*We have no reliable data for patients assessed for eligibility.
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table 1. Baseline Characteristics
everolimus- eluting stent 
(N=897)
Paclitaxel- eluting stent
(N=903)
Age (years) 62.9 (11) 63.8 (11)
Men 619 (69%) 654 (72%)
Diabetes mellitus 153 (17%) 172 (19%)
Chronic renal failure * 25 (3%) 24 (3%)
Hypertension 417 (46%) 447 (49%)
Hypercholesterolaemia 477 (53.2%) 451 (49.9%)
Current smoker 295 (32.9%) 262 (29.0%)
Family history of CAD 399 (44%) 403 (45%)
History of MI 136 (15%) 159 (18%)
History of PCI 117 (13%) 123 (14%)
History of CABG 60 (6.7%) 53 (5.9%)
Stable angina pectoris 331 (37%) 349 (39%)
Silent ischemia 23 (3%) 17 (2%)
Acute coronary syndrome 541 (60%) 534 (59%)
   Unstable angina 107 (12%) 105 (12%)
   Non-ST segment elevation MI 194 (22%) 217 (24%)
   ST segment elevation MI 240 (27%) 212 (23%)
Glycoprotein IIbIIIa antagonists 288 (32%) 290 (32%)
Multivessel treatment 244 (27%) 239 (26%)
Number of lesions treated per patient 1.4 (0.7) 1.4 (0.7)
Reference vessel diameter <2.75 mm 458 (51.%) 441 (49%)
Lesion length > 20 mm 290 (32.%) 263 (29.%)
Data are number (%), unless otherwise indicated. Percentages have been rounded. *Defi ned as treatment 
with diet or drugs for previously diagnosed diabetes. †Defined as serum creatinine greater than 130 
μmol/L or patient on dialysis.
table 2. Baseline Lesion and Procedural Characteristics
everolimus-  
eluting stent 
(1286 lesions)
Paclitaxel- 
eluting stent
(1294 lesions)
p value
Target lesion coronary artery 
    Left main 21 (1.6%) 21 (1.6%) 0.99
    Left anterior descending 513 (39.9%) 485 (37.4%) 0.20
    Left circumflex 299 (23.3%) 333 (25.7%) 0.15
    Right 426 (33.2%) 431 (33.2%) 0.94
    Bypass graft 27 (2.1%) 24 (1.8%) 0.69
ACC-AHA lesion class
    A 81 (6.3%) 61 (4.8%) 0.08
    B1 255 (19.8%) 278 (21.5%) 0.31
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(37%) in the paclitaxel-eluting stent group (p=0,17). Table 4 shows the major 
adverse cardiac events during
follow-up. The primary endpoint occurred in fewer patients in the 
everolimus-eluting stent group than in the paclitaxel-eluting stent group 
(table 4; figure 2A). The difference resulted from a lower rate of myocardial 
infarction and of target vessel revascularisation at 12 months in patients with 
    B2 355 (27.6%) 379 (29.3%) 0.36
    C 595 (46.3%) 576 (44.5%) 0.35
De novo lesions 1252 (97.4%) 1267 (97.9%) 0.34
Ostial lesion 242 (18.8%) 243 (18.8%) 0.31
Calcified lesion 422 (32.8%) 444 (34.3%) 0.55
Bifurcated lesion 223 (17.3%) 237 (18.3%) 0.24
Thrombus present 310 (24.1%) 314 (24.3%) 0.62
Chronic total occlusion 39 (3.0%) 53 (4.1%) 0.15
Pre procedure TIMI flow
    Grade 0 221 (17.2%) 213 (16.4%) 0.61
    Grade 1 47 (3.6%) 56 (4.3%) 0.39
    Grade 2 85 (6.6%) 102 (7.9%) 0.22
    Grade 3 933 (72.5%) 926 (71.4%) 0.53
Data are mean (SD) or number (%). ACC denotes American College of Cardiology, AHA American Heart 
Association. TIMI= thrombolysis in myocardial infarction.
table 3. Quantitative coronary angiography and procedural results
everolimus-  
eluting stent 
(1286 lesions)
Paclitaxel- 
eluting stent
(1294 lesions)
p value
Lesion length (mm) 16.8 (9.5-31.5) 16.0(9.2-31.0) 0.44
Diameter of reference vessel (mm) 2.56 (2.19-2.95) 2.55 (2.21-3.0) 0.61
Baseline minimal lumen diameter (mm) 0.90 (0.62-1.21) 0.91 (0.66-1.22) 0.66
Baseline stenosis ( lumen diameter %) 64 (53-77) 64 (53-76) 0.98
Postprocedure stenosis (lumen diameter %) 17 (11-24) 16 (10-24) 0.39
Postprocedure minimum lumen diameter (mm) 2,14 (1,82– 2,51) 2,15 (1,80–2,55) 0,88
Acute gain (mm) 1.24 (0.82-1.76) 1.24 (0.81-1.71) 0.71
Number of stents per lesion 1.7 (0.9) 1.6 (0.9) 0.007
Total stent length per lesion (mm) 28 (18-46) 28 (18-44) 0.85
Direct stenting 432 (34%) 451 (35%) 0.37
Post dilatation 698 (54%) 668 (52%) 0.18
Data are median (IQR) or number (%), unless otherwise indicated. Data for quantitative coronary 
angiography (QCA) are presented only for lesions with matched views for QCA before and after procedure 
(1977 lesions).
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table 4. Clinical events during follow-up
everolimus-
eluting stent
(n=897)
Paclitaxel-
eluting stent
(n=903)
relative risk
(95% CI)
p value
events at 30 days
All cause mortality 7 (0.8%) 6 (0.7%) 1.17 (0.40-3.48) 0.77
Cardiac Death 7 (0.8%) 6 (0.7%) 1.17 (0.40-3.48) 0.77
Myocardial infarction 15 (2%) 28 (3%) 0.53 (0.29-1.00) 0.05
    Q-wave 3 (0.3%) 8 (0.9%) 0.38 (0.10-1.42) 0.13
    Non-Q-wave 12 (1%) 21 (2%) 0.57 (0.28-1.16) 0.12
Death or myocardial infarction 21 (2%) 33 (4%) 0.64 (0.37-1.10) 0.10
Cardiac death or myocardial infarction 21 (2%) 33 (4%) 0.64 (0.37-1.10) 0.10
Target vessel revascularisation
(clinically justified)
4 (0.4%) 18 (2.0%) 0.22 (0.08-0.66) 0.003
    Percutaneous 1 (0.1%) 16 (2%) 0.06 (0.01-0.47) 0.0003
    Surgical 3 (0.3%) 2 (0.2%) 1.51 (0.25-9.02) 0.65
Target vessel revascularisation (Any) 5 (0.6%) 19 (2%) 0.26 (0.10-0.71) 0.004
    Percutaneous 2 (0.2%) 17 (2%) 0.12 (0.03-0.51) 0.0006
    Surgical 3 (0.3%) 2 (0.2%) 1.51 (0.25-9.02) 0.65
Target lesion revascularisation (Clinically Driven) 3 (0.3%) 16 (2%) 0.19 (0.06-0.65) 0.003
    Percutaneous 0 14 (2%) . 0.0005
    Surgical 3 (0.3%) 2 (0.2%) 1.51 (0.25-9.02) 0.65
Target lesion revascularisation (Any) 4 (0.4%) 17 (2%) 0.24 (0.08-0.70) 0.005
    Percutaneous 1 (0.1%) 15 (2%) 0.07 (0.01-0.51) P<0.001
    Surgical 3 (0.3%) 2 (0.2%) 1.51 (0.25-9.02) 0.65
Primary endpoint 25 (3%) 35 (4%) 0.72 (0.43-1.19) 0.20
Secondary endpoint 23 (3%) 34 (4%) 0.68 (0.40-1.15) 0.15
Stent Thrombosis (definite and probable) 2 (0.2%) 15 (2%) 0.13 (0.03-0.59) 0.002
    Acute Stent Thrombosis (On date of procedure) 1 (0.1%) 1 (0.1%) 1.01 (0.06-16.07) 0.99
    Sub-Acute Stent Thrombosis (1-30 days post
    procedure)
1 (0.1%) 14 (2%) 0.07 (0.01-0.55) 0.0008
    Early Stent Thrombosis (0-30 days post 
    procedure)
2 (0.2%) 15 (2%) 0.13 (0.03-0.59) 0.002
    Definite Stent Thrombosis 2 (0.2%) 12 (1%) 0.17 (0.04-0.75) 0.008
events at 12 months
All-cause mortality 18  (2%) 15 (2%) 1.21 (0.61-2.38) 0.58
Cardiac Death 11 (1%) 10 (1%) 1.11 (0.47-2.59) 0.81
Myocardial infarction 25 (3%) 48 (5%) 0.52 (0.33-0.84) 0.007
    Q-wave 3 (0.3%) 11 (1%) 0.27 (0.08-0.98) 0.03
    Non Q-wave 22 (2%) 39 (4%) 0.57 (0.34-0.95) 0.03
All-cause mortality or myocardial infarction 42 (5%) 62 (7%) 0.68 (0.47-
1.00) *
0.05 *
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everolimus-eluting stents, whereas all-cause mortality did not differ between 
the groups (figure 2B–D). Periprocedural myocardial infarction occurred in 15 
(2%) patients in the everolimus-eluting stent group and 19 (2%) patients in 
the paclitaxel-eluting stent group (p=0,49). The lower rate of non-fatal myo-
cardial infarction during 12 months in patients given everolimus-eluting stents 
reflects a significant difference in early stent thrombosis (table 4; figure 3A). 
The rate of definite and probable stent thrombosis for up to 1 year remained 
significantly lower in the everolimus-eluting stent group compared with the 
paclitaxel-eluting stent group (table 4). There were more late-stent thrombo-
ses in the paclitaxel-eluting stent group than in the everolimus-eluting stent 
group at 1 year but the difference was not significant (figure 3B). The rate 
of target vessel revascularisation was significantly lower in patients who had 
everolimus-eluting stents. This difference between the groups was already ap-
parent at 30 days, and remained significant at 1 year (figure 2D; table 4). The 
main secondary endpoint occurred in fewer patients in the everolimus-eluting 
stent group than in the paclitaxel-eluting stent group (table 4). We did an ex-
everolimus-
eluting stent
(n=897)
Paclitaxel-
eluting stent
(n=903)
relative risk
(95% CI)
p value
Cardiac death or myocardial infarction 35 (4%) 57 (6%) 0.62 (0.41-0.93) 0.02
Target vessel revascularisation (Clinically justified) 19 (2%) 51 (6%) 0.38 (0.22-0.63) 0.0001
    Percutaneous 13 (1%) 38 (4%) 0.34 (0.18-0.64) 0.0004
    Surgical 6 (0.7%) 13 (1%) 0.46 (0.18-1.22) 0.11
Target vessel revascularisation (Any) 21 (2%) 54 (6%) 0.39 (0.24-0.64) 0.0001
    Percutaneous 15 (2%) 41 (5%) 0.37 (0.21-0.66) 0.0005
    Surgical 6 (0.7%) 13 (1%) 0.46 (0.18-1.22) 0.11
Target lesion revascularisation (Clinically justified) 15 (2%) 43 (5%) 0.35 (0.20-0.63) 0.0002
    Percutaneous 9 (1.0%) 31 (3%) 0.29 (0.14-0.61) 0.0005
    Surgical 6 (0.7%) 12 (1%) 0.50 (0.19-1.34) 0.16
Target lesion revascularisation (Any) 18 (2%) 48 (5%) 0.38 (0.22-0.64) 0.0002
    Percutaneous 12 (1%) 36 (4%) 0.34 (0.18-0.64) 0.0005
    Surgical 6 (0.7%) 12 (1%) 0.50 (0.19-1.34) 0.16
Primary endpoint 56 (6%) 82 (9%) 0.69 (0.50-0.95) 0.02
Secondary endpoint 44 (5%) 74 (8%) 0.60 (0.42-0.86) 0.005
Stent Thrombosis (definite and probable) 6 (0.7%) 23 (3%) 0.26 (0.11-0.64) 0.002
    Late Stent Thrombosis (30 days – 1 year post
    procedure
4 (0.4%) 8 (0.9%) 0.50 (0.25-1.67) 0.25
    Definite Stent Thrombosis 4 (0.4%) 18 (2%) 0.22 (0.08-0.66) 0.003
Data are number (%). Percentages have been rounded. *The 1,00 upper limit of 95% CI was 0,998, 
and p value was 0,047.
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ploratory stratified analysis of the primary endpoint that was not prespecified 
in the protocol (figure 4). The outcome of the primary endpoint was consistent 
across all but two subgroups ie, patients with diabetes (n=325) and those with 
long lesions (n=553). CIs were wide and the results of a test of interaction were 
not significant. Compliance with aspirin and clopidogrel was 809 (91%) in the 
everolimus-eluting stent group versus 829 (92%) in the paclitaxel-eluting stent 
group at 1 month; 805 (91%) and 815 (91%), respectively, at 6 months; and 611 
(70%) in the everolimus-eluting stent group and 625 (70%) in the paclitaxel-
eluting stent group at 1 year.
DISCuSSIOn
The use of second-generation everolimus-eluting stents, compared with pacl-
itaxel-eluting stents, was associated with a significant reduction in the risk of 
major adverse cardiac events at 1 year. This difference was a result of reduction 
in the rate of myocardial infarction, a safety component of the primary end-
point, and reduction in repeat revascularisation of the target vessel. Rates of 
all-cause or cardiac mortality did not differ between the two groups; however 
 
 
 
 
Figure 2: Kaplan-Meier cumulative events curves at 12 months for primary endpoint (A), 
mortality (B), myocardial infarction (C), and target vessel revascularisation (D) 
 
Figure 2 Kaplan-Meier cumulative events curves at 12 months for primary endpoi t (A), mortality (B), 
myocardial infarction (C), and target vessel revascularisation (D)
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the rate of myocardial infarction was significantly reduced in the everolimus 
eluting stent group. This reduction was already apparent at 1 month. The sig-
nificantly lower rate of myocardial infarction at 30 days with the everolimus 
stent was attributable to a significantly lower rate of early stent thrombosis 
because there was no significant difference between the groups in the rate of 
periprocedural myocardial infarction. Use of the paclitaxel-eluting stent was 
associated with a higher rate of early stent thrombosis in the unselected popu-
lation we studied than that reported in previous randomised trials in selected 
patient populations.8,12 A large proportion of the unselected patients enrolled 
had high-risk clinical or angiographic characteristics. Since the proportion of 
patients with such high-risk characteristics did not differ significantly between 
groups, differences between the devices—stent design, polymer coating, or 
the drug used—are the most plausible explanations for the high rate of stent
thrombosis with the paclitaxel stent. By contrast, the rate of stent thrombo-
sis with the everolimus-eluting stent in our study was similar to that reported 
in the randomised trials of selected populations that led to marketing ap-
proval.8,12 The significant difference in stent thrombosis at 12 months between 
the two groups was mainly attributable to early stent thrombosis. Because 
the groups did not differ in terms of baseline characteristics, preprocedural 
and postprocedural antiplatelet and antithrombotic drugs, or procedural 
technique, we believe that the noted difference in early stent thrombosis 
rates relate to differences between the two devices that become apparent in 
an unselected population. An open-cell, thin-strut stent frame mounted on a 
semicompliant balloon might result in better apposition and less side-branch 
compromise than would a closed-cell, thick-strut device on a non-compliant 
balloon. The thinner layer of polymer on the everolimus-eluting stent might 
also play a part. Preclinical data have shown that the everolimus -eluting stent 
has more rapid and more extensive re-endothelialisation than has the second-
generation paclitaxel-eluting stent.15 Numerically more stent thromboses were 
noted in the paclitaxel-eluting stent group than in the everolimus-eluting 
stent group between 1–12 months.
The absolute numbers were small and the differences were not significant. 
However, definitive conclusions about late stent thrombosis must await the 
prespecified analyses at 3 years and 5 years because results from several stud-
ies have shown a predictable, continued, risk of stent thrombosis with time, 
particularly with paclitaxel-eluting stents.6
As with safety, a significant difference in efficacy was also noted with the 
everolimus-eluting stent. Both target vessel and target lesion revascularisation 
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were significantly reduced in the everolimus-eluting stent group compared 
with the paclitaxel-eluting stent group.
This difference was already evident at 30 days and continued to increase 
up to 1 year, with similar relative risk ratios at 30 days and at 12 months, 
consistent with a continued treatment effect. Up to 30 days, the difference 
in revascularisation between groups was related to the lower rate of stent 
thrombosis in the everolimus-eluting stent group than in the paclitaxel-eluting 
stent group. At 12 months, the difference suggested a significantly lower rate 
of clinically justified reinterventions for restenosis and lower rate of stent 
thrombosis in the everolimus-eluting stent group. The lower rate of reinter-
vention might relate to the more potent reduction in neointimal hyperplasia 
with the everolimus-eluting stent than with the paclitaxel-eluting stent. The 
rate of major adverse cardiac events with the everolimus-eluting stent in our 
trial is similar to the rates reported in registries that also enrolled unselected 
populations—namely, the X-Search study16 and the Spirit V registry (E Grube, 
Helios Heart Centre, personal communication). Since the test for interaction 
was not significant, the post-hoc exploratory subgroup analyses we did do not 
 
 
 
 
 
Figure 3: Kaplan-Meier event curves at 12 months for stent thrombosis (A) and late stent 
thrombosis (B) 
 
Figure 3 Kaplan-Meier event curves at 12 months for stent thrombosis (A) and late stent thrombosis (B)
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allow us to infer whether the superiority of the everolimus-eluting stent differs 
between subgroups. However, in a similar analysis done in the SPIRIT IV trial (G 
Stone, New York-Presbyterian Hospital, Columbia University Medical Center, 
personal communication), the superiority of everolimus-eluting compared 
with paclitaxel-eluting stents was less apparent in patients with diabetes. This 
finding can only be regarded as exploratory. Patients with diabetes under go-
ing percutaneous coronary intervention have poorer outcomes overall than do 
those without diabetes even when treated with drug-eluting stents. However, 
results from previous studies have consistently suggested that stents eluting 
limus derivatives might offer an advantage over paclitaxel-eluting stents in 
patients with diabetes.17,18 Enrolment of unselected patients and the entirely 
clinical follow-up were the strengths of our study. Further more, we studied 
the second-generation paclitaxel-eluting stent whereas the first-generation 
paclitaxel-eluting stent was used in previous comparisons.19
There are some limitations to our investigation. The trial was done in one, 
high-volume, tertiary centre in which implantation of drug-eluting stents was 
the default strategy for coronary intervention, and therefore the results might 
not be applicable in other settings.
Consistent with usual clinical practice in our institution, systematic sampling 
of cardiac biomarkers was not done for all patients, and is unlikely to have 
affected the outcome because the proportion of patients who had biomarkers 
 
 
 
 
 
 
 
Figure 4: Subgroup analysis 
Data are n/N (%). Percentages have been rounded. 
 
Figure 4 Subgroup analysi
Data are n/N (%). Percentages have been rounded.
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measured did not differ significantly between groups. In the Spirit III trial,8 
more postprocedure infarctions were noted in the paclitaxel-eluting stent 
group than in the everolimus-eluting stent group, whereas no significant dif-
ference was noted in the rate of periprocedural infarctions between groups 
in our study. Our conclusions about safety and efficacy are consistent with the 
outcome of previous studies of selected patient cohorts in which everolimus-
eluting and paclitaxel-eluting stents were compared 8,12 and with the results of 
an all-comer registry in which the everolimus-eluting stent was compared with 
the first-generation paclitaxel-eluting stent.16
In conclusion, we have shown that the everolimus-eluting Xience V stent 
is better than the second-generation paclitaxel-eluting Taxus Liberte stent in 
treatment of patients in real-life practice in terms of safety and efficacy. On 
the basis of our results, we suggest that paclitaxel-eluting stents should no 
longer be used in everyday clinical practice.
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AbStrACt
Objectives 
The purpose of this study was to compare the safety and efficacy of the Xience 
V (Abbott Vascular, Santa Clara, California) everolimus-eluting stent (EES) with 
the Taxus Liberté (Boston Scientific, Natick, Massachusetts) paclitaxel-eluting 
stent (PES) at 2-year follow-up.
background 
COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the 
paclitaxel eluting TAXUS LIBERTE´ stent in all-comers: a randomized open label 
trial) demonstrated a superior clinical outcome of EES over PES at 1 year in all 
comers. Whether this superiority is maintained after discontinuation, at 12 
months, of dual antiplatelet therapy is unclear.
Methods 
Patients undergoing percutaneous coronary intervention with limited exclu-
sion criteria were randomly allocated to EES or PES. The 2-year pre-specified 
endpoints are composites of safety and efficacy and stent thrombosis.
results 
Follow-up was completed in 1,795 of 1,800 patients (99.7%). The groups had 
similar baseline characteristics. At 2 years, significantly fewer EES patients took 
dual antiplatelet therapy (11.4% vs. 15.4%, p =0.02). The primary composite 
of all death, nonfatal myocardial infarction, and target vessel revasculariza-
tion occurred in 9.0% of EES patients and 13.7% of PES patients (relative risk 
[RR]: 0.66; 95% confidence interval [CI]: 0.50 to 0.86) driven by a lower rate 
of myocardial infarction (3.9% vs. 7.5%; RR: 0.52; 95% CI: 0.35 to 0.77) and 
target vessel revascularization (3.2% vs. 8.0%; RR: 0.41; 95% CI: 0.27 to 0.62), 
in parallel with a lower rate of definite or probable stent thrombosis (0.9% 
vs. 3.9%; RR: 0.23; 95% CI: 0.11 to 0.49). Differences significantly increased 
between 1- and 2-year follow-up for the primary composite endpoint (p = 
0.04), target vessel revascularization (p = 0.02), and definite or probable stent 
thrombosis (p = 0.02).
Conclusions 
The substantial clinical benefit of the EES over the PES with regard to measures 
of both safety and efficacy is maintained at 2 years in real-life practice with 
an increasing benefit in terms of safety and efficacy between 1 year and 2 
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years. Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel 
eluting TAXUS LIBERTE´ stent in all-comers: a randomized open label trial: The 
COMPARE Trial [COMPARE 1]; NCT01016041) (J Am Coll Cardiol 2011; 58:11–8) 
© 2011 by the American College of Cardiology Foundation
IntrODuCtIOn 
Previous randomized trials involving highly selected patients with either 1 or 2 
de novo coronary artery lesions have shown that the everolimus-eluting stent 
(EES) has a superior angiographic outcome in comparison with the paclitaxel-
eluting stent (PES) (1,2). COMPARE (Comparison of the everolimus eluting 
XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE´ stent in all-comers: 
a randomized open label trial) and SPIRIT IV trials, in less selected patient 
populations, showed that the use of EES was associated with a significantly 
lower rate of the pre-specified primary endpoints compared to PES (3,4). In 
the COMPARE trial, the composite of all death, myocardial infarction (MI), 
and target vessel revascularization (TVR) was reduced by 31%. In the SPIRIT IV 
(Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System 
in the Treatment of Subjects With de Novo Native Coronary Artery Lesions) 
trial, the rate of target lesion failure (TLF) at 12 months was reduced by 39%. 
In addition, both trials showed significant decreases in rates of MI, ischemia-
driven target lesion revascularization (TLR), and definite or probable stent 
thrombosis (ST) with EES. Whether the demonstrated superiority of EES over 
PES at 1 year is maintained at 2 years remains unclear.
MetHODS
The methodology of the trial has been published previously (3). In summary, 
consecutive patients, between 18 and 85 years of age, referred to Maasstad 
Ziekenhuis for elective or emergent percutaneous coronary intervention were 
eligible to participate. There were no limitations on the number of lesions or 
vessels, the location of lesions, or their length. Major exclusion criteria were 
contraindications to or expected nonadherence to dual antiplatelet therapy 
(DAPT) in the 12 months after the procedure, planned major surgery within 
30 days, and inability to give informed consent. Patients were assigned on 
a 1:1 basis to EES or PES. All patients provided written informed consent. 
The study was investigator-initiated. Funding was provided by unrestricted 
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research grants from Abbott Vascular and Boston Scientific, which had no 
involvement in the study. The study was approved by the institutional ethics 
committee of the Maasstad Ziekenhuis, Rotterdam, the Netherlands, and the 
Dutch Central Committee on Research Involving Human Subjects (CCMO trial 
no. NL15206.101.06).
Medication
Details of periprocedural oral antiplatelet and anticoagulant therapy have 
been published (3). At discharge, all patients were receiving 100 mg of aspirin 
daily indefinitely and 75 mg of clopidogrel daily for 12 months.
Study endpoints and definitions 
Adverse events were assessed in the hospital, and at 1, 12, and 24 months. 
Study monitors collected data by visits, phone calls, and postal questionnaires. 
Data were stored in our institution. Data processing and adjudication of ad-
verse events, including ST, were done in a blinded fashion by an independent 
contract research organization and core laboratory (Cardialysis, Rotterdam, 
the Netherlands). The pre-specified primary endpoint was a composite of all 
death, nonfatal MI, and TVR at 12 months. The secondary endpoints were the 
primary composite endpoint at 2-year follow-up and the composite of major 
adverse cardiac events (cardiac death, nonfatal MI, and clinically driven TLR at 
2-year follow-up). Definitions of endpoints are presented elsewhere (3).
Statistical analysis
Categorical variables, including events between 1 year and 2 years and up to 2 
years, were evaluated using the chi-square test or Fisher’s exact test, whereas 
continuous variables were evaluated with use of Wilcoxon ranksum test. 
Events between 1 year and 2 years were evaluated with Fisher’s exact test after 
patients with the specified event up to 1 year were removed from the analy-
sis. The time to the pre-specified endpoints was evaluated according to the 
Kaplan-Meier method, and the log-rank test was used to compare endpoint 
frequencies between groups. Relative risk (RR) with 95% confidence interval 
(CI) were calculated using the normal approximation to the binomial distribu-
tion. The statistical analysis was performed according to the intention-to-treat 
principle. All p values were 2-sided, and a p value < 0.05 was considered to 
indicate statistical significance. Analyses were performed using SAS version 
8.02 (SAS Institute, Cary, North Carolina).
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reSultS
Between February 2007 and September 2008, 1,800 patients were enrolled. 
Randomization and patient flow is summarized in Figure 1.
baseline demographic data
Baseline demographic data and lesion characteristics (Table 1) were compa-
rable between groups (3). A high number of patients presented with an acute 
coronary syndrome (59% PES vs. 60% EES). Most lesions treated were complex 
(74% type B2 or C), resulting in a mean stented length of 28 mm in both 
groups.
Clinical outcomes
Table 2 shows clinical events at 1- and 2-year follow-up. At 2-year follow-up, 
the primary endpoint (Fig. 2A) occurred in 9.0% of the EES group versus 13.7% 
in the PES group (RR: 0.66, 95% CI: 0.50 to 0.86, p = 0.002). This reflected a 
lower rate of both MI and TVR in the EES group. All-cause mortality did not 
differ between groups (Figs. 2B to 2D). Between 1-year and 2-year follow-up, 
the event curves for the primary composite endpoint (p = 0.04) and TVR (p 
= 0.02) (Table 3) widened significantly. The secondary endpoint, a composite 
of cardiac death, nonfatal MI, and TLR, occurred in 7.4% of EES patients and 
1800 patients enrolled and 
randomly assigned
897 allocated to everolimus-eluting 
Xience V stent (1286 lesions)
903 allocated to paclitaxel -eluting 
Taxus Liberte stent (1294 lesions)
2 lost to follow-up, 4 no study stent
N = 895
0 lost to follow-up 
N = 895
1 lost to follow-up, 6 no study stent 
N = 902
2 lost to follow-up, 
N= 900
1 year 
follow-up
2 year 
follow-up
Figure 1 Patient  diagram and follow-up
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table 1: Baseline patient and lesion characteristics
everolimus-eluting stent 
(n=897)
Paclitaxel-eluting stent     
(n=903)
Age (years; median) 62.9 63.6
Men 619 (69%) 654 (72%)
Diabetes mellitus * 153 (17%) 172 (19%)
Chronic renale failure † 25 (3%) 24 (3%)
Hypertension 417 (46%) 447 (50%)
Hypercholesterolaemia (477 (53%) 451 (50%)
Current smoker 295 (33%) 262 (29%)
Family history of CAD 399 (44%) 403 (45%)
History of  myocardial infarction 136 (15%) 159 (18%)
History of percutaneous coronary intervention 117 (13%) 123 (14%)
History of coronary artery bypass surgery 60 (7%) 53 (6%)
Stable angina pectoris 331 (37%) 349 (39%)
Acute coronary syndrome 541 (60%) 534 (59%)
Unstable angina 107 (12%) 105 (12%)
Non ST-segment elevation myocardial 
infarction
194 (22%) 217 (24%)
ST-segment elevation myocardial infarction 240 (27%) 212 (23%)
Multivessel treatment 244 (27%) 239 (26%)
Number of treated lesions per patient (SD) 1.4 (0.7) 1.4 (0.7)
Lesion Length ≥ 20mm 290 (32%) 263 (29%)
Number of lesions 1286 1294
Number of stents per lesion (mean, SD) 1.7 (0.9) 1.6 (0.9)
Total stent length per lesion (mm) 28 (18-46) 28 (18-44)
Direct stenting 432 (34%) 451 (35%)
Type B2 or C lesion 950 (74%) 955 (74%)
Bifurcation lesions 223 (17%) 237 (18%)
Thrombus present 310 (24%) 314 (24%)
Chronic total occlusion 39 (3%) 53 (4%)
Data are median, n (%), or mean ± SD. Percentages have been rounded. *Defined as treatment with diet or 
drugs for previously diagnosed diabetes mellitus. †Defined as serum creatinine >130 µmol/l or patient on 
dialysis. CABG = coronary artery bypass graft surgery; CAD = coronary artery disease; EES = everolimus-eluting 
stent(s); MI = myocardial infarction; PCI = percutaneous coronary intervention; PES = paclitaxel-eluting stent(s).
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table 2. Clinical Events during Follow-up
everolimus 
eluting stent
(897 
Patients)
Paclitaxel 
eluting stent
(903 patients)
relative 
risk
lower 
limit 
rr*
upper 
limit 
rr*
P Value
events at 12 months
Death 18  (2.0) 15 (1.7) 1.21 0.61 2.38 0.58
Cardiac Death 11 (1.2) 10 (1.1) 1.11 0.47 2.59 0.81
MI 25 (2.8) 49 (5.4) 0.51 0.32 0.82 0.005
    Q-wave 3 (0.3) 11 (1.2) 0.27 0.08 0.98 0.03
    Non Q-wave 22 (2.5) 40 (4.4) 0.55 0.33 0.92 0.02
Death or MI 42 (4.7) 63 (7.0) 0.67 0.46 0.98 0.04 
Cardiac death or MI 35 (3.9) 58 (6.4) 0.61 0.40 0.91 0.02
TVR , clinically riven 19 (2.1) 49 (5.4) 0.39 0.23 0.66 <0.001
    Percutaneous 13 (1.4) 36 (4.0) 0.36 0.19 0.68 <0.001
    Surgical 6 (0.7) 13 (1.4) 0.46 0.18 1.22 0.11
TVR, any 21 (2.3) 52 (5.8) 0.41 0.25 0.67 <0.001
    Percutaneous 15 (1.7) 39 (4.3) 0.39 0.22 0.70 0.001
    Surgical 6 (0.7) 13 (1.4) 0.46 0.18 1.22 0.11
TLR, clinically driven 15 (1.7) 40 (4.4) 0.38 0.21 0.68 <0.001
    Percutaneous 9 (1.0) 28 (3.1) 0.32 0.15 0.68 0.002
    Surgical 6 (0.7) 12 (1.3) 0.50 0.19 1.34 0.16
TLR, any 18 (2.0) 45 (5.0) 0.40 0.24 0.69 <0.001
    Percutaneous 12 (1.3) 33 (3.7) 0.37 0.19 0.70 0.002
    Surgical 6 (0.7) 12 (1.3) 0.50 0.19 1.34 0.16
Primary endpoint † 56 (6.2) 83 (9.2) 0.68 0.49 0.94 0.02
Secondary endpoint ‡ 44 (4.9) 74 (8.2) 0.60 0.42 0.86 0.005
ST, definite and probable 5 (0.6) 23 (2.5) 0.22 0.08 0.57 <0.001
  Early ST, 0-30 days after 
procedure
2 (0.2) 15 (1.7) 0.13 0.03 0.59 0.002
  Late ST, 30 days – 1 yr after 
procedure
3 (0.3) 8 (0.9) 0.38 0.10 1.42 0.13
  Definite ST 3 (0.3) 18 (2.0) 0.17 0.05 0.57 0.001
events at 24 months
Death 30  (3.3) 27 (3.0) 1.12 0.67 1.87 0.67
Cardiac Death 20 (2.2) 16 (1.8) 1.26 0.66 2.41 0.49
MI 35 (3.9) 68 (7.5) 0.52 0.35 0.77 <0.001
    Q-wave 3 (0.3) 17 (1.9) 0.18 0.05 0.60 0.002
    Non Q-wave 32 (3.6) 53 (5.9) 0.61 0.40 0.93 0.02
Death or MI 63 (7.0) 93 (10.3) 0.68 0.50 0.93 0.01
Cardiac death or MI 53 (5.9) 82 (9.1) 0.65 0.47 0.91 0.01
TVR, clinically driven 27 (3.0) 69 (7.6) 0.39 0.25 0.61 <0.001
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everolimus 
eluting stent
(897 
Patients)
Paclitaxel 
eluting stent
(903 patients)
relative 
risk
lower 
limit 
rr*
upper 
limit 
rr*
P Value
    Percutaneous 20 (2.2) 52 (5.8) 0.39 0.23 0.64 <0.001
    Surgical 7 (0.8) 19 (2.1) 0.37 0.16 0.88 0.02
TVR, any 29 (3.2) 72 (8.0) 0.41 0.27 0.62 <0.001
    Percutaneous 22 (2.5) 55 (6.1) 0.40 0.25 0.65 <0.001
    Surgical 7 (0.8) 19 (2.1) 0.37 0.16 0.88 0.02
TLR, clinically driven 23 (2.6) 53 (5.9) 0.44 0.27 0.71 <0.001
    Percutaneous 16 (1.8) 40 (4.4) 0.40 0.23 0.71 0.001
    Surgical 7 (0.8) 15 (1.7) 0.47 0.19 1.15 0.09
TLR, any 26 (2.9) 58 (6.4) 0.45 0.29 0.71 <0.001
    Percutaneous 19 (2.1) 45 (5.0) 0.43 0.25 0.72 0.001
    Surgical 7 (0.8) 15 (1.7) 0.47 0.19 1.15 0.09
Primary endpoint † 81 (9.0) 124 (13.7) 0.66 0.50 0.86 0.002
Secondary endpoint ‡ 66 (7.4) 102 (11.3) 0.65 0.48 0.88 0.004
ST, definite and probable 8 (0.9) 35 (3.9) 0.23 0.11 0.49 <0.001
    Very late  ST >1 yr after 
procedure
3 (0.3) 13 (1.4) 0.23 0.07 0.81 0.01
    Definite ST 5 (0.6) 24 (2.7) 0.21 0.08 0.55 <0.001
Values are n (%). *Relative risk (RR) and p values are from the chi-square test. Lower and upper limit of 
RR represent the 95% confidence intervals. †The pre-specified primary endpoint was a composite of all 
death, nonfatal MI and target vessel revascularization (TVR). ‡The principal secondary endpoint was a 
composite of cardiac death, nonfatal MI, and clinically driven target lesion revascularization (TLR).
ST = stent thrombosis; other abbreviations as in Table 1
table 3. Outcome differences between 1 and 2 year.
everolimus eluting 
stent
Paclitaxel eluting 
stent
% Patients With Event Between 1and 2 yrs
No Event First Year
OR 95% CI p Value
Primary endpoint 3.0 (25/841) 5.0 (41/820) 0.58 0.34-0.99 0.04
Death 1.4 (12/879) 1.4 (12/888) 1.01 0.41-2.47 1.00
Cardiac death 1.0 (9/879) 0.7 (6/888) 1.52 0.45-5.21 0.45
TVR, clinically driven 0.9  (8/878) 2.3 (20/854) 0.38 0.15-0.92 0.02
TLR, clinically driven 0.9 (8/882) 1.5 (13/863) 0.60 0.21-1.57 0.28
MI 1.2 (10/872) 2.2 (19/854) 0.51 0.21-1.16 0.09
ST, definite and probable 0.3 (3/892) 1.4 (12/880) 0.24 0.04-0.91 0.02
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11.3% of PES patients at 2 years (RR: 0.65, 95% CI: 0.48 to 0.88, p = 0.004). As 
for the primary endpoint, this difference was driven by a reduction in MI and 
TLR. The rate of cardiac death did not differ between groups. In accordance 
with European percutaneous coronary intervention guidelines, the protocol 
specified that DAPT should be prescribed for 1 year after stent implantation. 
At 1 year of follow-up, 70% of patients in both groups were receiving DAPT. 
At 2 years, 11.4% of patients in the EES group and 15.2% in the PES group (p 
= 0.02) were receiving DAPT (Fig. 3). Definite and probable ST rate differed 
significantly between groups at 1 year (0.6% for EES vs. 2.5% for PES, RR: 0.22, 
95% CI: 0.08 to 0.57, p = 0.001). At 2 years of follow-up, this absolute differ-
ence increased to 3.0% (0.9% for EES vs. 3.9% for PES, RR: 0.23, 95% CI: 0.11 to 
 
Figure 2 Kaplan-Meier Cumulative Event Curves for Primary Endpoints
Kaplan-Meier cumulative event curves for (A) the primary endpoint, (B) all death, (C) myocardial infarction 
(MI), and (D) target vessel revascularization (TVR). The absolute
difference in the primary endpoint between groups was 3.0% at 1 year, which significantly increased 
to 4.7% at 2 years. The absolute difference in MI increased from 2.6% at 1 year to 3.6% at 2 years. The 
absolute difference in TVR significantly increased from 3.5% at 1 year to 4.8% at 2 years. Red lines indicate 
paclitaxel-eluting
stent (PES); blue lines indicate everolimus-eluting stent (EES). PLR _ p value according to the log-rank test.
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Figure 3 Baseline and Follow-Up DAPT
Dual antiplatelet therapy (DAPT) at baseline and at 1, 6, 12, and 24 months of follow-up in the paclitaxel-
eluting stent (PES) group (red bars) and the everolimus- eluting stent (EES) group (blue bars). At 2 years, 
significantly more patients were on DAPT in the PES group (*p = 0.02).
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Figure 4 Kaplan-Meier Cumulative Event Curves for ST at 2-Year Follow-Up
Kaplan-Meier cumulative event curves for definite and probable stent thrombosis (ST) at 2 year follow-
up as defined by the Academic Research Consortium. The absolute difference in rates of definite and 
probable ST between stent groups was 1.9% at 1 year, which significantly increased to 3.9% at 2 years. Red 
line indicates PES; blue line indicates EES. Abbreviations as in Figure 2.
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0.49, p = 0.001) (Fig. 4). Between 1-year and 2-year follow-up, this event curve 
widened significantly (p = 0.02) (Table 3).
Early definite and probable ST occurred significantly more often in the PES 
group (0.2% EES vs. 1.7% PES, RR: 0.13, 95% CI: 0.03 to 0.59, p = 0.002). The 
rate of late definite and probable ST was numerically higher in the PES group, 
but did not differ significantly between groups. The rate of very late definite 
and probable ST was significantly higher in the PES group (0.3% EES vs. 1.4% 
PES, RR: 0.23, 95% CI: 0.07 to 0.81, p = 0.01) (Fig. 5).
Subgroup analysis
In a stratified analysis of the primary endpoint, the difference between EES 
and PES was consistent across all subgroups apart from patients with diabetes 
mellitus, for whom no difference in the primary composite outcome was noted 
at 1- or 2-year follow-up; however, the test of interaction was not significant 
(Fig. 6). In a more detailed analysis of the diabetic population, no differences 
were found in mortality, MI, and ST at 2 years; however, significantly more 
patients had clinically indicated TVR (9.3% vs. 2.0%, RR: 0.20, 95% CI: 0.04 
to 0.70, p = 0.008), and there was a trend toward more TLR in the PES group 
compared with the EES group (5.8% vs. 2.0%, respectively; p = 0.09).
DISCuSSIOn
Our major finding was that the demonstrated superiority at 1 year of EES over 
PES in terms of safety and efficacy was maintained at 2 years. Indeed, the event 
curves continued to diverge in favor of the EES. This difference, at 2 years, was 
driven by reductions in both MI and TVR. At 1 year, the EES group showed a 
significant absolute risk reduction of 2.6% compared with the PES group in 
the rate of a first MI. The magnitude of the difference for this safety endpoint 
widened in the subsequent year, resulting in an absolute risk reduction of 
3.6% at 2 years for the EES group. The COMPARE, SPIRIT III, and SPIRIT IV trials 
all showed either a significant reduction or a trend toward fewer MIs with the 
EES in the first 30 days (2– 4). That might reflect differences in stent design, 
leading to less side branch compromise with the EES (4). Our results suggest 
that other mechanisms may also contribute. When periprocedural and early 
(30 days) events were excluded, we observed that event curves significantly 
diverged from the 30-day timepoint up to 2 years (data not shown). A similar 
trend (p = 0.22) was noted in the pooled SPIRIT II and III trial reports; between 
1- year and 2-year follow-up, MI occurred in 0.8% of EES patients versus 1.7% 
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Figure 5 Kaplan-Meier Cumulative Event Curves for Early, Late, and Very Late ST
Kaplan-Meier cumulative event curves for definite and probable stent thrombosis (ST) in the (A) early, (B) 
late, and (C) very late time periods, as defined by the Academic Research
Consortium. Red lines indicate PES; blue lines indicate EES. RR = relative risk; other abbreviations as in 
Figure 2.
 
Figure 6 Post-Hoc Subgroup Analysis
Results of a post-hoc subgroup analysis performed with 9 clinical or angiographic variables. The treatment 
effect was consistent across subgroups, apart from patients with diabetes mellitus. However, the test for 
interaction was not significant. ACS = acute coronary syndrome; LAD = left anterior descending artery; MI 
= myocardial infarction; RVD = reference vessel diameter.
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of PES patients (5). As previously reported, the rate of ST in the COMPARE 
study at 1 year was significantly lower with EES. Between 1 and 2 years, there 
was a further significant divergence of the event curves due to a significantly 
lower definite and probable ST in the EES group, despite low rates of DAPT, 
which were not protocol mandated after 1 year. The small, but significantly 
higher rate of DAPT in the PES group at 2 years parallels differences in MI 
and ST rates, events that likely led to prolongation or reinstitution of DAPT. 
With first-generation DES, the promising low ST rates in initial clinical trials 
(6) have shown a consistent increase as the patient populations enrolled ex-
panded from those with favourable “research” lesions to “real-world” lesions. 
Registry studies have clearly demonstrated a continuing risk of very late ST, 
with annual increments in ST of 0.4% and 0.6% for SES and PES, respectively 
(7,8). In our all-comer trial, the annual increase of definite ST with PES was 
comparable (0.7%). Against this background, the ST rates reported with EES 
to date are much lower and of the same order of magnitude as for bare-metal 
stents (6,7,9). Two-year pooled (892 patients) STrates for the SPIRIT II and III 
studies, with restrictive inclusion criteria, showed a 1.2% rate of probable or 
definite ST, remarkably similar to that of COMPARE (0.9%) (5).
Differences in stent design, strut thickness, delivery platform, polymer coat-
ing, drug, and drug release profile could all play a role in the difference in ST 
rates between PES and EES.
Other potential explanations may be more rapid reendothelialization with 
EES, documented in the rabbit iliac model, or the more biocompatible fluori-
nated copolymer (10–12). Both TLR and TVR were significantly lower for EES at 
2 years, with relative risk reductions of 55% and 60%, respectively. Between 1 
and 2 years, the absolute difference for TVR between the PES and EES groups 
increased significantly from 3.5 to 4.8%. The recently published SPIRIT IV 
trial showed results for safety and efficacy endpoints similar to those for the 
COMPARE trial at 1 year of follow-up (4). At 2-year follow-up, there was a 
continuing benefit of EES in TLF and ST rates. However, no divergence of the 
curves between 1 and 2 years was observed. Whether the inclusion of patients 
and lesions at lower risk in the SPIRIT IV study or the very high rate (72%) of 
DAPT at 2-year follow-up might account for this discordance is unclear (13).
COnCluSIOnS
In summary, we have shown that the substantial clinical benefit of the EES 
Xience V stent over the PES Taxus Liberté with regard to measures of both 
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safety and efficacy is maintained at 2 years in real-life practice with an increas-
ing benefit in terms of safety and efficacy
between 1 and 2 years. Further research is required to understand the lack 
of benefit of EES over PES in the diabetic population.
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AbStrACt
Aims: 
Although large clinical trials have shown that everolimus-eluting stents (EES) 
significantly reduce target vessel revascularisation (TVR), myocardial infarction 
(MI) and stent thrombosis (ST) compared to paclitaxel-eluting stents (PES) 
in diverse populations, there is a paucity of data comparing EES and PES in 
patients presenting with MI.
Methods and results: 
We performed a post hoc subgroup analysis on COMPARE, an all-comer trial 
comparing EES to PES. We identified 863 patients (EES=434, PES=429 treated 
for MI: 452 ST-elevation MI (STEMI) and 411 non ST-elevation MI (NSTEMI). 
EES was associated with a significant reduction in the primary endpoint, a 
composite of all-cause mortality, MI, and TVR, at two years (RR=0.57; 95% CI: 
0.40- 0.83, p=0.002). While the effect was more marked in the STEMI (RR=0.51; 
95%CI: 0.30-0.87, p=0.01) than the NSTEMI subgroup (RR=0.65; 95% CI: 
0.39-1.08, p=0.09), the interaction p value (0.5) suggests that a difference in 
treatment effect between presentations is unlikely. ST rates were significantly 
lower with EES (RR=0.30; 95% CI: 0.12-0.73, p=0.005).
Conclusions: 
At two years, EES results are superior to PES in terms of safety and efficacy 
endpoints in treatment of MI.
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IntrODuCtIOn
Paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES) substantially 
reduce the need for re-intervention compared to bare metal stents.1,2 How-
ever, increased rates and ongoing propensity for stent thrombosis (ST) remain 
a matter of concern.3-7 Specific concerns have been raised with respect to the 
unrestricted use of first generation DES in patient populations presenting 
with AMI.8 Second generation drug-eluting stents were designed to improve 
safety, efficacy and procedural success rates. Specifically, a second generation, 
thin-strut, cobalt-chromium, everolimus-eluting stent (EES) demonstrated sig-
nificant improvements in angiographic and clinical outcomes when compared 
to PES in two early randomised trials.9,10 Thereafter, two large clinical trials, 
SPIRIT IV and COMPARE, independently demonstrated that the EES was supe-
rior to the PES with regard to broadly similar primary composite safety and 
efficacy endpoints in less selected populations.11-14 Both trials showed strikingly 
similar relative risk reductions in thrombotic events with EES compared with 
PES at 30 day, 1- and 2-year follow- up. No study has compared EES with PES 
in patients presenting with myocardial infarction (MI). To investigate whether 
these promising results with EES can be replicated in this high risk category of 
patients, we performed a post hoc subgroup analysis comparing the outcomes 
of EES and PES in patients treated for MI in the COMPARE trial.
MetHODS
We performed a subgroup analysis of patients presenting with myocardial 
infarction from the population of the COMPARE trial.12 The methodology of 
the COMPARE trial has been published previously.12 In summary, consecutive 
patients, between 18 and 85 years, referred to the Maasstad Ziekenhuis 
(Hospital) Cardiology Centre for elective or emergent percutaneous coronary 
intervention, were eligible to participate in the study. There were no limita-
tions on the number of lesions or vessels, on the location of lesions, or on their 
length. Exclusion criteria were contraindications or expected nonadherence to 
dual antiplatelet drug therapy in the 12 months after the procedure; planned 
major surgery within 30 days; inability or refusal to comply with follow-up 
procedures; participation in other coronary-device trials; and inability to give 
informed consent. For the present analysis, the same primary and secondary 
endpoints as well as the same definitions as for the COMPARE trial were used12.
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As the majority of patients were treated in the setting of an evolving MI, the 
periprocedural infarctions were adjudicated in the following manner: If the 
peak total CK (or CK-MB) from the index infarction had not yet been reached: 
recurrent chest pain lasting >20 minutes (or new ECG changes consistent with 
MI) AND the peak CK (or CK-MB in absence of CK) level measured within 24 
hours after the event is elevated by at least 50% above the previous level.
If the elevated CK (or CK-MB) levels from the index infarction are falling or 
have returned to normal within 24 hours post-index PCI: either a new eleva-
tion of CK >2 x ULN within 24 hours post-index PCI if the CK level has returned 
to <ULN or a rise by >50% above the previous nadir level if the CK level has not 
returned to <ULN. Randomisation was performed by means of sealed, opaque, 
sequentially numbered allocation envelopes after passage of the guidewire. 
The allocation schedule was based on computer-generated random numbers. 
(SAS, release 8.02; Cary, NC, USA). Patients were assigned on a 1:1 basis to 
treatment with a polymer-based, everolimus-eluting stent (XIENCE V®, Abbott 
Vascular, Santa Clara, CA, USA) or a polymer-based, paclitaxel-eluting stent 
(Taxus Liberté™, Boston Scientific, Natick, MA, USA). Staged procedures were 
permitted, and the same stent type, allocated at initial randomisation, was 
used. All patients provided written informed consent. The study was investi-
gator-initiated. Funding for the study was provided by unrestricted research 
grants from Abbott Vascular and Boston Scientific, who had no involvement 
in the design, conduct or analysis of the study. The study complied with the 
Declaration of Helsinki regarding investigation in humans and was approved 
by the Institutional Ethics committee of the Maasstad Ziekenhuis, Rotterdam, 
Netherlands and the Dutch Central Committee on Research Involving Human 
Subjects (CCMO trial nr: NL15206.101.06). 
Medication
All patients not on dual antiplatelet therapy received a dose of 100 or 300 mg 
aspirin and 300 or 600 mg of clopidogrel before the procedure. The higher 
doses of aspirin and clopidogrel were given to patients in acute settings. 
An initial bolus of unfractionated heparin (70 to 100 IU/kg) was given to all 
patients, and additional boluses given to achieve and maintain an activated 
clotting time of >250 seconds, which was checked every 30 minutes. The use of 
bivalirudin or low-molecular heparin was prohibited. The use of glycoprotein
IIb/IIIa antagonists was at the discretion of the operator, even in the setting 
of primary PCI. At the time of discharge, all patients were receiving 100 mg 
of aspirin once daily for an indefinite period, as well as 75 mg of clopidogrel 
daily for 12 months.
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Study endpoints and definitions
Adverse events were assessed in the hospital, and at 1, 12 and 24 months. Data 
were collected by study monitors who visited the hospitals where follow-up 
was undertaken, reviewed the patients’ clinical notes, and collected the source 
documents. Furthermore, medical questionnaires were posted to all patients 
at 1, 6, 12 and 24 months to check for adverse events and establish current 
antiplatelet medication. In case of no response, information was obtained by 
telephone contact. Data were stored in our institution. Data processing and 
adjudication of adverse events, including stent thrombosis, were done by an 
independent contract research organisation and corelab (Cardialysis, Rotter-
dam, The Netherlands).
The pre-specified primary endpoint was a composite of all death, non-fatal 
myocardial infarction and target vessel revascularisation at 12 months. The 
secondary endpoints were the primary endpoint at two year follow-up and 
the composite of major adverse cardiac events (cardiac death, non-fatal 
myocardial infarction and clinically driven target-lesion revascularisation at 
two year follow-up). The same endpoints and definitions were used as well in 
this current study. Definitions of endpoints are presented elsewhere.12 Acute 
myocardial infarction was defined as a typical rise and fall in concentrations of 
troponin or creatinine kinase-MB with at least one of the following: ischaemic 
symptoms, development of pathological Q-waves, ischaemic electrocardio-
graphic changes or pathological findings of an acute myocardial infarction. 
ST-elevation MI was defined as patients with ST segment elevation: new or 
presumed new ST segment elevation at the J point in two or more contiguous 
leads with the cut-off points ≥0.2 mV in leads V1, V2, or V3 and ≥0.1 mV in 
other leads (contiguity in the frontal plane is defined by the lead sequence 
aVL, I, inverted aVR, II, aVF, III).15
Statistical analysis
A new database with only patients presenting with MI was created. Categori-
cal variables of all AMI patients were evaluated using the chi-square or Fisher’s 
exact tests, whereas continuous variables were evaluated using the Wilcoxon 
rank-sum test. The time to the pre-specified endpoints was evaluated accord-
ing to the Kaplan-Meier method and the log-rank test was applied to compare 
the incidence of the endpoints between groups. Relative risks with 95% 
confidence intervals, were calculated using the delta method for binomially 
distributed data. This analysis was performed for all MI patients as well as 
for patients presenting with non-ST elevation myocardial infarction (NSTEMI) 
or ST-elevation myocardial infarction (STEMI) separately. Formal interaction 
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testing was performed to determine whether treatment for NSTEMI or STEMI 
influenced the relative risk of EES versus PES for the occurrence of primary 
and secondary endpoints at two years. The statistical analysis was performed 
according to the intention to treat principle. All p values were two-sided, and 
a p value of less than 0.05 was considered to indicate statistical significance. 
Analyses were performed using SAS version 8.02 (SAS Institute Inc. Cary, NC, 
USA).
reSultS
From the COMPARE database we identified 863 patients (EES=434, PES=429) 
that were treated with PCI for MI. From these patients 452 (EES=240, PES=212) 
had a STEMI at presentation and 411 patients were treated for NSTEMI 
(EES=217, PES=194). Baseline demographic and angiographic data. The base-
line demographic data is presented in Table 1. Baseline characteristics did 
not differ significantly between groups. The use of DAPT was also similarly 
distributed in both groups (Table 2). The use of glycoprotein IIbIIIa blockers 
did not differ significantly between groups in the overall population (49.8% 
vs. 49.6% in EES and PES, respectively) or in the subgroup undergoing primary 
PCI for STEMI (62.6% vs. 61.1% in EES and PES, respectively). In addition, the 
angiographic findings were similar between groups. No significant differences 
were observed in lesion numbers and distribution, lesions quantified coronary 
analysis results, TIMI flow at baseline and presence of thrombus. Although 
the total stent length was similar between the two groups, a slight, but not 
significantly, higher number of stents was used in the EES group (Table 3). This 
dissimilarity can be attributed to the difference in the maximal device length 
available for use (32 mm for PES and 28 mm for EES) during the trial. TIMI 
flow 0 (60% vs. 55.2%, p=0.3) and the use of thrombosuction catheters (47.3% 
vs. 46.2% p=0.6) during primary PCI for STEMI did not differ significantly in 
EES and PES respectively. There were no statistical differences in angiographic 
baseline characteristics between EES and PES groups in either STEMI or NSTEMI 
subgroups.
Clinical outcomes
table 4 shows the clinical outcomes at 30 days, one year and two years follow-
up. At one year, the primary endpoint, a patient oriented composite of all-
cause mortality, non-fatal MI and TVR, occurred in 28 (6.4%) of patients in the 
EES group versus 45 (10.5%) in the PES (RR=0.62; 95% CI:0.39-0.97, p=0.03). At 
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the two year follow-up, the primary endpoint occurred in 40 (9.2%) of patients 
assigned to EES and 69 (16.1%) of patients assigned to PES (RR=0.57; 95% CI: 
0.40-0.83, p=<0.002). This difference was mainly driven by a significantly lower 
rate of both non-fatal myocardial infarction and target vessel revascularisation 
at one and two years in patients with EES; all-cause mortality did not differ 
significantly between treatment groups (figure 1). At two years, the primary 
endpoint remained significantly lower for EES treated patients in STEMI (EES: 
19 (7.9%) vs. PES: 33 (15.6%); RR=0.51; 95% CI: 0.30-0.87, p=0.01) where it 
was mainly driven by a significant reduction in TVR and a trend towards less 
non-fatal MI. The primary endpoint was also lower for EES treated patients 
in NSTEMI (EES: 21 (10.8%) vs. PES 36 (16.6%); RR=0.65; 95% CI: 0.39-1.08, 
p=0.09) but failed to reach significance. The same trend was observed also for 
the TVR and non-fatal MI in this subgroup whereas no clinically relevant dif-
ferences were observed in all-cause mortality. However, the results of formal 
interaction testing for the primary and secondary endpoint resulted in a RR 
for interaction of 1.13; 95% CI: 0.79-1.63, interaction p=0.5 and 1.05; 95% 
CI: 0.70-1.56 interaction p=0.8, respectively, suggesting that a difference in 
table 1: Baseline characteristics: 
everolimus- eluting 
stent 
(n=434)
Paclitaxel- 
eluting stent
(n=429)
P-value
Age (years) 61.5 ±11.5 62.4± 11.8 0.23
Men 302 (69.6%) 318 (74.1%) 0.14
Diabetes mellitus 
    - not insulin dependent
    - insulin dependent
62 (14.3%)
52 (12.0%)
10 (2.3%)
63 (14.7%)
45 (10.5%)
18 (4.2%)
0.87
0.49
0.12
Hypertension 180 (41.5%) 184 (43.0%) 0.65
Hypercholesterolaemia 180 (41.5%) 162 (37.8%) 0.26
Current smoker 191 (44.0%) 166 (38.7%) 0.11
Family History of CAD 189 (43.6%) 192 (44.8%) 0.72
History of MI 52 (12.0%) 52 (12.1%) 0.95
History of PCI 33 (7.6%) 30 (7.0%) 0.73
History of CABG 15 (3.5%) 16 (3.7%) 0.83
   Non-ST segment elevation MI 194 (44.7) 217(50.6) 0.08
   ST segment elevation MI 240 (55.3) 212 (49.4) 0.08
Glycoprotein IIbIIIa antagonists 213 (49.8%) 213 (49.6%) 0.89
Multivessel treatment 111 (25.6) 101 (23.6) 0.50
Number of lesions treated per patient 1.4 (0.7) 1.4 (0.7) 0.27
Values are percentages or mean ±SD; CABG: coronary artery bypass grafting; CAD: coronary artery 
disease; MI: myocardial infarction; PCI: percutaneous coronary intervention 
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table 2: Antiplatelet therapy for the entire patient population presenting with AMI and in the subgroups 
presenting with NSTEMI and STEMI
All AMI nSteMI SteMI
everolimus- 
eluting 
stent 
(n=434)
Paclitaxel- 
eluting 
stent
(n=429)
p 
value
everolimus- 
eluting stent 
(n=194)
Paclitaxel- 
eluting 
stent
(n=217)
p 
value
everolimus- 
eluting stent 
(n=240)
Paclitaxel- 
eluting 
stent
(n=212)
p 
value
discharge
Aspirin
94·8% 
(404/426)
95.7% 
(403/421)
0·54
95·8% 
(184/192)
95.3% 
(202/212)
0·79
94·0% 
(220/234)
96.2% 
(201/209)
0·30
Clopidogrel
99·1% 
(422/426)
99·8% 
(420/421)
0·37
99·5% 
(191/192)
99·5% 
(211/212)
1.00
98·7% 
(231/234)
100·0% 
(209/209)
0·25
Aspirin + 
Clopidogrel
94.4% 
(402/426)
95·5% 
(402/421)
0·46
95.3% 
(183/192)
94.8% 
(201/212)
0·82
93.6% 
(219/234)
96.2% 
(201/209)
0·22
6-months
Aspirin
93·9% 
(398/424)
93·0% 
(386/415)
0·62
96·3% 
(184/191)
92·9% 
(196/211)
0·13
91·8% 
(214/233)
93·1% 
(190/204)
0·61
Clopidogrel
96·9% 
(411/424)
98·3% 
(408/415)
0·19
95·8% 
(183/191)
97·2% 
(205/211)
0·46
97·8% 
(228/233)
99·5% 
(203/204)
0·22
Aspirin + 
Clopidogrel
91·8% 
(389/424)
91·3% 
(379/415)
0·83
92·7% 
(177/191)
90·0% 
(190/211)
0·35
91·0% 
(212/233)
92·6% 
(189/204)
0·53
1-Year
Aspirin
94·8% 
(400/422)
91·9% 
(376/409)
0·10
98·9% 
(187/189)
92·2% 
(190/206)
0·001
91·4% 
(213/233)
91·6% 
(186/203)
0·94
Clopidogrel
77·7% 
(328/422)
77·3% 
(316/409)
0·87
73.5% 
(139/189)
76·2% 
(157/206)
0·54
81·1% 
(189/233)
78·3% 
(159/203)
0·47
Aspirin + 
Clopidogrel
73·9% 
(312/422)
70·2% 
(287/409)
0·23
72·5% 
(137/189)
69·9% 
(144/206)
0·57
75·1% 
(175/233)
70·4% 
(143/203)
0·27
2-Years
Aspirin
91·1% 
(379/416)
92·8% 
(373/402)
0·38
95·1% 
(174/183)
93·6% 
(189/202)
0·52
88·0% 
(205/233)
92·0% 
(184/200)
0·17
Clopidogrel
14·9% 
(62/416)
17·7% 
(71/402)
0.29 12.6% (23/183)
16·8% 
(34/202)
0.24
16·7% 
(39/233)
18·5% 
(37/200)
0.63
Aspirin + 
Clopidogrel
12·5% 
(52/416)
15·9% 
(64/402)
0.16 10·9% (20/183)
14·8% 
(30/202)
0.25
13·7% 
(32/233)
17·0% 
(34/200)
0.35
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table 3: Lesion characteristics
Characteristic everolimus- eluting 
stent 
(619 lesions)
Paclitaxel- eluting 
stent
(589 lesions)
p value
Target lesion coronary artery 
    Left main 7 (1.1%) 8 (1.4%) 0.72
    Left anterior descending 245 (39.6%) 213 (36.2%) 0.14
    Left circumflex 152 (24.6%) 161 (27.3%) 0.22
    Right 215 (34.7%) 207 (35.1%) 0.87
    Bypass graft 15 (2.4%) 9 (1.5%) 0.67
ACC-AHA lesion class
    A 37 (6.0%) 16 (2.7%) 0.01
    B1 117 (18.9%) 122 (20.7%) 0.43
    B2 176 (28.4%) 188 (31.9%) 0.21
    C 289 (46.7%) 263 (44.6%) 0.51
De novo lesions 602 (97.2%) 582 (98.6%) 0.14
Thrombus present 272 (43.9%) 262 (44.5%) 0.87
Calcified lesion 172 (27.8%) 174 (29.5%) 0.47
Lesion length, mm (N) 22.3±17.2 (346) 22.8±19.1 (354) 0.68
Reference vessel diameter, mm (N) 2.67±0.58 (419) 2.70±0.65 (412) 0.55
Baseline minimal luminal diameter., mm (N) 0.78±0.58 (436) 0.84±0.58 (435) 0.10
Baseline stenosis, % lumen diameter (N) 72.4±21.2 (469) 70.7±20.4 (452) 0.22
Pre procedure TIMI flow
    Grade 0 171 (27.6%) 151 (25.6%) 0.45
    Grade 1 32 (5.2%) 36 (6.1%) 0.49
    Grade 2 58 (9.4%) 66 (11.2%) 0.20
    Grade 3 358 (57.8%) 336 (57.0%) 0.78
Number of stents per lesion* 1.6±0.8 1.5±0.8 0.06
Total stent length per lesion (mm)* 33.5±19,0) 33.0±21.5 0.70
TIMI flow: Thrombolysis in myocardial infarction flow. * data presented as mean± standard deviation
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table 4. Events and Endpoints 
everolimus-
eluting stent
(n=434)
Paclitaxel-
eluting stent
(n=429)
relative risk
(95% CI)
p value
events at 30 days
All-cause death 6  (1.4%) 5 (1.2%) 1.19 (0.36-3.86) 0.78
Cardiac death 6 (1.4%) 5 (1.2%) 1.19 (0.36-3.86) 0.78
Myocardial infarction 5 (1.2%) 11 (2.6%) 0.44 (0.16-1.28) 0.12
Q-wave 2 (0.5%) 3 (0.7%) 0.66 (0.11-3.92) 0.69
Non-Q-wave 3 (0.7%) 8 (1.9%) 0.37 (0..10-1.39) 0.12
Mortality or myocardial infarction 10 (2.3%) 15 (3.5%) 0.66 (0.30-1.45) 0.30
Cardiac mortality or myocardial infarction 10 (2.3%) 15 (3.5%) 0.66 (0.30-1.45) 0.30
TVR (Clinically Driven) 3 (0.7%) 9 (2.1%) 0.33 (0.09-1.21) 0.08
Percutaneous 0 (0.0%) 8 (1.9%) N.A. 0.004
Surgical 3 (0.7%) 1 (0.2%) 2.97 (0.31-28.4) 0.62
TVR (Any) 3 (0.7%) 9 (2.1%) 0.32 (0.09-1.21) 0.078
Percutaneous 0 (0.0%) 8 (1.9%) N.A. 0.004
Surgical 3 (0.7%) 1 (0.2%) 2.97 (0.31-28.4) 0.62
TLR (Clinically Driven) 3 (0.7%) 8 (1.9%) 0.37 (0.10-1.39) 0.12
Percutaneous 0 (0.0%) 7 (1.6%) N.A. 0.007
Surgical 3 (0.7%) 1 (0.2%) 2.97 (0.31-28.4) 0.62
TLR (Any) 3 (0.7%) 8 (1.9%) 0.37 (0.10-1.39) 0.12
Percutaneous 0 (0.0%) 7 (1.6%) N.A. 0.007
Surgical 3 (0.7%) 1 (0.2%) 2.97 (0.31-28.4) 0.62
Primary endpoint † 12 (2.8%) 17 (4.0%) 0.70 (0.34-1.44) 0.33
Secondary endpoint ‡ 12 (2.8%) 16 (3.7%) 0.74 (0.35-1.55) 0.42
ST (Definite and Probable) 1 (0.2%) 9 (2.1%) 0.11 (0.01-0.86) 0.01
Acute (On date of procedure) 0 (0.0%) 1 (0.2%) N.A. 0.50
Sub-Acute (1-30 days post-procedure) 1 (0.2%) 8 (1.9%) 0.12 (0.02-0.98) 0.020
(Definite) 1 (0.2%) 7 (1.6%) 0.14 (0.02-1.14) 0.037
Acute (On date of procedure) 0 (0.0%) 1 (0.2%) N.A. 0.50
Sub-Acute (1-30 days post-procedure) 1 (0.2%) 6 (1.4%) 0.16 (0.02-1.36) 0.068
events at 12 months
All-cause death 11 (2.5%) 14 (3.3%) 0.78 (0.36-1.69) 0.52
Cardiac death 8 (1.8%) 9 (2.1%) 0.88 (0.34-2.26) 0.79
Myocardial infarction 13 (3.0%) 24 (5.6%) 0.54(0.28-1.04) 0.06
Q-wave 2 (0.5%) 4 (0.9%) 0.49 (0.09-2.68) 0.45
 Non Q-wave 11 (2.5%) 20 (4.7%) 0.54 (0.26-1.12) 0.09
mortality or myocardial infarction 23 (5.3%) 37 (8.6%) 0.61 (0.37-1.02) 0.06
Cardiac mortality or myocardial infarction 20 (4.6%) 32 (7.5%) 0.62 (0.36-1.06) 0.08
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everolimus-
eluting stent
(n=434)
Paclitaxel-
eluting stent
(n=429)
relative risk
(95% CI)
p value
TVR (Clinically Driven) 9 (2.1%) 23 (5.4%) 0.39 (0.18-0.83) 0.01
Percutaneous 5 (1.2%) 18 (4.2%) 0.27 (0.10-0.73) 0.006
Surgical 4 (0.9%) 5 (1.2%) 0.79 (0.21-2.92) 0.75
TVR (Any) 9 (2.1%) 24 (5.6%) 0.37 (0.17-0.79) 0.007
Percutaneous 5 (1.2%) 19 (4.4%) 0.26 (0.10-0.69) 0.003
Surgical 4 (0.9%) 5 (1.2%) 0.79 (0.21-2.92) 0.75
TLR (Clinically Driven) 9 (2.1%) 20 (4.7%) 0.44 (0.20-0.97) 0.03
Percutaneous 5 (1.2%) 16 (3.7%) 0.31 (0.11-0.84) 0.01
Surgical 4 (0.9%) 4 (0.9%) 0.99 (0.25-3.93) 1.0
TLR (Any) 9 (2.1%) 22 (5.1%) 0.40 (0.19-0.87) 0.02
Percutaneous 5 (1.2%) 18 (4.2%) 0.27 (0.10-0.73) 0.006
Surgical 4 (0.9%) 4 (0.9%) 0.99 (0.25-3.93) 1.0
Primary endpoint † 28 (6.4%) 45 (10.5%) 0.62 (0.39-0.97) 0.03
Secondary endpoint ‡ 25 (5.8%) 38 (8.9%) 0.65 (0.40-1.06) 0.08
ST (Definite and Probable) 3 (0.7%) 13 (3.0%) 0.23 (0.07-0.79) 0.012
Late (30 days – 1 year post procedure) 2 (0.5%) 4 (0.9%) 0.49 (0.09-2.68) 0.45
Definite 1 (0.2%) 10 (2.3%) 0.10 ( 0.01-0.77) 0.006
Late (30 days – 1 year post procedure) 0 (0.0%) 3 (0.7%) N.A. 0.12
events at 24 months
All-cause death 17 (3.9%) 21 (4.9%) 0.80 (0.43-1.50) 0.48
Cardiac death 13 (3.0%) 13 (3.0%) 0.99 (0.46-2.11) 0.98
Myocardial infarction 18 (4.2%) 35 (8.2%) 0.51 (0.29-0.88) 0.01
Q-wave 2 (0.5%) 8 (1.9%) 0.25 (0.05-1.16) 0.06
Non Q-wave 16 (3.7%) 27 (6.3%) 0.59 (0.32-1.07) 0.08
Mortality or myocardial infarction 33 (7.6%) 55 (12.8%) 0.59 (0.39-0.89) 0.01
Cardiac mortality or myocardial infarction 29 (6.7%) 47 (11.0%) 0.61 (0.39-0.95) 0.03
TVR (Clinically Driven) 13 (3.0%) 34 (7.9%) 0.38 (0.20-0.71) 0.001
Percutaneous 9 (2.1%) 26 (6.1%) 0.34 (0.16-0.72) 0.003
Surgical 4 (0.9%) 9 (2.1%) 0.44 (0.14-1.42) 0.16
TVR (Any) 13 (3.0%) 35 (8.2%) 0.37 (0.20-0.68) < 0.001
    Percutaneous 9 (2.1%) 27 (6.3%) 0.33 (0.16-0.69) 0.002
    Surgical 4 (0.9%) 9 (2.1%) 0.44 (0.14-1.42) 0.16
TLR (Clinically Driven) 13 (3.0%) 28 (6.5%) 0.46 (0.24-0.87) 0.02
Percutaneous 9 (2.1%) 23 (5.4%) 0.39 (0.18-0.83) 0.01
Surgical 4 (0.9%) 6 (1.4%) 0.66 (0.19-2.32) 0.54
TLR (Any) 13 (3.0%) 30 (7.0%) 0.43 (0.23-0.81) 0.007
Percutaneous 9 (2.1%) 25 (5.8%) 0.36 (0.17-0.75) 0.005
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treatment effect in the NSTEMI subgroup and the remaining patients from 
the MI population (STEMI subgroup) is unlikely. The secondary endpoint, a 
device-oriented composite of cardiac death, non-fatal MI and TLR, at two 
years, occurred in 36 (8.3%) of patients assigned to EES and in 56 (13.1%) 
assigned to PES, (RR=0.64; 95% CI: 0.43-0.95, p=0.02). Similar to the primary 
endpoint, this difference was driven by a reduction in rates of both nonfatal 
MI and TLR, while no differences were observed in the rates of cardiac death 
(figure 1 and table 4). The stent thrombosis (definite and probable) rate at 
two years was significantly lower in the EES group: six (1.4%) compared to 
PES group: 20 (4.7%); RR=0.30; 95%CI: 0.12-0.73, p=0.005). As was the case 
in the general COMPARE population, a significant reduction in ST (definite 
and probable) was already evident at 30 days (EES: 1 (0.2%) vs. PES: 9 (2.1%); 
RR=0.11; 95%CI: 0.01-0.86, p=0.01) and the curves continued to diverge to 
the end of the second year (figure 2A). A significant reduction in ST (definite 
and probable) was also observed (figure 2b) also in the NSTEMI group at one 
year (EES: one (0.5%) vs. PES: nine (4.2%); RR=0.12; 95%CI: 0.02-0.97, p=0.02) 
and two years (EES: three (1.6%) vs. PES 13(6.0%); RR=0.26; 95%CI: 0.07-0.89, 
p=0.02). In the STEMI subgroup, the ST rates were lower in the EES group but 
the observed reduction in ST did not reach statistical significance (figure 2C). 
The lower rates of ST in the overall MI population treated with EES paralleled 
significantly better outcomes in the safety endpoint of all-cause mortality and/
or MI, with differences that continued to enhance during the two year follow-
up (table 4).
everolimus-
eluting stent
(n=434)
Paclitaxel-
eluting stent
(n=429)
relative risk
(95% CI)
p value
Surgical 4 (0.9%) 6 (1.4%) 0.66 (0.19-2.32) 0.54
Primary endpoint † 40 (9.2%) 69 (16.1%) 0.57 (0.40-0.83) 0.002
Secondary endpoint ‡ 36 (8.3%) 56 (13.1%) 0.64 (0.43-0.95) 0.02
Stent Thrombosis ARC  
   (Definite and Probable)
6 (1.4%) 20 (4.7%) 0.30 (0.12-0.73) 0.005
Late (30 days – 1 year) 2 (0.5%) 4 (0.9%) 0.49 (0.09-2.68) 0.45
Very late (1year  – 2 year ) 3 (0.7%) 7 (1.6%) 0.42 (0.11-1.63) 0.22
(Definite) 3 (0.7%) 14 (3.3%) 0.21 (0.06-0.73) 0.007
Late (30 days – 1 year) 0 (0.0%) 3 (0.7%) N.A. 0.12
Very late (1year  – 2 year ) 2 (0.5%) 4 (0.9%) 0.49 (0.09-2.68) 0.45
ST = stent thrombosis; TLR = target lesion revascularisation; TVR = target vessel revascularisation; ARC = 
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Figure 1 Kaplan-Meier cumulative event curves for all AMI patients and events rates split between STEMI 
and non-STEMI patients (bars) for (A) the primary endpoint, (b) secondary endpoint, (C) target vessel 
revascularization (TVR), (D) target lesion revascularization (TLR), (e) myocardial infarction (MI) and (f) All-
cause mortality, (G) Cardiac mortality. 
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Figure 2 Kaplan-Meier cumulative event curves for stent thrombosis (ST) for (A) all AMI patients, (b) 
STEMI patients, (C) non-STEMI patients. 
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DISCuSSIOn
The major finding of this study is that the use of the second generation EES, 
compared to PES, during percutaneous coronary intervention for myocardial 
infarction was associated with a significant reduction in the risk of both the 
primary endpoint –a patient-oriented composite of all-cause mortality, non-
fatal MI and TVR– and the principal secondary endpoint –a device-oriented 
composite of cardiac mortality, non-fatal MI and TLR. The improvement in 
event-free survival with the EES was driven by a reduction in repeat TVR, re-
flecting superiority in terms of efficacy, as well as a reduction in non-fatal MI, 
a safety component of the primary and secondary endpoint. There were no 
significant differences in rates of all-cause or cardiac mortality. With respect 
to the primary and secondary endpoints, the curves separated early and the 
effect grew in magnitude over the 2-year follow-up period. Another notable 
finding of this study is that the use of EES was associated with a significant re-
duction in ST, when compared to PES. The difference in ST outcomes between 
devices was apparent early and persisted at the end of the second year. As no 
significant differences were observed in baseline demographic or angiographic 
outcomes, the pathophysiologic mechanism(s) underlying the marked reduc-
tion in ST following EES, although speculative, may relate to specific design 
features of this stent. The combination of thin fracture-resistant struts, the low 
dose of everolimus, and the thromboresistant non-inflammatory proprieties 
of the fluorinated polymer, may contribute to the lower rates of early ST with 
EES.16,17 The lower rates of ST following EES at 30 days, one year and two years 
may be explained by more rapid and complete stent reendothelialisation as 
observed in pre-clinical animal models.18 As expected, the reduction in ST was 
paralleled by a significant reduction in the safety composite of cardiac death 
or MI. The use of EES was associated with a reduction in major adverse cardiac 
events in the subgroup of patients presenting with STEMI. This is the first study 
in which the outcome with EES has been shown to be superior to PES for a 
composite of all-cause mortality, non-fatal myocardial infarction and target 
vessel revascularisation, in the setting of STEMI. However, our findings are 
consistent with the results of other studies that used the same stents in this 
setting. The PES subgroup of the HORIZONS-AMI trial had similar clinical out-
comes to the PES subgroup of the present trial.3 Similarly, the outcomes with 
EES in our study are consistent with those observed in the STEMI subgroup 
of the RESOLUTE ALL-COMER trial.19 In the NSTEMI subgroup, a clear trend 
towards significance, with respect to the primary and secondary endpoint, was 
observed with EES. As the interaction p values for the primary and second-
Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction 65
Ch
ap
te
r 2
.3
ary endpoints, were not significant, it appears reasonable to conclude that a 
difference in the treatment effect tendency between STEMI and NSTEMI is un-
likely. Taken together, these findings suggest that the previously documented 
superiority, with regards to efficacy and safety endpoints, observed with EES 
can be extended to a high risk patient population presenting with AMI11,12. The 
ST rates with EES in the current study are comparable and numerically superior 
to those reported with BMS in historical comparisons20-22. This conclusion is also 
supported by the findings of the recently presented EXAMINATION trail, where 
EES is associated with significantly lower rates of definite as well as definite 
and probable ST compared to identically designed BMS, in setting of STEMI.23 
More widespread use of DES for treatment of AMI should be guided by cost 
effectiveness trials now that safety concerns have been largely resolved. This 
study has several limitations. This study presents a subgroup analysis from the 
randomised COMPARE study. However, randomisation was not stratified for 
the current subgroups, and therefore the number of patients in each treat-
ment arm is not completely balanced. Nevertheless, the baseline characteristics 
were well matched between groups. The study was not powered for any of 
the individual endpoints therefore, for certain endpoint components, this may 
result in beta-errors, especially when data are further divided and analysed 
in STEMI and NSTEMI subgroups. Therefore, larger randomised trials will be 
needed in the setting of MI. Finally, these results reflect the outcomes of PCI 
for treatment of MI from a single tertiary centre.
In conclusion, we have shown that the use of second-generation EES as 
compared to PES, is associated with significantly better outcomes, in terms 
of safety and efficacy endpoints at two year follow-up in patients presenting 
with MI. The use of EES compared to PES, is also associated with a significant 
reduction in rates of ST in MI patients. However, larger randomised trials, as 
well as cost-effectiveness analysis are required to further guide device choice 
in this setting.
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The XIENCE V (Abbott Vascular, CA, USA; also distributed as the PROMUS stent 
by Boston Scientific, MA, USA) everolimus-eluting stent (EES) is a second-
generation drug-eluting stent (DES) designed to overcome the limitations 
of earlier DESs. Clinical studies with first-generation sirolimus-eluting stents 
(SESs) and paclitaxel-eluting stents (PESs) dem onstrated a dramatic reduc-
tion in resteno sis rates compared with bare-metal stents (BMSs) 1,2; however, 
reintervention rates were still high in patients with complex coronary artery 
disease3, and an ongo ing propensity for stent thrombosis beyond 1 year raised 
further concerns regard ing safety issues with these devices4 . Furthermore, as 
both of these devices were relatively high-profile stainless steel stents, they 
were difficult to deliver in complex anatomy, and the SES in particular was 
prone to a high fracture rate, contributing to late adverse events. 
In the EES, everolimus, a rapamycin derivative, is released from a thin layer 
(7.8-μm) of a biocompatible fluoropolymer coated on an open-cell, thin-strut 
(81-μm) flexible and highly deliverable cobalt–chro mium stent. The polymer 
is inert and non inflammatory, and the stent is extremely resistant to fracture. 
Two moderate-sized trials with the EES demonstrated a sig nificant reduction 
in angiographic in-stent and in-segment late lumen loss compared with the 
first-generation TAXUS Express (PES) (Boston Scientific), and noninferior ity in 
major clinical end points 5,6. These findings suggested that, if tested in larger 
populations, the EES might achieve supe rior clinical outcomes compared with 
the earlier predicate devices. However, given the favorable outcomes with PES, 
large studies would be required to elicit small differences in low frequency but 
impor tant clinical end points. Toward this end, two large-scale randomized 
trials have been performed, the SPIRIT IV and COMPARE trials. 
SPIRIT IV was a prospective, multi center trial that randomized 3690 US patients 
in a 2:1 ratio to EES versus the TAXUS Express PES 7. The primary end point was 
a composite of target lesion failure (defined as cardiac death, tar get vessel 
myocardial infarction [MI] or ischemia-driven target lesion revascular ization 
[TLR]); the major secondary end points were ischemia-driven TLR and a com-
posite end point of cardiac death or target vessel MI at 1 year. SPIRIT IV is the 
largest completed randomized con trolled trial comparing two DESs to date, 
and was powered for sequential testing of noninferiority and superiority in its 
primary and both major sec ondary end points. The trial was large enough to 
provide data on other secondary end points and important subgroups, particu-
larly patients with diabetes mellitus, but excluded patients with acute coronary 
syndromes (ACSs) and ST-segment elevation MI (STEMI), large bifurcations and 
other complex lesion subsets. 
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Almost simultaneously, another prospective, randomized inves tigator-
initiated, single-center study, the COMPARE trial, was performed in The 
Netherlands 8. This trial randomized 1800 ‘all-comer’ patients (i.e., with limited 
exclusion criteria) in a 1:1 ratio between the EES and TAXUS Liberté PES, which 
shares the same polymer, drug and release kinetics with the TAXUS Express PES, 
but has thinner struts and more uniform scaffolding. The primary end point of 
COMPARE was a composite of all-cause mortality, non-fatal MI and clinically 
driven target vessel revascularization (TVR). Like SPIRIT IV, COMPARE was also 
powered for both noninferiority and superiority testing. This trial population 
rep resents a real-world population as there were no exclusion criteria other 
than general contraindications for DES (e.g., inability to take dual antiplatelet 
therapy), and was large enough to provide data on complex patient subsets 
including those with ACS and STEMI. In contrast to many prior DES studies, 
routine angiographic follow-up was not performed in either SPIRIT IV or COM-
PARE to avoid unnecessary and unplanned revascularization procedures 9–11. 
Both trials independently showed that the EES was superior to the PES 
(regardless of the TAXUS platform) with regard to their respective primary 
composite safety and efficacy end points (Table 1). These results were driven by 
table 1. One year clinical outcomes in the SPIRIT IV and COMPARE traials
Outcomes SPIrIt IV COMPAre
EES
(n = 2458)
PES
(n = 1229)
p value
EES
( n = 897)
PES
(n = 903)
p value
Death 1.0% 1.3% 0.61 2.0% 1.7% 0.58
Cardiac death 0.4% 0.4% 1.00 1.2% 1.1% 0.81
Non cardiac death 0.6% 0.8% 0.52
MI 1.9% 3.1% 0.02 2.8% 5.3% 0.007
-Q-wave 0.1% 0.4% 0.13 0.3% 1.2% 0.03
-Non-Q-wave 1.7% 2.8% 0.05 2.5% 4.3% 0.03
Target vessel MI 1.8% 2.9% 0.04
Ischemic TLR 2.5% 4.6% 0.001 1.7% 4.8% <0.001
Ischemic TVR 3.9% 5.9% 0.009 2.1% 5.6% <0.001
Stent thrombosis
(ARC def/prob†)
0.3% 1.1% 0.003 0.7% 2.5% 0.002
Major adverse cardiac events 
(death, MI or ischemic TLR)
6.2% 9.1% 0.02
Target lesion failure (cardiac death, 
target vessel MI or ischemic TLR)
4.2% 6.9% <0.001
†Definite and probable stent thrombosis referring to ARC definitions. ARC: Academic Research 
Consortium; EES: Everolimus-eluting stent; MI: Myocardial infarction; PES: Paclitaxel-eluting stent; TLR: 
Target lesion revascularization; TVR: Target vessel revascularization.
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significant reductions in clinically driven TLR and MI, findings that were in part 
due to a significant reduction in the rates of stent thrombosis with the EES, as 
well as to reduced late recurrent ischemia necessitating repeat percutane ous 
coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). 
No significant differences were observed in the rates of all-cause or cardiac 
mortality between the different stent platforms at 1 year. 
Based on the results of these two trials, the belief that had previously been 
held by some that clinically relevant differences between DES of various designs 
do not exist has clearly been discredited. These trials have also shown that low 
angiographic late loss (resulting in greater efficacy) as well as improved safety 
may be simultaneously achieved in a single DES platform. Although the lower 
rates of TLR and TVR with EES were predictable from previous studies in which 
late loss with EES was significantly lower than with PES, the marked (nearly 
75%) reduc tion in stent thrombosis observed with the EES was a surprising 
finding in its magnitude. Both trials showed strikingly similar relative risk 
reductions in thrombotic events with EES compared with PES at 30-day and 
1-year follow-up, with the majority of the stent thromboses occurring during 
the first 30 days. EES reduced stent thrombosis compared with PES in both the 
early (<30-day) and late (30-day to 1-year) phases. Until recently, the inter-
ventional community has been focused on very late stent thrombosis (after 1 
year) given the ongoing propensity of first-generation DES to occlude acutely 
after    1 year when compared with BMS 4,12. However, early stent thrombosis 
accounts for the majority of stent thrombosis events during follow-up13. This is 
even more evident in complex populations. In the Harmonizing Outcomes with 
Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) 
[14] and Synergy Between Percutaneous Coronary Intervention with Taxus and 
Cardiac Surgery (SYNTAX) [3] trials, stent thrombosis rates at  1 year were 3.2 
and 3.3%, respectively; 30-day stent thrombosis was responsible for approxi-
mately two-thirds of the events in both tri als. SPIRIT IV and COMPARE have 
now demonstrated that use of EES during this critical time period can markedly 
reduce the incidence of stent thrombosis. Longer-term follow-up from both 
studies is required to determine whether these findings persist or become even 
more pronounced. The mechanistic underpinnings of the marked reduction in 
stent thrombosis with EES (despite low angiographic late loss) are speculative, 
but may relate to certain stent design features. Specifically, the thinner stent 
struts in combination with a bio compatible fluoropolymer may result in more 
rapid strut coverage with functional endothelium15. Fluorinated polymers are 
also known to resist platelet and thrombus deposition16, 17. Because these trials 
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were not designed to study these issues, additional mechanistic studies are 
required to confirm the reasons underlying the enhanced safety of EES. 
Another important finding from the SPIRIT IV and COMPARE trials is that 
significantly fewer adverse events were observed with EES in complex patient 
and lesion subgroups, such as multivessel and small-vessel disease, chronic 
total occlusions, long lesions and ACS. Based on data from the SPIRIT IV and 
COMPARE trials, we examined how the results of the randomized SYNTAX trial 
3, a 1700-patient study of PES versus CABG in patients with left main and three-
vessel coronary artery disease, might have been influenced if EES was used in 
place of PES. SYNTAX showed superiority of CABG compared with PES at 1 year, 
a finding driven by more revascularization procedures in the PCI arm. In order 
to reach noninferiority between the PCI and CABG groups, a reduc tion of 20 
events with PCI was needed. Use of EES rather than PES in SYNTAX might have 
led to a total reduction of 81 events in the PCI group, such that the SYNTAX 
trial could have declared noninferiority for PCI. This analysis, of course, is only 
a hypothesis-generating exercise; whether PCI with the EES is truly noninferior 
(or superior) to CABG in patients with complex coronary artery disease can only 
be determined by a dedicated large randomized controlled trial. Such a study 
has recently been announced. The international Evaluation of XIENCE Prime 
versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascu-
larization (EXCEL) trial, set to begin in late 2010, will randomize approxi mately 
2500 patients with unprotected left main disease to CABG versus PCI with the 
next-generation EES (XIENCE Prime). For many years the relative clinical utility 
of rapamycin ana logue-based DES compared with PES in patients with diabe tes 
mellitus has been debated. With nearly 5500 randomized patients in SPIRIT IV 
and COMPARE (1510 [28%] of whom had diabetes), these trials had significant 
power to examine clin ical outcomes in this subgroup. Of note, while there was 
marked reduction in death or MI, stent thrombosis and TLR in non diabetic 
patients in both studies with EES compared with PES, no statistically signifi-
cant benefits were apparent with EES in diabetic patients. While differences 
may emerge between these devices with longer follow-up from SPIRIT IV and 
COMPARE, currently there is no conclusive clinical evidence that one stent is 
superior in diabetic patients. Larger dedicated randomized trials in diabetic 
patients would be useful. Considering that approximately 1 million patients 
with diabetes worldwide are treated with PCI each year, even small differences 
in treatment outcomes would have important implications for global health. 
Conversely, for every 1000 nondiabetic patients treated with the EES rather 
than the PES, approximately 14 stent thromboses and 52 occurrences of death, 
MI or TLR within 1 year would be prevented. 
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AbStrACt
Aims:
Recent studies have suggested that EES may reduce ST compared to PES, but no 
individual trial has been adequately powered for this endpoint. The incidence 
of stent thrombosis, as well as the impact of dual antiplatelet therapy (DAPT) 
discontinuation during the first 2 years following everolimus-eluting stent 
(EES) and paclitaxel-eluting stent (PES) deployment were therefore analyzed 
from a pooled, patient-level database derived from four randomized clinical 
trials.
Methods and results: 
Data from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials (n=6,789 pa-
tients) were analyzed. Two-year ST rates were determined using time-to-event 
methods and compared with the log-rank test. ST rates were also determined 
after DAPT discontinuation. EES compared to PES significantly reduced the 
2-year rates of ST (0.7% versus 2.3%, p=0.0001), including the interval rates 
of ST up to 30 days (0.2% versus 1.0%, p<0.0001), between 31 days and 1 year 
(0.2% versus 0.6%, p=0.02), and after 1 year (0.3%  versus 0.8%, p=0.001). EES 
also reduced the 2-year composite rate of cardiac death or MI (4.0% versus 
6.6%, p=0.0001). Increased rates of ST after DAPT discontinuation beyond 6 
months were observed in the PES cohort, but not in the EES cohort. 
Conclusion: 
In this large pooled analysis from four randomised trials, treatment with EES 
compared to PES significantly reduced the rates of ST through 2 years of follow-
up, with a concomitant reduction in cardiac death or MI. DAPT discontinuation 
beyond 6 months may be safe with EES. 
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IntrODuCtIOn
Paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES) substantially 
reduce target lesion and vessel re-intervention rates compared to bare metal 
stents.1,2 However, increased rates of very late stent thrombosis (ST), particu-
larly in high risk patient populations,3,4 remain a matter of concern with these 
first generation drug-eluting stents.5 
Second generation drug-eluting stents have been designed to improve 
procedural performance as well as safety and efficacy of the first gen-
eration devices. Specifically, a second generation, thin-strut, cobalt-chromium, 
everolimus-eluting stent (EES) demonstrated significant improvements in 
angiographic and clinical outcomes when compared to PES in two small to 
moderate sized randomised trials6,7. Thereafter two large clinical trials, SPIRIT 
IV8 and COMPARE9, tested the same hypothesis in greater numbers of patients 
with either non-complex coronary artery disease or all-comers, respectively. 
Both trials reported significant improvements in safety and efficacy endpoints 
as well as reductions in definite ST and definite/probable ST rates, in favour 
of EES. However, no individual trial was adequately powered to examine the 
incidence rates of ST, or to determine the impact of dual antiplatelet therapy 
(DAPT) interruption on ST outcomes in the EES and PES cohorts separately. For 
this purpose we pooled patient-level data from the four randomized trials 
in which the outcomes of EES compared to PES in 6,789 patients have been 
examined.  
MetHODS
The designs of SPIRIT II, SPIRIT III, IV and COMPARE trials have previously been 
described.6-9 Briefly, each study was a prospective, single-blind, randomized 
controlled clinical trial in which patients were assigned to receive either EES 
(manufactured and distributed as Xience V by Abbott Vascular, Santa Clara, 
CA; also distributed as Promus by Boston Scientific, Natick, MA) or PES (TAXUS 
Express2, or TAXUS Liberté, Boston Scientific). The SPIRIT trials enrolled pa-
tients with simple and moderately complex coronary lesions, excluding those 
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with acute or recent myocardial infarction and difficult or high-risk lesions 
such as chronic total occlusions, true bifurcations, thrombus, and lesions in the 
left main coronary artery or a saphenous vein graft. COMPARE was an “all-
comers” trial, excluding from randomization only patients unable to comply 
with DAPT for a period of 12 months, and those presenting in cardiogenic 
shock. Aspirin ≥75 mg daily was recommended for a minimum of 1 year in 
SPIRIT II and indefinitely in the other trials.  Clopidogrel (75 mg daily) was 
prescribed by protocol for ≥6 months in SPIRIT II and III and for ≥12 months in 
SPIRIT IV and COMPARE.  Each study employed an independent, angiographic 
core laboratory as well as independent clinical event adjudication committees, 
blinded to stent assignment. Follow-up is planned for 5 years in each trial, and 
is currently complete through at least 2 years in all four studies. 
 For the present analysis, baseline clinical, angiographic and procedural data 
of these four trials were pooled to allow for a patient-level analysis. Events 
as adjudicated in each trial were utilized. The purpose of this analysis was 
to examine the incidence rates of ST as defined by the ARC definite and/or 
probable definition,10 including examining the outcomes after DAPT discon-
tinuation. The rates of definite ST and definite/probable ST were examined in 
the following periods: early (0-30 days); late (31 days to 1 year); cumulative to 
1 year; very late (1-2 years); and cumulative to 2 years.
To analyze the impact of DAPT interruption on subsequent, definite ST and 
definite/probable ST, four groups of patients were identified: patients who 
permanently discontinued DAPT (either aspirin and/or a thienopyridine) be-
tween 1 and 6 months, between 6 and 12 months, between 12 and 24 months, 
and those who were still taking DAPT at 24 months. DAPT compliance was 
ascertained for all studies at discharge, 1, 6, 12, and 24 months, as well as 
at the time of adverse events. Patients in whom a ST occurred while not on 
DAPT were included in the respective DAPT interruption group based on their 
DAPT status at the time of the event, regardless of DAPT usage afterwards. 
Moreover, only patients with definitely known DAPT status at each time point 
through the 2-year follow-up were included in the present analysis. Thus, 183 
patients (2,7% ), including seven of whom (0,1%) who had a ST (all between 
0-30 days) were not included in this analysis due to unknown DAPT status after 
the event. Only 36 patients (0,5%), discontinued DAPT before 1 month; given 
the small size of this group these patients were excluded from the analysis. 
Only the first ST episode was considered; patients with ST were not included 
in the denominator of subsequent time periods. Finally, to test whether DAPT 
may be safely permanently discontinued beyond 6 months after DES implanta-
tion, definite ST and definite/probable ST rates at 2 years were compared in 
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following groups using a landmark analysis beyond 6 months: patients who 
permanently discontinued DAPT between 6 and 12 months, those who per-
manently discontinued DAPT between 12 and 24 months, and those who were 
still taking DAPT at 24 months. 
All analyses were done by intention to treat. Categorical outcomes were 
compared by chi-square or Fisher’s exact test. Continuous variables are pre-
sented as mean ± S.D. and were compared by t-test. The 2-year event analyses 
were performed using time-to-event data, are displayed using Kaplan-Meier 
plots, and were compared with the log-rank test. To adjust for slight differ-
ences in the baseline characteristics of the study population, a propensity score 
matching analysis was performed using the covariates in Tables 1 and 2. The 
propensity score estimates were entered into the multivariable model, and 
adjusted Kaplan-Meier curves and HR were derived.  A two-sided α=0.05 was 
used for all superiority testing. All statistical analyses were performed by SAS 
version 9.1.3 (SAS Institute, Cary, NC).
reSultS
baseline characteristics. 
Pooling the four trials resulted in a total of 6,789 patients randomized to 
treatment with EES (n=4247; 63%) or PES (n=2542; 37%). Clinical follow-up at 
2 years was available in 96,2% EES and 96,1% PES treated patients. Baseline 
patient demographic characteristics as well as angiographic and procedural 
characteristics are shown in Tables 1 and 2 respectively. Baseline coronary risk 
factors were similar between randomly assigned stent types except that EES 
patients had a slightly higher incidence of hyperlipidemia and hypertension, 
while PES patients had a slightly higher rate of ACS at presentation. Minor 
imbalances in several angiographic variables, including the rates of total 
occlusion, presence of thrombus, moderate or severe calcification, modified 
ACC/AHA Class C lesion morphology, target lesion length and stented length 
were also present. Compliance with DAPT was similar between the randomly 
assigned stent types through 1-year of follow-up; at 2 years, aspirin usage was 
not significantly different between the groups, but thienopyridine usage was 
slightly more common in the EES group (Table 3).
Clinical events. 
Outcomes of unadjusted early, late and very late definite ST and definite/
probable ST as well as rates of cardiac death or MI with follow-up to 2 years 
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table 1.   Baseline patient demographic characteristics
  everolimus-eluting stents Paclitaxel-eluting stents P-Value
Age (years) 63.09 ± 10.61 (4247) 63.36 ± 10,68 (2541) 0.30
Gender: Male 68.5% (2911/4247) 69.5% (1766/2541) 0.42
Diabetes mellitus 28.0% (1188/4244) 26.9% (681/2536) 0.31
   - Insulin-treated 7.3% (310/4244) 7.3% (184/2536) 0.96
Smoking During Past Year 25.0% (1042/4176) 25.0% (624/2493) 0.95
Hypertension 70.1% (2976/4243) 66.1% (1677/2537) 0.0006
Hyperlipidemia 70.5% (2949/4184) 65.8% (1658/2518) <0.0001
Prior CABG 7.2% (306/4244) 6.0% (153/2541) 0.06
Prior myocardial infarction 20.4% (847/4157) 19.0% (476/2508) 0.17
Prior percutaneous intervention 14.5% (610/4194) 13.9% (350/2516) 0.49
Stable angina 53.8% (2254/4193) 49.8% (1248/2506) 0.002
Unstable angina 22.9% (959/4193) 22.3% (559/2506) 0.61
Stable ischemic heart disease 67.2% (2854/4247) 61.1% (1551/2539) <0.0001
Acute coronary syndrome 32.8% (1393/4247) 38.9% (988/2539) <0.0001
table 2. Baseline angiographic and procedural characteristics.
  everolimus-eluting stents
Paclitaxel-eluting 
stents
P-Value
Vessel Location--RCA 34.2% (1865/5460) 33.8% (1132/3353) 0.71
Vessel Location--LAD 40.5% (2209/5460) 39.6% (1329/3353) 0.45
Vessel Location--LCX 25.0% (1364/5460) 25.9% (870/3353) 0.31
Vessel Location--LM 0.4% (22/5460) 0.7% (22/3353) 0.12
Vessel Location--SVG 0.5% (27/5460) 0.7% (24/3353) 0.19
Total Occlusion - Baseline 2.0% (109/5460) 3.5% (117/3353) <0.0001
Calcification, Mod-Severe 14.3% (775/5433) 17.8% (596/3341) <0.0001
Thrombus 7.2% (392/5434) 10.3% (346/3345) <0.0001
Modified ACC/AHA Lesion Class A 9.0% (487/5417) 9.3% (309/3334) 0.67
Modified ACC/AHA Lesion Class B1 33.6% (1820/5417) 31.8% (1060/3334) 0.08
Modified ACC/AHA Lesion Class B2 31.7% (1716/5417) 31.0% (1034/3334) 0.52
Modified ACC/AHA Lesion Class C 25.7% (1394/5417) 27.9% (931/3334) 0.02
Baseline  TIMI Flow: 0 4.8% (241/5068) 7.0% (217/3095) <0.0001
Baseline  TIMI Flow: 1 2.2% (110/5068) 2.6% (80/3095) 0.23
Baseline  TIMI Flow: 2 6.6% (337/5068) 7.9% (246/3095) 0.03
Baseline  TIMI Flow: 3 86.4% (4380/5068) 82.5% (2552/3095) <0.0001
Number treated lesions 1.29 ± 0.53 (4246) 1.32 ± 0.57 (2540) 0.02
Number treated vessels 1.20 ± 0.43 (4246) 1.22 ± 0.44 (2541) 0.04
Pre-procedure lesion length (mm) 15.96 ± 9.50 (4963) 16.78 ± 11.60 (2867) 0.001
Pre-procedure reference vessel diameter 
(mm)
2.68 ± 0.51 (5077) 2.68 ± 0.54 (2958) 0.88
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Pre-procedure MLD (mm) 0.80 ± 0.42 (5103) 0.83 ± 0.44 (2986) 0.01
Pre-procedure% diameter stenosis 70.3 ± 14.7 (5147) 69.5 ± 15.5 (3007) 0.03
Total stent length implanted (mm) 32.2 ± 21.6 (4227) 34.0 ± 25.8 (2530) 0.004
Total number stents implanted 1.7 ± 1.0 (4238) 1.7 ± 1.1 (2538) 0.05
RCA = Right coronary artery; LAD = Left anterior descending; LCX= Left circumflex; LM = Left main; MLD = 
Minimal lumen diameter SVG = Saphenous vein graft; TIMI score = Thrombolysis In Myocardial Infarction 
score.
table 3.   Dual antiplatelet therapy compliance according to stent type
 
everolimus-eluting 
stents
Paclitaxel-eluting 
stents
P-Value
discharge      
Aspirin 97.3% (4123/4238) 96.9% (2454/2533) 0.33
Clopidogrel 98.9% (4191/4238) 99.1% (2509/2533) 0.62
Ticlopidine 0.4% (15/4238) 0.3% (8/2533) 1.00
Any thienopyridine 99.3% (4208/4238) 99.4% (2517/2533) 0.76
Aspirin + any thienopyridine 96.9% (4106/4238) 96.7% (2449/2533) 0.67
6-months
Aspirin 95.9% (4047/4220) 94.5% (2379/2517) 0.01
Clopidogrel 95.3% (4021/4220) 95.7% (2408/2517) 0.51
Ticlopidine 0.2% (10/4220) 0.2% (5/2517) 1.00
Any Thienopyridine 96.8% (4085/4220) 96.9% (2439/2517) 0.89
Aspirin + any thienopyridine 93.6% (3964/4233) 92.5% (2338/2528) 0.07
1-Year      
Aspirin 93.7% (3929/4194) 92.7% (2318/2501) 0.12
Clopidogrel 80.6% (3379/4194) 80.4% (2010/2501) 0.85
Ticlopidine 0.2% (9/4194) 0.2% (5/2501) 1.00
Any thienopyridine 81.7% (3428/4194) 81.3% (2033/2501) 0.65
Aspirin + any thienopyridine 78.3% (3310/4230) 77.0% (1941/2522) 0.23
2-Year      
Aspirin 91.0% (3772/4144) 91.1% (2243/2461) 0.89
Clopidogrel 52.4% (2170/4144) 47.3% (1163/2461) <0.0001
Ticlopidine 0.2% (8/4144) 0.1% (2/2461) 0.34
Any thienopyridine 53.3% (2209/4144) 47.8% (1177/2461) <0.0001
Aspirin + any thienopyridine 50.0% (2107/4215) 44.5% (1117/2508) <0.0001
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are shown in Table 4 and Figure 1a and 1b. EES resulted in a 70% reduction in 
the rate of definite/probable ST at 2 years compared to PES, with significant 
interval reductions in early, late and very late ST. Similarly, EES resulted in a 
70% reduction in the rate of angiographically confirmed definite ST at 2 years 
compared to PES, with significant reductions in definite ST during each interval, 
including at 30 days and 1 year. After propensity adjustment for differences in 
the baseline clinical and angiographic characteristics, EES showed comparable 
reductions in rates of definite/probable ST at 30 days (0.3% (8) versus 1.0% 
(24), HR: 0.33, 95% CI [0.15,0.74], p=0.005), 1 year (0.6% (13) versus 1.5% (35); 
HR: 0.37; 95% CI: [0.20, 0.70], p=0.0001) and 2 years (0.9% (19) versus 2.2% 
(51); HR: 0.37; 95% CI [0.22,0.63], p=0.0001), (Figure 1c and 1d).
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Figure 1dFigure 1 Time-to-event c rves for ARC definite/probable stent thrombosis (A) and ARC definite stent 
thrombosis (B), propensity score adjusted ARC definite/probable stent thrombosis (C) and propensity 
score adjusted ARC definite stent thrombosis (D) through 2-year follow-up. EES denotes everolimus-
eluting stents. PES denotes paclitaxel-eluting stents. 
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Reduced definite ST and definite/probable ST rates with EES paralleled a sig-
nificant reduction in the composite rate of cardiac death or MI in each time 
period and at 2 years (Table 4). 
Stent thrombosis according to dual anti-platelet therapy use.
The 2-year ST rates from the four groups according to DAPT compliance in 
the EES and PES cohorts are presented in Table 5. No significant differences 
in 2-year definite ST and definite/probable rates according to early DAPT 
discontinuation were observed between the four groups in the EES cohort. In 
contrast, a significant increase in the rate of definite/probable ST was observed 
in the PES patients who interrupted DAPT between 1 and 6 months. After 
excluding the ST events of the first 6 months, the overall 2-year definite/prob-
table  4. Unadjusted rates of stent thrombosis, cardiac death and myocardial infarction 
 
everolimus-
eluting stents
Paclitaxel-
eluting stents
Hazard ratio
[95% C.I.]
P-Value
Early Stent Thrombosis (0-30 Days)
ARC Definite 0.2% (9) 0.8% (19) 0.28 [0.13,0.63] 0.0009
ARC Probable 0.0% (0) 0.2% (6) - 0.001
ARC Definite/Probable 0.2% (9) 1.0% (25) 0.21 [0.10,0.46] <0.0001
Late Stent Thrombosis (31-365 Days)
ARC Definite 0.1% (5) 0.4% (10) 0.30 [0.10,0.87] 0.02
ARC Probable 0.1% (4) 0.2% (5) 0.48 [0.13,1.77] 0.26
ARC Definite/Probable 0.2% (9) 0.6% (14) 0.38 [0.17,0.88] 0.02
Stent Thrombosis (0-365 Days)
ARC Definite 0.3% (14) 1.2% (29) 0.29 [0.15,0.54] <0.0001
ARC Probable 0.1% (4) 0.4% (11) 0.22 [0.07,0.68] 0.004
ARC Definite/Probable 0.4% (18) 1.5% (38) 0.28 [0.16,0.49] <0.0001
Very Late Stent Thrombosis (366-730 
Days)
ARC Definite 0.2% (6) 0.5% (11) 0.32 [0.12,0.87] 0.02
ARC Probable 0.1% (4) 0.3% (8) 0.30 [0.09,0.99] 0.04
ARC Definite/Probable 0.3% (10) 0.8% (19) 0.31 [0.14,0.67] 0.001
Stent Thrombosis (0-730 Days)
ARC Definite 0.5% (20) 1.6% (39) 0.30 [0.18,0.52] <0.0001
ARC Probable 0.2% (8) 0.8% (19) 0.25 [0.11,0.57] 0.0004
ARC Definite/Probable 0.7% (28) 2.3% (56) 0.30 [0.19,0.47] <0.0001
Cardiac Death or MI (0-30 Days) 1.6% (68) 2.8% (70) 0.58 [0.41,0.81] 0.001
Cardiac Death or MI (0-365 Days) 2.7% (113) 4.5% (114) 0.59 [0.45,0.76] <0.0001
Cardiac Death or MI (0-730 Days) 4.0% (166) 6.6% (163) 0.60 [0.48,0.74] <0.0001
 ARC = Academic Research Consortium; MI = Myocardial Infarction
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Figure 2
Two-year Cumulative Definite/Probable Stent Thrombosis (ARC)
Landmark Analysis Beyond 6 Months
Figure 2 Cumulative 2 year rates of definite or probable stent thrombosis after excluding events from 
the first 6 months in subjects that discontinued dual antiplatelet therapy (DAPT) between 6-12 months, 
between 12-24 months, and subjects still on DAPT at 24 months in the everolimus-eluting stent EES  
and paclitaxel-eluting stent cohorts respectively. EES denotes everolimus-eluting stents. PES denotes 
paclitaxel-eluting stents. 
table 5. Stent thrombosis rates at 2 years according to randomized stent type and dual antiplatelet 
therapy compliance 
Group a Group b Group c Group d Combined p value
eeS cohort* 75.0% 
(75/100)
92.3% 
(562/609)
97.8% 
(1168/1194)
97.5% 
(1969/2019)
96.2% 
(3774/3922)
<0.0001
ARC Definite 1.1% (1) 0.2% (1) 0.3% (4) 0.6% (11) 0.5% (17) 0.43
ARC Probable 0.0% (0) 0.3% (2) 0.2% (2) 0.2% (4) 0.2% (8) 0.86
ARC Def/Prob 1.1% (1) 0.5% (3) 0.5% (6) 0.8% (15) 0.7% (25) 0.75
PeS cohort* 74.3% (55/74)
94.6% 
(336/355)
98.2% 
(808/823)
97.1% 
(1023/1054)
96.4% 
(2222/2306)
<0.0001
ARC Definite 6.2% (4) 1.1% (4) 1.4% (11) 1.3% (14) 1.5% (33) 0.01
ARC Probable 0.0% (0) 1.2% (4) 1.0% (8) 0.3% (3) 0.7% (15) 0.16
ARC Def/Prob 6.2% (4) 2.3% (8) 2.3% (19) 1.5% (16) 2.1% (47) 0.05
* Patients without events that had at least 700 days of follow-up. Group a: DAPT interrupted between 1-6 
months; Group b: DAPT interrupted between 6-12 months; Group c: DAPT interrupted between 12-24 
months; Group d: No DAPT interruption up to 24 months; EES denotes everolimus-eluting stent. PES 
denotes paclitaxel-eluting stent; ST : Stent Thrombosis; ARC : Academic Research Consortium; DAPT : Dual 
Antiplatelet Therapy; Def/Prob: Definite and Probable 
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able ST rates in the groups of  patients who permanently discontinued DAPT 
between 6-12 months, between 12-24 months and who were still on DAPT at 
24 months were 0.3% (n=2), 0.4%  (n=5) and 0.4% (n=8), respectively in the 
EES cohort (p for trend=0.97), and 1.2% (n=4), 1.7% (n=14) and 0.5% (n=5) in 
the PES cohort (p for trend=0.04) (Figure 2).
DISCuSSIOn
The major finding of the present pooled analysis from 4 randomized trials is 
that EES markedly reduced the 2-year rates of definite ST and definite/prob-
able ST compared to PES. A significant difference in ST frequency was present 
at every interval examined through the 2-year follow-up period. The reduction 
in definite ST and definite/probable ST was accompanied by a reduction in the 
composite occurrence of cardiac death or MI. Finally, DAPT discontinuation be-
yond 6 months (and any time before 2 years) was associated with an increased 
risk of ST with PES, but not with EES. 
The benefits of reduced clinical restenosis achieved with first generation DES 
compared to BMS were offset in many studies by higher rates of very late ST.4.5 
Furthermore, the on-going propensity for ST with first generation DES has 
generated reluctance regarding unrestricted use of DES, and recommenda-
tions for long-term use of DAPT, despite the lack of evidence that such an 
approach improves clinical outcomes post PCI.  The present study establishes 
that gains in safety as well as efficacy11,12 may be achieved by a single stent 
platform (EES). Of note, however, the present pooled analysis refers only to 
the results of EES vs PES; further study is required to determine whether these 
results apply to other second and third generation DES. 
Stent thrombosis.
Both unadjusted and propensity score adjusted  multivariable analysis, showed 
significant and important reductions on rates of definite ST and definite/prob-
able ST. The pathophysiologic mechanism(s) underlying the marked reduction 
in ST following EES are speculative, but may relate to specific stent design 
features.  The combination of thin fracture-resistant struts with everolimus 
released from a thromboresistant non-inflammatory fluorinated polymer13,14  
may contribute to the lower rates of early ST with EES.  In pre-clinical animal 
models more rapid and complete stent re-endothelialization has been seen 
with EES compared to other DES.15 Reduction in inflammation along with the 
faster and more complete reendothelialisation may result in lower rates of 
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early, late and very late ST.  Moreover, despite the focus of the physician and 
public on very late ST (beyond 1 year) with first-generation DES when com-
pared with BMS,3,16 early ST accounts for a substantial proportion of total ST 
events. While low rates of late and very late ST have been reported with other 
new DES,17-19 the EES is the only second generation DES which has repeatedly 
shown a reduced rate of definite ST events, especially in the early period.9,18.
DAPt interruption analysis. 
The premise that EES-treated patients may require shorter durations of DAPT is 
supported by the findings of the current analyses. Interruption of DAPT at any 
time point after the first month did not influence the rate of ST at two years in 
the EES cohort. After excluding events within the first 6 months, no difference 
was observed with regard to definite ST and definite/probable ST rates in the 
EES cohort regardless of DAPT compliance, suggesting that permanent DAPT 
interruption beyond 6 months following EES implantation may be safe. This 
observation is consistent with the Xience USA registry where DAPT interrup-
tion at any time point beyond 180 days following EES implantation was safe 
in an unselected (all-comers) population.20 Continued exposure to DAPT after 
6 months may expose EES-treated patients to increased bleeding risk without 
efficacy benefit.21 However, large-scale randomized trials are required to con-
firm the safety of permanent DAPT discontinuation at 6 months (or earlier) in 
EES-treated patients before this practice can be routinely recommended.
In contradistinction, we found that discontinuation of DAPT following PES de-
ployment any time before 24 months (but especially between 1 and 6 months) 
was associated with increased rates of definite/probable ST. Similarly, Eisenstein 
and colleagues reported increased rates of death or myocardial infarction when 
DAPT was discontinued after 6 months or after 12 months with first generation 
DES.22 In contrast, Airoldi et al reported that ST rates with first generation DES 
were increased when DAPT discontinuation occurred prior to 6 months (com-
pared with continued DAPT therapy), but not after 6 months,23 and Park and 
colleagues did not find that extended clopidogrel use after 1 year prevented 
ST.24 Additional large-scale randomized trials are underway to clarify the relative 
risks and benefits of prolonged DAPT use after first generation DES.25
limitations.
This study has several limitations.  Despite the randomized design of the 4 
component trials, slight imbalances in baseline covariates between the two 
randomly assigned stents were observed after pooling. However, after pro-
pensity score adjustment the HRs for definite ST and definite/probable ST did 
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not directionally differ from the unadjusted HRs. Additional confounding 
variables (either measured or unmeasured) not incorporated in this analysis 
may have influenced the study observations as well. Angiographic measures of 
reference vessel diameter and lesion length were assessed by an independent 
core laboratory in the SPIRIT trials, and by operator assessment in COMPARE. 
Outcomes of ST in high risk categories of patients presenting with acute 
coronary syndromes or diabetes mellitus were not the focus of this analysis, 
as they have previously been. 26,27 Subjects in the present analysis were not 
randomized by duration of DAPT compliance. A small percentage of patients 
with definite ST and definite/probable ST were excluded from this analysis 
due to unknown DAPT status at multiple time points after the event; however 
all patients in whom ST occurred between 0-30 days were taking DAPT at the 
time of the event. Finally, bleeding was not a focus of these trials, and long-
term DAPT may entail hemorrhagic risks which may offset their advantages. 
For all of these reasons the findings of the present study should be considered 
hypothesis-generating, requiring confirmation in appropriately designed and 
powered randomized trials.
Conclusions.
The present large-scale patient-level pooled database from four randomized 
trials has shown that EES significantly reduces definite ST and definite/prob-
able ST rates compared to PES. This major safety benefit was evident early 
(within 30 days) and increased in magnitude during the 2-year follow-up dura-
tion. The reduction in ST was paralleled by a reduction in the combined rate 
of cardiac death or MI with EES compared to PES. Finally the present analysis 
suggests that permanent DAPT discontinuation beyond 6 months may be safe 
following EES implantation.  
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AbstrAct
background
Some (but not all) prior trials have reported differential outcomes after percu-
taneous coronary intervention with paclitaxel-eluting stents versus stents elut-
ing rapamycin analogs according to the presence of diabetes mellitus These 
studies lacked sufficient power to examine individual safety and efficacy end 
points.
Methods and results
To determine whether an interaction exists between the presence of diabe-
tes mellitus and treatment with everolimus-eluting stents compared with 
paclitaxel-eluting stents, we pooled the databases from the Clinical Evaluation 
of the Xience V Everolimus Eluting Coronary Stent System in the Treatment 
of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) II, SPIRIT 
III, SPIRIT IV, and A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting 
Stents for Coronary Revascularization in Daily Practice (COMPARE) trials in 
which percutaneous coronary intervention was performed in 6780 patients, 
1869 (27.6%) of whom had diabetes mellitus. Patients without diabetes mel-
litus treated with everolimus-eluting stents compared with paclitaxel-eluting 
stents had significantly reduced 2-year rates of mortality (1.9% versus 3.1%; 
P=0.01), myocardial infarction (2.5% versus 5.8%; P<0.0001), stent thrombosis 
(0.3% versus 2.4%; P<0.0001), and ischemia-driven target lesion revasculariza-
tion (3.6% versus 6.9%; P<0.0001). In contrast, among patients with diabetes 
mellitus, there were no significant differences between the 2 stent types in any 
measured safety or efficacy parameter. Significant interactions were present 
between diabetic status and stent type for the 2-year end points of myocardial 
infarction (P=0.01), stent thrombosis (P=0.0006), and target lesion revascular-
ization (P=0.02).
Conclusions
We have identified a substantial interaction between diabetes mellitus and 
stent type on clinical outcomes after percutaneous coronary intervention. In 
patients without diabetes mellitus, everolimus-eluting stents compared with 
paclitaxel-eluting stents resulted in substantial 2-year reductions in death, 
myocardial infarction, stent thrombosis, and target lesion revascularization, 
whereas no significant differences in safety or efficacy outcomes were present 
in diabetic patients.
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Clinical trial registration
URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00180310 (SPIRIT II),
NCT00180479 (SPIRIT III), NCT00307047 (SPIRIT IV), and NCT01016041 (COM-
PARE).
(Circulation. 2011;124:893-900.)
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IntroductIon 
Patients with diabetes mellitus undergoing percutaneous coronary interven-
tion with bare metal stents have higher rates of angiographic and clinical re-
stenosis than patients without diabetes mellitus.1,2 Compared with bare metal 
stents, drug-eluting stents (DES) have been shown to be safe3 and to result 
in greater absolute reductions in target lesion revascularization (TLR) and 
target vessel revascularization in patients with versus those without diabetes 
mellitus.4–6 However, whether the presence of diabetes mellitus differentially 
affects the relative clinical outcomes with different types of DES is a matter 
of considerable debate. Most prior studies have shown comparable rates of 
angiographic in-stent late loss and clinical restenosis with paclitaxel-eluting 
stents (PES) in patients with versus without diabetes mellitus.7 In contrast, 
whether the relatively greater suppression of neointimal hyperplasia observed 
from stents that elute rapamycin analogs (such as sirolimus or everolimus) is 
preserved in patients with diabetes mellitus is unsettled. In this regard, several 
small to moderate-sized studies have provided conflicting results.8,9 Moreover, 
none of these prior trials was powered to deter-mine whether there are dif-
ferences in safety outcomes between different DES according to the presence 
of diabetes mellitus.
The outcomes of patients undergoing percutaneous coronary intervention 
with PES compared with everolimuseluting stents (EES) have been examined in 
4 prospective randomized trials that have demonstrated that EES is both safer 
and more effective over a broad cross section of patients and lesion types.10–15 
We therefore pooled the databases from these 4 trials to determine whether 
an interaction exists between the presence of diabetes mellitus and treatment 
with EES compared with PES.
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MetHODS
Study Protocols
The features of the Clinical Evaluation of the Xience V Everolimus Eluting Coro-
nary Stent System in the Treatment of Patients With De Novo Native Coronary 
Artery Lesions (SPIRIT) II, SPIRIT III, SPIRIT IV, and A Trial of Everolimus-Eluting 
Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily 
Practice (COMPARE) trials are shown in Table 1. As previously described, 10–15 
each study was a prospective, randomized, single-blind trial of EES versus PES. 
Randomization in the SPIRIT II, SPIRIT III, and SPIRIT IV trials was stratified by 
the presence of medically treated diabetes mellitus. The PES platform used in 
the SPIRIT trials was the TAXUS EXPRESS; the TAXUS Liberte´ was used in COM-
PARE. The SPIRIT trials enrolled patients with simple and moderately complex 
coronary artery disease, excluding patients with acute or recent myocardial 
table 1. Description of the prospective, randomized SPIRIT and COMPARE trials
SPIrIt II SPIrIt III SPIrIt IV COMPAre
Geography
EU, India, and 
New Zealand
US US Netherlands
Number of sites 28 65 66 1
Number of ITT patients 300 1,002 3,687 1,800
Number of patients with 
diabetes mellitus*
69/299 (23.1%) 290/999 (29.0%) 1195/3683 (32.4%) 325/1799 (18.1%)
Randomization EES:PES 3:1 2:1 2:1 1:1
PES platform Express Express Express Liberté
Primary endpoint(s)
In-stent LL at 
6 months
In-segment LL 
at 8 months and 
TVF at 9 months
TLF at 12 months
MACE at 12 
months
Recruitment period
July, 2005 - 
November, 2005
June, 2005 
-March, 2006
August, 2006 -
July, 2008
February, 2007 
-September, 2008
RVD (mm) 2.5-4.25 2.5-3.75 2.5-3.75
No pre-specified 
criteria
Lesion length (mm) ≤28 ≤28 ≤28 No limit
Maximum lesions/patient 2 2 3 No limit
Major patient and lesion 
exclusion criteria**
Complex or 
high-risk†
Complex or  
high-risk†
Complex or high-
risk†
None
Routine angiographic follow-
up 
  - Timing 6 and 24 months 8 months None None
  - Number intended 300 and 152 564 0 0
  - Number completed 275 and 115 436 0 0
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infarction and difficult or high-risk lesions such as chronic total occlusions, true 
bifurcations, and lesions in the left main coronary segment or a saphenous 
vein graft. In contrast, COMPARE was an “all-comers” trial, excluding from 
randomization only patients unable to comply with dual antiplatelet therapy 
or study procedures, those who required major surgery within 30 days, and 
those who were unable to provide informed consent. A proportion of enrolled 
patients underwent protocol specified routine angiographic follow-up in the 
SPIRIT II and SPIRIT III trials, whereas only clinical follow-up was performed in 
the larger SPIRIT IV and COMPARE trials (Table 1). Follow-up is planned for 5 
years in each trial and is currently complete through 2 years in all 4 studies.
end Points and Statistical Methods
For the present analysis, the databases from the 4 trials were pooled to 
provide a patient-level analysis. The principal end points of interest included 
safety parameters (principally cardiac death, myocardial infarction [MI], and 
stent thrombosis according to the Academic Research Consortium definition 
of definite or probable)16; efficacy parameters, including ischemia-driven TLR; 
and major adverse cardiac events (MACE), a composite measure of safety and
efficacy consisting of cardiac death, MI, or ischemia-driven TLR. Other end 
points examined included all-cause mortality, Q-wave and non–Q-wave MI, and 
ischemia-driven target vessel revascularization. The definitions used for the end 
points assessed in the present analysis were similar in the SPIRIT and COMPARE 
trials.10–15 Events as adjudicated in each trial were used for the pooled analysis. 
All end points were assessed at 2 years. Outcomes of patients randomized to 
EES versus PES were evaluated stratified by the presence of medically treated 
diabetes mellitus. All analyses are by intention to treat. Categorical outcomes 
were compared by the χ2 test, unless the expected number of values in any cell 
of the 2x2 contingency table was < 5, in which case the Fisher exact test was 
used. Continuous variables are presented as mean SD and were compared by 
*Medically treated; 9 patients in whom the diabetic status prior to enrollment was unknown were 
excluded. **Patients in all trials were also excluded if unable to take an extended course of dual anti-
platelet therapy. †Including acute or recent myocardial infarction, left ventricular ejection fraction <30%, 
lesions which were in a bypass graft conduit, occluded, bifurcations (minor bifurcations were included 
in SPIRIT IV), ostial (ostial RCA lesions were included in SPIRIT IV), severe calcification or tortuosity. EES 
denotes everolimus-eluting stent; EU denotes Europe; ITT denotes intention to treat; LL denotes late 
loss; MACE denotes major adverse cardiac events (all-cause death, myocardial infarction or target vessel 
revascularization); PES denotes paclitaxel-eluting stent; RVD denotes reference vessel diameter; TLF 
denotes target lesion failure (cardiac death, target-vessel-related myocardial infarction or target lesion 
revascularization); TVF denotes target vessel failure (cardiac death, myocardial infarction or target vessel 
revascularization); US denotes United States.  
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the t test. Cumulative event rates were determined from time-to-event data 
(for which patients were censored at the time of withdrawal from the study 
or at last follow-up), are displayed through the use of Kaplan-Meier plots, and 
were compared by use of the log-rank test. A 2-sided α= 0.05 was used for all 
superiority testing.
Multivariable analyses were performed with the use of stepwise logistic re-
gression to adjust for differences in baseline variables. The following variables 
were entered into the multivariable models: age, sex, hypertension, hyper-
lipidemia, prior MI, prior percutaneous coronary intervention, prior coronary 
artery bypass graft surgery, presentation with acute coronary syndromes, 
number of treated lesions, and randomization to EES versus PES. Formal inter-
action testing was performed to determine whether the presence of diabetes 
mellitus influenced the relative risk of EES versus PES for the occurrence of 
safety or efficacy end points at 2 years. Among patients with medically treated 
diabetes mellitus, possible interactions between insulin treatment and stent 
type were also examined.
Poolability across the 4 trials was confirmed for the 2-year measures of 
cardiac death, cardiac death or MI, MACE, and stent thrombosis (for the study-
by-treatment interaction, P=0.53, P=0.91, P=0.83, and P=0.32, respectively). 
Poolability of the 3 SPIRIT trials versus
the COMPARE trial was also confirmed for these end points (for the study-
by-treatment interaction, P=0.15, P=0.84, P=0.91, and P=0.16, respectively). All 
statistical analyses were performed with SAS version 9.1.3 (SAS Institute, Inc, 
Cary, NC).
reSultS
Patients, Procedures, and Overall Impact of Diabetes Mellitus
Of the 6789 patients enrolled in the SPIRIT II, SPIRIT III, SPIRIT IV, and COMPARE 
trials, diabetic status at the time of admission was known for 6780 patients 
(99.9%), 1869 (27.6%) of whom had medically treated diabetes mellitus (Table 
1). As shown in Table 2, the 2-year rates of all-cause and cardiac mortality, 
ischemia-driven target vessel revascularization, stent thrombosis, and MACE 
were significantly greater in patients with versus without diabetes mellitus. 
Among patients with diabetes mellitus, 1188 were randomly assigned to EES 
and 681 were randomly assigned to PES. Among patients without diabetes mel-
litus (n=4911), random assignment to EES and PES occurred in 3056 and 1855 
patients, respectively. The baseline clinical and angiographic characteristics of 
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the stent-assigned patients in each group were well matched (Table 3). Pa-
tients assigned to EES, compared with PES had hyperlipidemia more frequently 
and fewer totally occluded lesions. Among patients without diabetes mellitus, 
those assigned to EES had hypertension more frequently, were less likely to 
present with acute coronary syndromes or with thrombotic or calcified lesions, 
and had slightly shorter lesion length.
Clinical Outcomes
As shown in Figure 1 and Table 4, patients without diabetes mellitus random-
ized to EES rather than PES had significantly lower 2-year rates of mortality, 
MI, stent thrombosis, ischemia- driven TLR and target vessel revascularization, 
and MACE. In contrast, there were no significant differences in any measured 
parameters of safety or efficacy in patients with diabetes mellitus randomized 
to EES versus PES. These findings were unchanged after multivariable correc-
tion for differences in baseline characteristics (Table 5). Statistically significant 
interactions were present between diabetic status and stent type for the end 
points of MACE (P=0.0009), MI (P=0.01), stent thrombosis (P=0.0006), and 
ischemia-driven TLR (P=0.02) but not for cardiac death (P=0.25).
Influence of Insulin treatment
Of the 1869 patients with diabetes mellitus at baseline, 494 (26.4%) were 
treated with insulin. Among patients treated with EES, a gradient was pres-
ent so that the 2-year rates of most adverse events were greatest among 
table 2. Two-year clinical outcomes in patients with vs. without diabetes mellitus, regardless of stent type
Diabetes (n=1,869) no diabetes (n=4,911) P value
Death 3.6% (64) 2.3% (110) 0.004
   - Cardiac 2.1% (37) 1.0% (49) 0.0009
   - Non-cardiac 1.5% (27) 1.3% (61) 0.45
MI 4.4% (80) 3.7% (179) 0.19
Ischemia-driven TLR 5.7% (101) 4.8% (228) 0.14
Ischemia-driven TVR 8.9% (157) 6.8% (319) 0.003
Stent thrombosis* 1.8% (31) 1.1% (53) 0.046
   - Definite 1.2% (22) 0.8% (37) 0.08
   - Probable 0.5% (9) 0.4% (18) 0.47
MACE 10.2% (182) 8.2% (391) 0.01
Event rates are shown as Kaplan-Meier estimates, % (number of events). MI denotes myocardial infarction 
denotes; TLR denotes ischemia-driven target lesion revascularization; TVR denotes ischemia-drive 
target vessel revascularization; MACE denotes major adverse cardiovascular events (cardiac death, MI, 
or ischemia-driven TLR). *According to the Academic Research Consortium (ARC) definite or probable 
definition.
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table 3. Baseline characteristics and anti-platelet agent use in the randomized groups according to 
diabetic status
Patients without diabetes (n=4,811) Patients with diabetes (n=1,869)
EES (N=3,056) PES (N=1,855) P value EES (N=1,188) PES (N=681) P value
Age (years) 62.9 ± 10.8 63.1 ± 10.9 0.58 63.5 ± 10.1 64.1 ± 10.2 0.23
Male
2151/3056 
(70.4%)
1337/1855 
(72.1%)
0.22
757/1188 
(63.7%)
426/681 (62.6%) 0.62
Insulin-treatment - - -
310/1188 
(26.1%)
184/681 (27.0%) 0.66
Smoking within past 
year
808/3013 
(26.8%)
498/1827 
(27.3%)
0.74
234/1160 
(20.2%)
125/662 (18.9%) 0.54
Hypertension
1975/3054 
(64.7%)
1116/1852 
(60.3%)
0.002
999/1186 
(84.2%)
558/681 (81.9%) 0.22
Hyperlipidemia
1988/3004 
(66.2%)
1133/1837 
(61.7%)
0.002
960/1177 
(81.6%)
552/677 (77.1%) 0.02
Prior myocardial 
infarction
588/3001 
(19.6%) 
343/1838 
(18.7%)
0.43
258/1153 
(22.4%)
133/666 (20.0%) 0.24
Prior PCI
409/3029 
(13.5%) 
241/1842 
(13.1%) 
0.70
201/1162 
(17.3%)
109/670 (16.3%) 0.61
Prior CABG
185/3054 
(6.1%)
92/1855 
(5.0%) 
0.11
121/1187 
(10.2%)
61/681 (9.0%) 0.42
Presentation with ACS
1031/3056 
(33.7%)
762/1854 
(41.1%)
<0.0001
362/1188 
(30.5%)
224/680 (32.9%) 0.28
# treated lesions 1.29 ± 0.53 1.32 ± 0.56 0.052 1.29 ± 0.53 1.33 ± 0.58 0.15
# treated vessels 1.20 ± 0.43 1.22 ± 0.44 0.13 1.20 ± 0.42 1.23 ± 0.46 0.14
Lesion location (core laboratory)
   - Native coronary 
artery
3907/3925 
(99.5%)
2426/2442 
(99.3%)
0.29
1522/1531 
(99.4%)
897/905 (99.1%) 0.45
   - Saphenous vein 
graft
18/3925 (0.5%)
16/2442 
(0.7%)
0.29 9/1531 (0.6%) 8/905 (0.9%) 0.45
   - Left main 12/3925 (0.3%)
18/2442 
(0.7%)
0.02 10/1531 (0.7%) 4/905 (0.4%) 0.59*
   - Left anterior 
descending
1597/3925 
(40.7%)
970/2442 
(39.7%)
0.45
611/1531 
(39.9%)
356/905 (39.3%) 0.80
   - Left circumflex
957/3925 
(24.4%)
627/2442 
(25.7%)
0.25
406/1531 
(26.5%)
240/905 (26.5%) 1.0
   - Right
1359/3925 
(24.4%)
827/2442 
(25.7%)
0.55
504/1531 
(32.9%)
305/905 (33.7%) 0.72
Total occlusion 90/3925 (2.3%)
91/2442 
(3.7%)
0.001 19/1531 (1.2%) 26/905 (2.9%) 0.005
Moderate or severe 
calcification
575/3905 
(14.7%)
449/2436 
(18.4%)
0.0001
200/1524 
(13.1%)
145/899 (16.1%) 0.05
Thrombus
317/3908 
(8.1%)
298/2437 
(12.2%)
<0.0001 75/1522 (4.9%) 48/902 (5.3%) 0.70
Baseline QCA
Coronary Stents in Patients With and Without Diabetes Mellitus 101
Ch
ap
te
r 4
.1
insulin-treated diabetic patients, intermediate in non–insulin-treated diabetic 
patients, and lowest in nondiabetic patients (Figure 2, top). In contrast, among 
patients treated with PES, the 2-year rates of adverse events were independent 
of diabetic status or insulin treatment (Figure 2, bottom). Among patients with 
diabetes mellitus, there were no significant differences in the 2-year rates of 
cardiac death, MI, or stent thrombosis for patients randomized to EES versus 
PES, regardless of treatment with insulin (Table 6). However, ischemia-driven 
TLR was reduced among non–insulin-treated diabetic patients assigned to EES 
compared with PES (3.7% versus 6.3%; P=0.04) but not in insulin-treated dia-
betic patients, in whom a trend was present for less TLR with PES (10.8% versus 
5.5%; P=0.08). Thus, a significant interaction was present in diabetic patients 
between the use of insulin and stent type for the occurrence of ischemia-driven 
TLR at 2 years (P=0.01).
DISCuSSIOn
The major findings from the present analysis, the largest study to date evaluat-
ing the relative safety and efficacy of different DES types stratified by the 
presence of diabetes mellitus, are (1) that a significant interaction was present 
between diabetic status and treatment with EES compared with PES on the 
relative risk of 2-year clinical outcomes, reflecting measures of both safety 
and efficacy; (2) that inpatients without diabetes mellitus, treatment with EES 
compared with PES reduced the 2-year rates of death, MI, stent thrombosis, 
Reference vessel 
diameter (mm)
2.69 ± 0.51 2.69 ± 0.55 0.66 2.66 ± 0.52 2.65 ± 0.51 0.70
Minimal luminal 
diameter (mm)
0.81 ± 0.43 0.83 ± 0.46 0.04 0.78 ± 0.41 0.81 ± 0.41 0.16
Diameter stenosis % 70.2 ± 14.9 69.5 ± 15.8 0.10 70.5 ± 13.9 69.6 ± 14.4 0.17
Lesion length (mm) 16.0 ± 9.8 17.1 ± 12.0 0.0006 15.8 ± 8.7 16.0 ± 10.5 0.69
Dual anti-platelet therapy†
   - At discharge
2960/3050 
(97.0%)
1789/1849 
(96.8%)
0.61
1143/1185 
(96.5%)
655/678 (96.6%) 0.90
   - At 6 months
2864/3045 
(94.1%)
1703/1834 
(92.9%)
0.10
1097/1172 
(93.6%)
628/677 (92.8%) 0.50
   - At 1 year
2384/3030 
(78.7%)
1413/1822 
(77.6%)
0.37
922/1161 
(79.4%)
523/673 (77.7%) 0.41
*Fisher’s Exact test; all other comparisons were Chi-square test. † Patient taking both aspirin and a 
thienopyridine. EES denotes everolimus-eluting stent; PES denotes paclitaxel-eluting stent; ACS denotes 
acute coronary syndrome; CABG denotes coronary artery bypass graft surgery; PCI denotes percutaneous 
coronary intervention; QCA denotes quantitative coronary angiography.
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ischemia-driven TLR, and MACE, whereas in patients with diabetes mellitus, 
there were no significant differences in clinical outcomes at 2 years between 
the stent types; and (3) that an additional interaction was identified among 
patients with diabetes mellitus so that the 2-year rate of ischemia-driven 
TLR was reduced with EES compared with PES in those not requiring insulin, 
whereas the opposite trend was observed in those who were treated with 
insulin.
With 1869 randomized diabetic patients (larger than the SPIRIT II, SPIRIT III, 
and COMPARE trials individually) and 4911 randomized nondiabetic patients, 
the present analysis is of sufficient magnitude to examine the outcomes of 
patients with diabetes mellitus randomized to EES versus PES and to examine 
whether significant interactions exist between the presence of diabetes mel-
litus and clinical outcomes according to randomly assigned stent type. Highly 
Figure 1 Time-to-event curves for major adverse cardiac events (cardiac death, myocardial infarction [MI], 
or ischemia-driven target lesion revascularization [TLR]; top left), cardiac death (top right); MI (middle 
left), ischemia-driven TLR (middle right), and stent thrombosis according to the Academic Research 
Consortium definition of definite or probable (bottom). EES indicates everolimus-eluting stents; PES, 
paclitaxel-eluting stents.
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statistically significant interactions were demonstrated between diabetes mel-
litus and stent type for the 2-year clinical end points of MI, stent thrombosis, 
TLR, and MACE. In patients without diabetes mellitus, significant improvements 
in nearly all measured safety and efficacy end points were present after treat-
ment with EES compared with PES. Perhaps most striking is the observation 
that in patients without diabetes mellitus, stent thrombosis to 2 years occurred 
table 4. Two-year event rates according to randomized stent type and diabetic status
Patients without diabetes (n=4,911) Patients with diabetes (n=1,869)
EES (n=3,056) PES (n=1,855) p EES (n=1,188) PES (n=681) p
Death 1.9% (56) 3.1% (54) 0.01 3.9% (45) 2.9% (19) 0.27
   - Cardiac 0.8% (25) 1.4% (24) 0.10 2.1% (24) 2.0% (13) 0.88
   - Non-cardiac 1.0% (31) 1.7% (30) 0.06 1.9% (21) 0.9% (6) 0.13
MI 2.5% (74) 5.8% (105) <0.0001 4.2% (48) 4.9% (32) 0.49
   - Q-wave 0.1% (3) 1.3% (24) <0.0001 0.5% (6) 0.7% (4) 0.79
   - Non-Q-wave 2.4% (71) 4.6% (84) <0.0001 3.7% (42) 4.4% (29) 0.43
Ischemic TLR 3.6% (105) 6.9% (123) <0.0001 5.5% (62) 6.1% (39) 0.60
Ischemic TVR 5.7% (166) 8.5% (153) <0.0001 8.3% (94) 9.8% (63) 0.29
Stent thrombosis* 0.3% (10) 2.4% (43) <0.0001 1.6% (18) 2.0% (13) 0.50
   - Definite 0.3% (8) 1.6% (29) <0.0001 1.1% (12) 1.5% (10) 0.36
   - Probable 0.1% (2) 0.9% (16) <0.0001 0.5% (6) 0.5% (3) 0.85
MACE 6.2% (185) 11.4% (206) <0.0001 10.1% (115) 10.3% (67) 0.86
Event rates are shown as Kaplan-Meier estimates, % (number of events). EES denotes everolimus-
eluting stent; PES denotes paclitaxel-eluting stent; MI denotes myocardial infarction denotes; TLR 
denotes ischemia-driven target lesion revascularization; TVR denotes ischemia-drive target vessel 
revascularization; MACE denotes major adverse cardiovascular events (cardiac death, MI, or ischemia-
driven TLR). * According to the Academic Research Consortium (ARC) definition.
table 5. Adjusted odds ratios for the effect of randomized stent type on 2-year event rates according to 
diabetic status
Patients without diabetes Patients with diabetes
2-Year Adverse Event
EES vs. PES           OR 
[95% CI]
p
EES vs. PES        OR 
[95% CI]
p
Cardiac death 0.66 [0.38, 1.17] 0.15 1.08 [0.54, 2.13] 0.83
MI 0.44 [0.32, 0.60] <0.0001 0.87 [0.55, 1.40] 0.58
Ischemia-driven TLR 0.50 [0.39, 0.66] <0.0001 0.90 [0.59, 1.37] 0.63
Stent thrombosis* 0.15 [0.07, 0.30] <0.0001 0.80 [0.39, 1.67] 0.56
MACE 0.53 [0.43, 0.65] <0.0001 0.94 [0.68, 1.30] 0.71
EES denotes everolimus-eluting stent; PES denotes paclitaxel-eluting stent; OR [95%CI] denotes odds ratio 
with 95% confidence interval. MI denotes myocardial infarction denotes; TLR denotes ischemia-driven 
target lesion revascularization; MACE denotes major adverse cardiovascular events (cardiac death, MI, or 
ischemia-driven TLR).
 *According to the Academic Research Consortium (ARC) definite or probable definition.
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in only 0.3% of patients with EES compared with 2.4% of patients with PES 
(P=0.0001). Conversely, no significant differences were observed at 2 years in 
the rates of any clinical outcomes (either efficacy or safety) after EES versus PES 
treatment in patients with medically treated diabetes mellitus, including stent 
thrombosis. The difference in the relative rates of TLR according to stent type 
and diabetic status is consistent with the angio-graphic substudy findings from 
the SPIRIT III study, in which the median difference in in-segment late loss at 
8 months in favor of EES compared with PES was 0.15 mm in patients without 
diabetes mellitus but only 0.06 mm in patients with diabetes mellitus.12 More-
over, prior studies with PES have shown comparable angiographic and clinical 
rates of restenosis in patients with and without diabetes mellitus.7 These data 
may reflect the different mechanisms of action through which paclitaxel and 
rapamycin analogs reduce restenosis. By disrupting microtubular function, 
paclitaxel interferes with multiple pathways of restenosis (including smooth 
muscle cell proliferation and migration, extracellular matrix production, and 
Figure 2 Two-year rates of adverse events according to diabetic status (no vs non–insulin-treated vs 
insulin-treated diabetes mellitus) in patients randomized to everolimus-eluting stents (EES; top) and 
paclitaxel-eluting stents (PES; bottom). TLR indicates target lesion revascularization; MACE, major adverse 
cardiac events.
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cell-to-cell signaling); thus, its effects appear to be relatively independent 
of the diabetic state.17 In contrast, the mechanism of rapamycin is limited to 
interfering with cellular mitosis, a process tightly regulated by glycosylation-
dependent enzymes.18 Even more unexpected than the observed differences 
in TLR were the significant interactions present for the relative risks of MI and 
stent thrombosis between EES and PES according to the presence of diabetes 
mellitus. Although the increase in restenosis observed in diabetic compared 
with nondiabetic patients with EES (but not PES) may in part have contributed 
to its greater rate of MI in this cohort,19 this mechanism is unlikely to completely 
explain the loss of the safety benefit for EES in the diabetic group. Further 
studies are required to elucidate the mechanisms underlying the higher rates 
of MI and stent thrombosis in diabetic patients treated with EES but not PES. 
Among patients treated with EES, an apparent gradient of effect was observed 
so that the 2-year rates of most adverse events were lowest in nondiabetic 
patients, intermediate in non–insulin-treated diabetic patients, and highest in 
insulin treated diabetic patients. Conversely, in patients treated with PES, no 
table 6. Two-year event rates among patients with diabetes according to randomized stent type and 
insulin treatment
2-Year events eeS (n=1188) PeS (n=681) p
Cardiac death
   - Insulin-treated 2.1% (6) 2.8% (5) 0.59
   - Non-insulin-treated 2.1% (18) 1.7% (8) 0.58
MI
   - Insulin-treated 5.0% (15) 7.2% (13) 0.32
   - Non-insulin-treated 3.9% (33) 4.0% (19) 0.93
Ischemia-driven TLR
   - Insulin-treated 10.8% (31) 5.5% (10) 0.08
   - Non-insulin-treated 3.7% (31) 6.3% (29) 0.04
Stent thrombosis*
   - Insulin-treated 1.5% (4) 2.2% (4) 0.44
   - Non-insulin-treated 1.7% (14) 1.9% (9) 0.75
MACE
   - Insulin-treated 14.8% (43) 11.1% (20) 0.34
   - Non-insulin-treated 8.4% (72) 10.1% (47) 0.39
Event rates are shown as Kaplan-Meier estimates, % (number of events). EES denotes everolimus-
eluting stent; PES denotes paclitaxel-eluting stent; MI denotes myocardial infarction denotes; TLR 
denotes ischemia-driven target lesion revascularization; TVR denotes ischemia-drive target vessel 
revascularization; MACE denotes major adverse cardiovascular events (cardiac death, MI, or ischemia-
driven TLR). 
*According to the Academic Research Consortium (ARC) definition.
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such relationships were apparent, and measures of both safety and efficacy 
occurred with similar frequency regardless of diabetic status or treatment. 
Furthermore, among medically treated diabetic patients, although the relative 
risk of safety end points (cardiac death, MI, and stent thrombosis) did not vary 
significantly between stent type according to insulin treatment, a significant 
interaction was observed between insulin use and stent type on the 2-year risk 
of ischemia-driven TLR. Treatment with EES (versus PES) was associated with 
a significant reduction in TLR among non–insulin-treated diabetic patients, 
whereas a nonstatistically significant trend toward an increase in TLR with EES 
was observed in diabetic patients treated with insulin (Pinteraction=0.01). Fur-
ther investigation is required to determine whether this observation may be 
explained by either inherent differences between the insulin-deficient versus 
-resistant state on the antirestenotic effects of rapamycin analogs or a direct 
inhibitory effect of insulin on the vascular response to rapamycin analog– 
eluting stents. Also of note is the observation that the 2-year rates of cardiac 
death, MI, and stent thrombosis were numerically but non significantly lower 
after EES versus PES implantation in patients with insulin treated diabetes 
mellitus, despite the directionally opposite increase in TLR. Larger studies are 
required to determine whether these directionally opposite trends in safety 
and efficacy reflect true differences between the stent types in insulin-treated 
diabetic patients or are due to chance. Several limitations of the present study 
should be considered.
As a post hoc analysis from 4 pooled, randomized trials, the results should be 
considered hypothesis generating. In particular, although with 1869 patients 
the present study is the largest randomized DES study to date in patients with 
diabetes mellitus, the sample size remains inadequate to exclude small differ-
ences between the 2 stent types in the diabetic cohort (whether favoring PES 
or EES). Given the observed event rates, a very large randomized trial (>5000 
patients) restricted to patients with diabetes mellitus would be required to 
determine whether meaningful differences in safety outcomes between EES 
and PES exist in this cohort. Conversely, the clinical outcomes observed in the 
nondiabetic group demonstrating statistical superiority in numerous safety 
and efficacy end points with EES compared with PES are consistent with the 
primary results from each of the individual trials and do not require replica-
tion. Moreover, although the present study was adequately powered for in-
teraction testing between stent type and diabetes mellitus versus no diabetes 
mellitus, sufficient power to uncover all significant interactions in the diabetic 
cohort according to insulin treatment may not have been present. As expected 
in analyses of subgroups, small differences in baseline characteristics in the 
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randomized stent groups were present, although the results regarding clinical 
outcomes were not altered by multivariable adjustment. Similarly, the results 
of the present study were consistent for both PES platforms (TAXUS Express 
and TAXUS Liberte´) for the end points analyzed. The present analysis was 
restricted to data available at 2 years after stent implantation. Longer-term 
follow-up is necessary to determine whether meaningful differences between 
the stent types in diabetic patients will emerge over time. Finally, the present 
study results specifically apply only to the comparison of PES with EES (and 
not necessarily to other rapamycin analog– eluting stents). In this regard, a 
previously reported metaanalysis of 5 modest-sized randomized trials of 
sirolimus-eluting stents versus PES in diabetic patients suggested a reduction 
in angiographic and clinical restenosis with sirolimus-eluting stents, although 
with comparable rates of cardiac death, MI, and stent thrombosis.20 This study, 
however, did not include stratified subgroup diabetic data from other large 
trials in which there were no significant differences in the repeat revascu-
larization rates between these 2 stents.6,8 Our study also showed a reduction 
in TLR with EES compared with PES in non–insulin-treated diabetic patients. 
Larger studies are thus warranted to determine whether the findings from 
the present analysis in diabetic patients are generalizable to all stents eluting 
rapamycin analogs, especially in those treated with insulin. Because the EES 
is currently the most commonly used stent in the United States and Europe, 
the clinical implications of the present study require careful consideration. 
In patients without diabetes mellitus who undergo percutaneous coronary 
intervention, treatment with EES compared with PES provides considerable 
benefit with respect to freedom from death, MI, stent thrombosis, and recur-
rent ischemia necessitating repeat TLR procedures. Thus, EES should clearly be 
preferred over PES in nondiabetic patients. In patients with diabetes mellitus, 
2-year outcomes in the present study did not vary substantially after treat-
ment with EES compared with PES, suggesting clinical equipoise between the 
devices. For those using EES routinely in patients with and without diabetes 
mellitus, the current analysis does not require a change in practice, especially 
because the present study suggests that EES compared with PES may reduce 
ischemia-driven TLR in non–insulin-treated diabetic patients. Further studies 
are required to determine the optimal stent choice for patients with insulin-
treated diabetes mellitus. 
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ClInICAl PerSPeCtIVe
Patients with diabetes mellitus are at high risk for major adverse cardiac events 
after percutaneous coronary intervention. Drug-eluting compared with bare 
metal stents improve event-free survival in diabetic patients by decreasing 
ischemiadriven repeat revascularization procedures (target lesion revascular-
ization). In large trials, everolimus-eluting stents have been shown to be safer 
and more effective than paclitaxel-eluting stents; whether this holds equally 
for diabetic patients has been debated. In the present large-scale study drawn 
from a pooled patient-level analysis of 4 randomized trials, patients without 
diabetes mellitus treated with everolimus-eluting stents compared with 
paclitaxel-eluting stents had significantly reduced 2-year rates of mortality, 
myocardial infarction, stent thrombosis, and ischemia-driven target lesion 
revascularization. In contrast, clinical outcomes with the 2 stents were not sig-
nificantly different in patients with diabetes mellitus. Statistically significant 
interaction effects were present, suggesting that the difference in the relative 
effects of these 2 stents is conditioned by the diabetic state. Furthermore, 
non–insulin-treated diabetic patients had reduced rates of ischemia-driven 
target lesion revascularization with everolimus-eluting stents, whereas insulin-
treated patients tended to have reduced rates of ischemia-driven target lesion 
revascularization with paclitaxel-eluting stents. These data thus demonstrate 
that the diabetic state, specifically insulin treatment, may substantially af-
fect the clinical outcomes of patients treated with everolimus-eluting stents 
and paclitaxel-eluting stents. Further studies are required to understand the 
mechanisms underlying these findings so that more effective therapies can be 
developed for high-risk patients with diabetes mellitus.
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AbStrACt 
Objectives:
To study the second-generation everolimus-eluting stent (EES) as compared to 
first-generation sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) in 
diabetes mellitus (DM) patients.
background: 
There is limited data available comparing EES with SES, while studies compar-
ing EES to PES are not powered for low-frequency endpoints. 
Methods:
All DM patients treated with EES, PES or SES from January 18th 2007 till July 
29th 2011 from the Swedish Coronary Angiography and Angioplasty Register 
(SCAAR) were included. EES was compared to SES or PES for clinically-driven 
detected restenosis, definite stent thrombosis (ST) and all-cause mortality. 
results:
In 4751 PCI-treated DM patients 8.134 stents were implanted (EES = 3928, PES 
= 2836, SES = 1370). The EES was associated with significantly lower all-cause 
mortality than SES and PES (EES vs. SES Hazard ratio (HR) 2.02; 95% Confidence 
Interval (CI) [1.03-3.98]; EES vs. PES HR, 1.69; 95% CI [1.06-2.72]). EES was also 
associated with significantly lower ST rates than SES while only a trend was 
observed in PES (EES vs. SES HR 2.87 95% CI [1.08-7.61]; EES vs. PES HR 1.74 CI 
[0.82-3.71]). No differences in restenosis rates were observed between EES and 
SES or PES (EES vs. SES HR 1.26; 95% CI[0.77-2.08]; EES vs. PES HR 1.05; 95% 
CI[0.71-1.55]). 
Conclusions: 
The EES is associated with significantly lower mortality rates when compared 
to SES and PES in all-comer DM patients, and with low rates of  ST. No differ-
ences in restenosis rates were observed with EES as compared to SES and PES.
KeY WOrDS:
Everolimus-eluting stent, Sirolimus-eluting stent, Paclitaxel-eluting stent, Dia-
betes Mellitus, Stent Thrombosis, Restenosis, all-cause mortality, SCAAR
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IntrODuCtIOn
The introduction of the first generation sirolimus- and paclitaxel -eluting stents 
(SES and PES) has led to markedly reduced restenosis rates and reduced need 
for target lesion revascularisation compared to bare metal stents, in diabetics 
as well as non-diabetic patients.1-5 However diabetes mellitus (DM) remains 
associated with increased risk of in-stent restenosis, target lesion revascularisa-
tion,  and target vessel revascularisation in patients undergoing percutaneous 
coronary interventions (PCI).6 The second generation everolimus-eluting stent 
(EES), has recently been found to be superior to the first-generation PES for 
reduction of  target lesion revascularisation, target vessel revascularisation and 
ST in two large randomised trials, however these significant improvements in 
safety and efficacy endpoints were limited to the non-diabetic subgroup of 
patients, as no differences in treatment effect between these two stents were 
observed in DM patients in both trials.7,8 These findings were further confirmed 
by a large patient-level pooled analysis from four randomised clinical trials 
comparing EES to PES.9 Furthermore, when stratified for insulin vs. non-insulin 
treatment, a statistically significant interaction emerged, suggesting a differ-
ence in the relative treatment effects of these two devices. Whether these 
results hold true in larger all-comer population is unknown. There is a paucity 
of data on differences in clinical outcomes between EES and SES in DM setting, 
as the only data available derives from relatively small series of patients and 
therefore are not adequately powered to detect low frequency endpoints.10 
Different issues regarding the impact of metal alloy, strut thickness, polymer 
biocompatibility and especially the effect of eluted active principle in patients 
with DM remain still unanswered. For this reason we compared the safety and 
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efficacy of the second generation EES as compared to the most studied first 
generation DES, represented by the SES and PES in diabetic patients using 
the data from the Swedish Coronary Angiography and Angioplasty Register 
(SCAAR).11
MetHODS
Study sample
For the present analysis we analyzed all PCI-treated DM patients from the 
SCAAR database between January 2007 (date when the first EES stent was im-
planted in a DM patient in Sweden) and July 30th 2011, that were treated with 
one of the following stents: EES, PES, or SES. The EES was compared individu-
ally with PES and SES for the  1-year incidence of clinically driven, angiography 
visualised in-stent restenosis,  stent thrombosis and all-cause mortality. 
The SCAAR has been previously described.11,12 Briefly, this registry holds data 
on consecutive patients from all 29 centres that perform coronary angiogra-
phy and percutaneous coronary intervention (PCI) in Sweden. The registry is 
sponsored by the Swedish Health Authorities and is independent of commer-
cial funding. The technology is developed and administered by the Uppsala 
Clinical Research Centre. Since 2001, SCAAR has been web-based, with record-
ing of data online through a Web-interface in the catheterization laboratory; 
data are transferred in an encrypted format to a central server at the Uppsala 
Clinical Research Centre. All patients undergoing a coronary angiography or a 
PCI procedure nation-wide are included. Since May 2005 all information with 
respect to restenosis and stent thrombosis of previously treated patients that 
return in the catheterisation lab for subsequent coronary angiography or PCI 
is entered in the SCAAR as well as the indication of such procedures. The web-
based system provides each centre with immediate and continuous feedback 
on processes and quality-of-care measures. Monitoring and verification of reg-
istry data are periodically performed in all hospitals since 2001 by comparing 
50 entered variables in 20 randomly selected interventions per hospital and 
year with the patients’ hospital records.
Study endpoints
The SCAAR register includes follow-up data for every implanted stent device 
permitting device-oriented as well as patient-oriented endpoint analysis. For 
the current study the analysis on restenosis and ST are performed at device level 
while mortality is analysed at patient level. The same definition for restenosis 
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as defined by the SCAAR steering committee were used. The SCAAR definitions 
of restenosis is defined as a stenosis assessed by angiographic visual estimation 
(>50%) or by fractional flow reserve value (FFR) of < 0.80 in a previously stented 
segments identified by coronary angiography for any clinical indication in any 
of the 29 centres in Sweden.11,12 The clinical relevance of restenotic lesions was 
detected by symptoms, routine non-invasive functional testing (exercise test, 
myocardial scintigraphy) and/or invasive functional evaluation by fractional 
flow reserve. The clinically driven detected restenosis, the efficacy endpoint in 
this study, differs from the classical target lesion revascularisation endpoints 
used in other large studies. The target lesion revascularisation combines 
revascularizations performed due to restenosis as well as ST and therefore 
may introduce biases, especially for high risk populations treated with first 
generation DES, where the ST can generate a consistent percentage of the 
target lesion revascularisation events. To avoid biases that can arise by pooling 
efficacy and safety endpoints, in our analysis we reported restenosis and ST 
separately. 
Stent thrombosis was defined in SCAAR as an angiographic occlusion or a 
non-occlusive thrombus in a previously implanted stent with an acute clinical 
presentation13,  definition that resembles highly the ACR definition of definite 
ST.14
All-cause mortality data were obtained from the National Population Death 
Registry. The merging of the registries was performed by the Epidemiologic 
Centre of the Swedish National Board of Health and Welfare and approved by 
the local ethical committee at the Uppsala University.
Statistical analysis
The baseline clinical and angiographic characteristics were compared by means 
of  the χ2 test for categorical variables and the t test for the continuous vari-
ables. Stent groups were compared using survival analyses. The Kaplan-Meier 
estimator was used to compute cumulative hazards and Cox proportional haz-
ards regression to estimate hazard ratios. Differences between stent groups 
in baseline characteristics were adjusted by using propensity score methods. 
Two different propensity scores were created, both defined as the conditional 
probability of having a Everolimus-eluting stent, one in a populations of stents 
with only Everolimus or Paclitaxel-eluting stents and the other in a population 
with only Everolimus or Sirolimus-eluting stents. The following variables were 
forced into logistic regression models: previous myocardial infarction, coro-
nary artery bypass grafting (CABG) or PCI; gender; hypertension; hyperlipid-
emia; smoking; prior aspirin, clopidogrel or warfarine use; anticoagulant use; 
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glycoprotein IIb/IIIa inhibitor use; number of vessel disease; graft; restenosis; 
chronic occlusion; indication for PCI; complete revascularisation; bifurcation 
lesion; type of lesion and hospital. These propensity scores were entered in 
Cox proportional hazards models together with the type of stent drug and 
the year of PCI procedure to calculate the adjusted hazard ratio for ST and 
restenosis. In a similar way two additional propensity scores were created and 
used in the outcome analysis of all-cause mortality including the following 
variables: previous myocardial infarction, CABG or PCI; gender; hypertension; 
hyperlipidemia; smoking; number of vessel disease; indication for PCI; com-
plete revascularisation; bifurcation lesion; hospital. 
The same endpoints were evaluated in medically treated DM as stratified for 
insulin treatment. Statistical interaction between insulin treatment and stent 
type was examined by introducing these variables as interaction terms in the 
Cox proportional hazard models.
All statistical analyses were performed with SPSS version 19 (Chicago, IL)
reSultS
A total of 4751 DM patients were treated with PCI and were included in the 
present study. These patients received 8.134 drug eluting stents; respectively 
3928 EES (average 2.23±1.25 stent per patient), 2836 PES (average 2.03±1.11 
stent per patient), 1370 SES (average 2.34±1.34 stent per patient).  Baseline 
characteristics of the groups are shown in Table 1. Although, baseline clinical 
and angiographic results were in general well balanced some significant dif-
ferences were detected. 
Clinical outcomes 
Clinical outcome data are presented in Table 2. 
The EES was associated with significantly lower rates of all-cause mortality 
compared to SES or PES after adjustment for propensity scores (EES vs. SES HR 
2.02, 95%CI[1.03-3.98]; EES vs. PES HR 1.69; 95% CI[1.06-2.72]). After strati-
fying for insulin dependence a trend to lower mortality rates with EES was 
maintained irrespective of insulin treatment, but reached significance only for 
the EES and SES comparison in the insulin treated group (Table 2).
No differences were seen in restenosis rates when comparing EES to SES or 
PES even after stratifying for insulin treatment (Figure 1). A trend towards 
better outcomes with EES was observed when compared to SES in non-insulin 
treated diabetes mellitus patients, while no differences were observed in 
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table 1.   Baseline clinical and angiographic characteristics
  everolimus Paclitaxel Sirolimus P-value
Number of stents (n) 3928 2836 1370
Patient background
Age (±SD) 66.7±10.1 67.4±9.865 65.9±9.8 <0.001
Female (%) 29.8 30.3 32.0 0.31
Never smoked (%) 36.0 41.5 39.0 <0.001
Hypertension treated (%) 82.3 79.5 77.7 0.001
Hyperlipidaemia 77.9 76.9 78.8 0.04
Previous MI (%) 46.1 46.4 44.2 0.50
Previous PCI (%) 41.3 44.9 46.4 <0.001
Previous CABG 17.8 18.5 18.2 0.74
Diabetes (%) 100 100 100 <0.001
- Insulin treatment 47.2 52.3 49.5
- No insulin treatment 52.4 47.7 50.2
GP IIbIIIa (%) 9.5 11.9 7.9 <0.001
Indication for index 
procedure
<0.001
Stable angina (%) 33.9 35.4 35.8
Unstable anigina (%) 53.8 50.6 54.7
STEMI (%) 10.0 11.5 8.1
Other (%) 2.3 2.6 1.3
treated vessel and lesion 
type
0.001
LM (%) 3.3 4.1 2.8
LAD (%) 42.8 39.9 42.6
LCX (%) 22.9 24.4 24.2
RCA (%) 26.2 26.3 25.2
Vein graft (%) 4.8 5.3 5.3
1-VD (%) 28.3 28.6 34.3 <0.001
2-VD (%) 33.7 32.9 33.4
3-VD (%) 28.2 26.6 25.5
Left main (%) 7.6 9.4 4.4
Type A-B1 lesion (%) 40.9 38.0 33.5 <0.001
Type B2-C lesion (%) 59.1 62.0 66.5
De novo (%) 89.8 86.6 80.7 <0.001
In stent restenosis (%) 10.2 13.4 19.3 <0.001
CTO (%) 4.9 4.3 6.1 0.08
Stent length (mm, SD) 19.4±7.4 19.4±6.9 18.6±7.2 <0.001
Stent diameter (mm, SD) 2.91±0.47 2.87±0.42 2.98±0.54 <0.001
Mean number of stents 2.23±1.25 2.03±1.11 2.34±1.34 <0.001
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Anticoagulant use
Heparin 74.1 84.2 59.0 <0.001
LMWH 7.4 3.6 9.3 <0.001
Bivalirudin 17.6 11.4 30.9 <0.001
Antiplatelet prior to PCI
Aspirin 96.2 96.4 95.8 0.74
Clopidogrel 88.2 85.5 85.7 0.002
Warfarin 1.2 1.8 1.2 0.03
CTO = chronic total occlusion; GP IIbIIIa = glycoprotein IIbIIIa inhibitor; LAD = left anterior descending; 
LCX = left circumflex artery; LM = left main; LMWH = low molecular weight heparin; PCI = percutaneous 
coronary intervention; RCA = right coronary artery; STEMI = ST-segment elevation myocardial infarction * 
1st generation
table 2. Adjusted hazard ratios for restenosis, stent thrombosis and all-cause mortality
Stent type
nr of 
stents
restenosis 
nr
Adjusted 
hazard ratio 
(95% CI)
Stent 
thrombosis 
nr
Adjusted 
hazard ratio 
(95% CI)
nr of 
patients
Deaths 
nr 
Adjusted 
hazard ratio 
(95% CI)
All diabetics
Everolimus 3928 113 1.0 27 1.0 1915 82 1.0
Paclitaxel
2836 96 1.05 (0.71-1.55) 34 1.74 (0.82-3.71) 1386 76 1.69 (1.06-
2.72)
Everolimus 3928 113 1.0 27 1.0 1915 82 1.0
Serolimus
1370 64 1.26 (0.77-2.08) 18 2.87 (1.08-7.61) 717 35 2.02 (1.03-
3.98)
Insulin-treated
Everolimus 1855 73 1.0 17 1.0 880 49 1.0
Paclitaxel
1484 68 1.21 (0.74-1.98) 30 2.37 (0.97-5.81) 703 50 1.99 (0.82-
4.86)
Everolimus 1855 73 1.0 17 1.0 880 49 1.0
Serolimus
678 36 0.95 (0.48-1.88) 12 2.67 (0.76-9.44) 357 24 1.98 (1.07-
3.68)
non-insulin treated
Everolimus 2060 40 1.0 10 1.0 1028 33 1.0
Paclitaxel
1352 28 0.81 (0.41-1.59) 4 0.69 (0.13-3.67) 683 26 1.44 (0.67-
3.11)
Everolimus 2060 40 1.0 10 1.0 1028 33 1.0
Serolimus
688 26 1.76 (0.82-3.77) 6 3.41 (0.70-16.57) 357 11 2.22 (0.75-
6.61)
95%CI = 95% confidence interval. 
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insulin dependent DM patients. In the EES to PES comparison no differences 
were observed between groups, however a small trend for better outcomes 
with EES was observed in insulin treated DM while the opposite trend was 
observed in non-insulin treated DM. A significant interaction between stent 
type and insulin dependence was found for restenosis outcomes for EES vs. PES 
(p<0.001) and EES vs. SES (p=0.001).
For all diabetics, rates of ST were numerically higher for both PES and SES 
as compared to EES, with a significantly higher risk for SES (Table 2). For the 
insulin-treated subgroup, stent thrombosis rates were not significantly differ-
ent among stents, albeit numerically higher for both PES and SES compared 
to EES. Among the non-insulin treated diabetics a trend towards higher stent 
thrombosis rates was found for SES compared to EES, whereas the opposite 
was found for PES. For cumulative 1-year rate of stent thrombosis (Figure 2) a 
significant interaction between stent type and insulin treatment was found for 
EES vs. PES (p<0.001), but not EES vs. SES (p=0.31).
Insulin treated Non-insulin treated
Insulin treated Non-insulin treated
Figure 1 Time to event Kaplan-Meier curves of propensity score adjusted in-stent restenosis. Data 
stratified to insulin treated (left) and non-insulin treated (right). 
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DISCuSSIOn 
The major findings of the present analysis, the largest study up to date compar-
ing the outcomes of first and second generation DES in DM, are  1) treatment 
with EES was associated with a significantly lower all-cause mortality when 
compared respectively to SES and PES, 2) that EES was associated with signifi-
cantly lower rates of  definite ST when compared to SES and a trend for lower 
ST when compared to PES, 3) no significant differences in restenosis rates were 
observed when comparing EES with PES and EES with SES in DM patients and 
finally 4) that there is a significant interaction for restenosis outcomes in EES 
and PES as well as EES and SES when stratified for non-insulin treated DM vs. 
insulin treated DM.
Insulin treated Non-insulin treated
Insulin treated Non-insulin treated
Figure 2 Time to event Kaplan-Meier curves of propensity score adjusted definite stent thrombosis. Data 
stratified to insulin treated (left) and non-insulin treated (right). 
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While the performance of EES and PES in DM has been extensively studied in 
large randomized trials as well as patient level pooled databases, there is a pau-
city of data when comparing the EES with SES in all-comer DM patients.8,9,15,16 
However all available studies comparing EES to SES or PES have been inad-
equately powered to provide answers on end-points such as all-cause mortality 
and ST, as well as providing insights on treatment effect differences on DM 
patients when further stratified according to insulin treatment. As dedicated 
randomised and adequately powered trials to study such low frequency events 
may represent significant organizatory or financial challenges, data from large 
national registers can be used to provide insights that can further guide our 
daily clinical practice and future research, as is the case here. Indeed this study 
reports for the first time a significant difference in all-cause mortality between 
EES as compared separately to SES and PES. Such a finding should mainly be 
attributed to the magnitude of this analysis that with its almost 5000 patients 
represents the largest study that has analysed the most used first generation 
SES and PES with a second generation drug eluting stent in a DM population. 
What is striking is that the mortality outcomes with EES as compared to SES or 
PES, in all DM patients, as well as in DM patients stratified for insulin depen-
dence closely parallel the outcomes of definite ST. The reduction in mortality 
rates with EES may be attributed to the lower rates of definite ST, which as 
shown in previous studies has a strong correlation with death or myocardial 
infarction.17 
The EES was associated with a significantly lower rate of  ST when compared 
to SES in the total DM population. The same trend was observed also after 
stratifying for insulin treatment. The second generation EES has emerged as 
a very promising stent with low rates of ST, as concluded from several large 
prospective randomised trials with moderate risk or all-comer patients, but 
this is the first time that such a finding was observed specifically in a large 
cohort of DM patients7,8. The pathophysiological mechanism(s) underlying 
the marked reduction in ST following EES implantation, although speculative, 
may relate to specific design features of this stent. The combination of thin, 
fracture-resistant struts, the low dose of everolimus, and the thromboresistant 
non-inflammatory proprieties of the fluorinated polymer may contribute to 
the lower rates of early ST with EES.18,19 Another possible mechanism may be a 
more rapid and complete stent re-endothelialisation as observed in pre-clinical 
animal models.19  However such advantages offered from EES as compared to 
PES in non-diabetics are less pronounced in DM patients as shown also from 
the present analysis.20 Interestingly, a significant reduction on definite ST with 
EES as compared to PES was observed also in the insulin treated DM patients, 
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while an opposite trend was observed in non-insulin treated DM. Although 
such findings can be due to chance, it is also known that insulin treated DM 
represents the most severe form of this condition, which often has a longer 
duration and therefore can be expected to be associated with a more severe 
form of coronary disease. This could be the reason why the rates of ST with 
PES (as shown in Figure 2) in the insulin treated IDDM patients were higher in 
this subgroup, similarly as observed in other high risk populations.21 However, 
it cannot be excluded that different treatment effects of EES as compared to 
PES may be present in DM patients when stratified for insulin dependence, 
therefore more evidence is needed to clarify this issue. 
Another important finding is that this study, despite its large size, could not 
detect any significant differences in restenosis rates between EES and PES as 
well as EES and SES. These results corroborate previous findings from other 
studies comparing EES to PES or SES in DM.9,10,22 No difference in restenosis rates 
between EES and PES or EES and SES could be detected even when the analysis 
was performed in DM patients stratified for insulin dependence, however a 
significant interaction was detected for EES as compared to PES or SES.  Indeed 
these findings reflect once more the severity and complexity of the coronary 
disease in DM patients. These patients are known to have increased oxidative 
stress and profound endothelial dysfunction, both factors which are believed 
to strongly impact intracellular signal transduction. As a result the cell growth 
and migration inhibition (anti-restenotic effect) exerted from both paclitaxel 
or rapamycin analogs is altered in these patients, resulting in a similarly af-
fected efficacy for both rapamycin-analogs or paclitaxel eluting stents.23,24 The 
imbalance in efficacy outcomes with EES as compared to PES, as indicated from 
the observed interaction when stratified for IDDM and NIDDM may also rely on 
the impact of the insulin resistance on the mechanism of action of the active 
principle eluted from these stents. While the mechanism of action of paclitaxel 
may be less influenced from the DM status, the rapamycin (and other rapa-
mycin analogs) inhibition of mTOR may be affected by the insulin resistance 
as it is regulated from glycosilation-dependent enzymes.25 However, as the 
intracellular signalling pathways in these patients are very complex and not 
entirely understood, this interpretation should be only regarded as a hypoth-
esis which needs further investigation.  A significant interaction was observed 
also in EES versus SES comparison in IDDM and NIDDM. Although both stents 
do elute a rapamycin-analog, the polymer and release kinetics of the SES and 
EES differ from each other in that sirolimus is released at a higher dose and for 
a longer period of time than everolimus.26 The SES specific release kinetics may 
offer some advantages in protection from restenosis in DM patients, which 
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magnitude seems to parallel the DM severity. However, although this release 
kinetics of SES may in a way counterbalance the design related disadvantages 
such as thicker stent struts and polymer layer, and in term of efficacy lead to 
similar outcomes as EES, it may render this device more vulnerable to ST, as 
indeed observedIn the light of this findings the newer, recently introduced, 
modern design, rapamycin-analogs or paclitaxel–eluting stents with durable, 
bioabsorbable or polymer-free platforms may theoretically represent valid 
alternatives on regards of both safety and efficacy in percutaneous treatment 
of DM patients, and therefore need to be studied in large and dedicated ran-
domised trials.
This study has several limitations. This analysis represents a retrospective 
register study, therefore due to lack of randomisation, differences may arise 
on baseline characteristics, however adjustments for baseline differences 
were implemented using propensity score analysis, for each individual stent 
comparison incorporating 22 baseline variables. In this study the analysis of 
device performance was performed on the device level and therefore can dif-
fer slightly from endpoints used in other trials. Indeed the clinically driven 
restenosis detection, the efficacy endpoint in this study, differs from the clas-
sical TVR/TLR endpoint, however, in our opinion, it offers an more accurate 
evaluation of device efficacy than the classical endpoints, as explained in the 
method section. 
This analysis incorporates only patients included in SCAAR, these results 
represent only the Swedish population  and the standard of care, however 
Sweden has adopted the ESC guidelines and therefore we do believe that they 
can be extrapolated to the rest of the western world. 
In conclusion, this analysis, the largest to date to study the impact of second 
generation EES in DM patients as compared to first generation PES and SES 
showed significantly lower rates of  all-cause mortality for EES; an effect that 
may mainly rely on the safety improvements with this device, as no differences 
in efficacy outcomes were observed between these stents. Further data from 
large clinical trials, are needed to clarify if either rapamycin-analogs or pacli-
taxel, eluted from modern stent designs, should become the eluting principle 
agent of choice in DM patients.
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SuMMArY Of tHe tHeSIS
Nowadays, as PCI has become the treatment modality of choice for patients with 
coronary heart disease and millions of  patients worldwide are treated with 
PCI each year, device short and long term differences in treatment outcomes 
do have important implications for global health. Thanks to improvements in 
device design and performance, new techniques and  treatment strategies, 
major achievements has been possible even in patients with complex and 
severe coronary disease. This thesis reflects the results of our research with 
the second generation EES in all-comer patients as well as high risk patients 
presenting with MI or diabetes mellitus. The results, their clinical impact, and 
future implications  will be discussed in detail below. 
Chapter 2. 
In the COMPARE trial the use of second-generation EES as compared with PES, 
was associated with a significant reduction in the risk of major adverse cardiac 
events at 1 year. The outcome of the primary endpoint was consistent across all 
but one subgroup:  patients with diabetes mellitus. The superior outcome with 
EES was a result of reduction in the rate of non-fatal MI, a safety component of 
the primary endpoint, and reduction in repeat revascularisation of the target 
vessel, while the rates of all-cause or cardiac mortality did not differ between 
the two groups.  The significantly lower rate of MI with  EES was already ap-
parent at 30 days and was attributable to a significantly lower rate of early 
ST as there was no significant difference between the groups in the rate of 
periprocedural MI.
In the second paper we have shown that the substantial clinical benefit of 
the EES stent over the PES with regard to measures of both safety and  ef-
ficacy is maintained at 2 years in real-life practice. We observed an increasing 
benefit in terms of safety and efficacy between one and two years. The benefit 
associated to EES usage, at 2 years, was driven by reductions in both MI and 
TVR. A further reduction in ST was observed between 1-2 years resulting in a 
reduction of cumulative ST at 2 years. As was the case at one year also at two 
years no differences were observed in the outcomes of the primary endpoint 
between EES and PES in the diabetic population. Further research was there-
fore required to understand the lack of benefit of EES over PES in this setting, 
or if larger populations should be studied to detect underlying differences in 
this subset of patients. 
Importantly the safety of the EES is maintained also in the subgroup of 
patients presenting with MI as shown in the third paper of this chapter. In this 
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study the use of the second generation EES in percutaneous coronary interven-
tion for acute myocardial infarction, as compared to PES, was associated with 
a significant reduction in the risk of both primary and secondary endpoint. 
These event-free survival improvements with EES were driven by a reduction in 
repeat TVR/TLR as well as non-fatal MI, a safety component of the primary and 
secondary endpoint, while no apparent differences were observed in rates of 
all-cause and cardiac mortality. In respect to the primary as well as secondary 
endpoints the curves separate already early, effect that grows in magnitude 
through the 2-year follow-up period.
Another notable finding of this study is that the use of EES was associated 
with a significant reduction in ST, when compared to PES. We also note that 
EES, in terms of safety performs at least as safe as BMS when used in MI set-
ting, when historically compared.
The treatment effect is maintained also for the STEMI and NSTEMI subgroups 
with respect to the primary and secondary endpoints, including their compo-
nent endpoints and ST.
The impact of the previous findings results in the following clinical impact 
and perspectives: (1) based on the finding of COMPARE and SPIRIT IV first 
generation PES is mainly not used any more worldwide, while the use of PES 
with modern designs in DM is being studied,  (2) COMPARE, was historically 
important as for the first time it showed that with the second generation 
EES, efficacy improvements could be matched also by safety improvements, 
even in all-comer populations, opening new bright horizons for percutaneous 
treatment in patients with complex coronary disease, (3) in setting of AMI, 
the long held concerns on safety of DES are no more grounded with the new 
generations of DES and particularly with the second-generation EES, and 
therefore the widespread use of DES for treatment of AMI should be guided 
by cost-effectively trials, (4) that the outcomes of the major cardiovascular 
events and ST in MI patients treated with EES are not different than those 
of the all-comer population, and therefore the  MI patients on a long term 
device outcome perspective should not be considered as high risk. Together 
with what discussed in point 3) treatment with modern generation DES offers 
new perspectives for new strategy approaches on regard to the  percutaneous 
intervention treatment as well as antiplatelet therapy of MI patients. 
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Chapter 3
The SPIRIT IV and COMPARE trials, discussed together in the first paper, have 
demonstrated that large-scale studies in complex patients and lesions are 
required to elicit important clinical differences between devices. 
Based on the results of these two trials, the belief that had previously been 
held by some that clinically relevant differences between DES of various de-
signs do not exist (the so called DES class effect)  has clearly been discredited. 
Greater mechanistic insights into how the design proper ties of the EES trans-
late into improved safety and effectiveness compared with earlier designs will 
no doubt spur development of even safer and more effective devices. These 
trials have also shown that low angiographic late loss (resulting in greater 
efficacy) as well as improved safety may be simultaneously achieved in a single 
DES platform. Both trials showed strikingly similar relative risk reductions in 
thrombotic events with EES compared with PES at 30-day and one-year follow-
up, with the majority of the stent thromboses occurring during the first 30 
days. Until recently, the interventional community has been focused on very 
late stent thrombosis (after one year) given the ongoing propensity of first-
generation DES to occlude acutely after one year when compared with BMS. 
However, early stent thrombosis accounts for the majority of stent thrombosis 
events during follow-up. This is even more evident in complex populations as 
shown in the COMPARE trail. It  becomes therefore evident that in order to 
reduce the ST outcomes with new devices, the technological improvements 
should focus not only on reduction of very late ST, but most importantly, in the 
reduction of early ST as is the case with EES. 
The second paper, a result of a collaboration with the New York based 
Cardiovascular Research Foundation and Columbia University as well as with 
the University of Cincinnati, Ohio and Erasmus Medical Centre affiliated to 
the Erasmus Universiteit Rotteradm, The Netherlands, with its 6785 patients 
represented the largest study comparing ST rates between a first and second-
generation DES at the moment is was performed, and was powered enough to 
study time frame outcomes (landscape analyses) as well as identify predictors 
of ST. The major finding of this analysis was that EES markedly reduced the 
2-year rates of ST compared to PES, with significant difference in ST frequency 
present at every time interval examined through the 2-year follow-up period. 
By multivariable analysis, stent type (PES compared to EES) was found to be an 
independent predictor of 2-year ST. Younger age, diabetes mellitus, multives-
sel treatment and lesion length were also predictive factors for ST. 
Importantly the reduction in ST was accompanied by a reduction in the com-
posite occurrence of cardiac death or MI.
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The premise that EES-treated patients, due to the improved safety profile 
compared to the first generation DES, may require shorter durations of DAPT 
is also supported by the findings of the current analyses. Indeed interruption 
of DAPT at any time point after the first month did not influence the rate of 
ST at two years in the EES cohort. After excluding events within the first 6 
months, no difference was observed with regard to ST rates in the EES cohort 
regardless of DAPT compliance, suggesting that permanent DAPT interruption 
beyond 6 months following EES implantation may be safe. In contradistinction, 
we found that discontinuation of DAPT following PES deployment any time 
before 24 months (but especially between 1 and 6 months) was associated 
with increased rates of ST.
Such findings remain hypothesis generating but shorter duration of DAPT, 
which may be associated with lower bleeding risks and therefore lower mortal-
ity,  are being intensively studied in different prospective randomised clinical 
trails worldwide. 
Chapter 4
The first paper represents the larges patient level pooled database ever anal-
ysed to date, evaluates the relative safety and efficacy of different DES types 
stratified by the presence of diabetes mellitus, showed the following impor-
tant findings: (1) that a significant interaction was present between diabetic 
status and treatment with EES compared with PES on the relative risk of 2-year 
clinical outcomes, reflecting measures of both safety and efficacy; (2) that in 
patients without diabetes mellitus, treatment with EES compared with PES 
reduced the 2-year rates of death, MI, stent thrombosis, ischemia-driven TLR, 
and MACE, whereas in patients with diabetes mellitus, there were no signifi-
cant differences in clinical outcomes at 2 years between the stent types; and 
(3) that an additional interaction was identified among patients with diabetes 
mellitus so that the 2-year rate of ischemia-driven TLR was reduced with EES 
compared with PES in those not requiring insulin, whereas the opposite trend 
was observed in those who were treated with insulin. 
The second paper represents the largest retrospective register analysis which 
focuses only on treatment differences with first and second generation DES 
in patients with medically treated diabetes mellitus, was performed using the 
data of the Swedish Coronary Angiography and Angioplasty Register (SCAAR) 
thanks to the cooperation with the Department of Medical Sciences Uppsala 
University , Department of Cardiology, Lund University, and the Cardiology 
Department, Heart and Lung Institute of the Sahlgrenska University Hospital, 
Göteborg, Sweden.
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The outcomes of this study, representing all-comer patients DM patients 
treated with PCI in Sweden, showed that:   (1) treatment with EES was associ-
ated with a significant lower rates of all-cause mortality when compared re-
spectively to SES and PES,  (2) that there is a significant lower rate of definitive 
ST with EES as compared to SES and, although significance was not reached, 
the same important trend was observed also when compared to  PES,  (3) that 
no significant differences in restenosis rates were observed when comparing 
EES with PES and EES with SES in DM patients and finally, ( 4) that there is a 
significant interaction for restenosis outcomes in EES and PES as well as EES 
and SES when stratified for NIDDM vs. IDDM.
While pointing for the first time to important safety improvements, as rep-
resented from the lower rates of mortality with EES, this study concords with 
the previous one in that there is room for improvement, especially in efficacy 
outcomes in patients with diabetes mellitus and that other large size stud-
ies are required to study: (1) whether rapamycin-analogs or paclitaxel should 
become the eluting principle agent of choice in DM patients, (2) the impact 
of drug -elution profile and especially of the elution time, (3) the impact of 
the stent design focusing in the type of metal alloys, strut thickens and role 
of polymer.
new clinical trials and future perspectives 
The research presented in this thesis has opened new horizons for the in-
terventional cardiology. Indeed different hypothesis, generated on the base 
of the outcomes with EES from our own studies and from the results of the 
patient –level pooled database of SPIRIT II, III, IV and COMPARE trials, have 
now been transformed in new already ongoing clinical trials. 
Based on the improved outcomes with EES in MI patients (STEMI and NSTEMI) 
in efficacy and specifically, safety endpoints, new treatment strategies in STEMI 
are being tested. The COMPARE -ACUTE is a prospective, randomised, multi-
centre trail that is comparing (for superiority) the clinical outcomes between 
two treatment strategies in almost 900 STEMI patients: a new revascularisation 
strategy, guided by fractional flow reserve measurements, for treatment of 
non-culprit arteries during the same procedure or hospitalisation versus the 
staged revascularisation based on evidence of ischemia on non invasive tests, 
which  represents the actual strategy of choice, as recommended from the 
guidelines.  
Another prospective, randomised, multicentre trial (DAPT-STEMI) is testing 
(for non-inferiority in terms of net (TIMI major bleeding included) clinical 
major cardiovascular events) the duration of DAPT after stenting with DES 
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in STEMI patients. In this trial approximately 1100 patients will be enrolled 
and the event-free patients at 6 months (approximately 1000) will be further 
randomised in single (aspirin alone) arm versus double antipaletelet therapy 
(aspirin and a P2Y12 inhibitor) arm and will be followed for 18 months after 
randomisation.  
Furthermore results of the SPIRIT series of trials and COMPARE trials, allowed 
us to examine how the results of the randomized SYNTAX trial, a 1700-patient 
study of PES versus CABG in patients with left main and three-vessel coronary 
artery disease, might have been influenced if EES was used in place of PES. As 
result of this paper, published last year in the Netherlands Heart Journal to-
gether with the colleagues from the Academic Medical Centre affiliated to the 
University of Amsterdam,  we concluded that the use of EES rather than PES 
in the SYNTAX trial might have led to a total reduction of 81 events in the PCI 
group, much more than the 20 needed events to declare noninferiority for PCI 
in this trial. This analysis, of course, is only a hypothesis-generating exercise; 
whether PCI with the EES is truly noninferior (or superior) to CABG in patients 
with complex coronary artery disease can only be determined by a dedicated 
large randomized controlled trial. Indeed such trial (The international Evalua-
tion of XIENCE Prime versus Coronary Artery Bypass Surgery for Effectiveness 
of Left Main Revascularization (EXCEL)), a large-scale randomized trial of EES 
versus CABG for left main disease, which plans to randomise 2500 patients 
has started, and if positive will establish PCI as the treatment of choice for the 
most complex patients with coronary artery dis ease. 
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Conclusions 
The present thesis has shown that
a) The second generation everolimus-eluting stent is associated with signifi-
cant improvements in both efficacy and safety outcomes compared to the 
first generation paclitaxel-eluting stent in all-comer patients at one and 
two years, and proved for the first time that differences in the stent tech-
nology between different DES can lead to significant clinical benefits. 
b) These results hold true at two years also in the subgroup of patients pre-
senting with myocardial infractions, either STEMI or NSTEMI, and therefore 
have help to mitigate the long disbelieve in DES safety in this setting. 
c) That by reducing ST in all time points up to two years, everolimus-eluting 
stents have set new standards in term of DES safety. This device favorable 
safety profile might open the way to shorter dual antiplatelet therapy 
regimens, which in turn might result in important clinical benefits, due to 
less bleeding complications. 
d) That the better safety outcomes, of everolimus-eluting stent as compared 
to the most used first-generation DES might be extended also to the sub-
group of patients with diabetes mellitus, while this is not yet the case for 
the efficacy endpoints, where further research is needed.
e) And finally the improvement on clinical outcomes with this device has 
opened the way to new clinical trials which outcomes may further shape 
the future of interventional cardiology. 
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Korte samenvatting van het proefschrift
Er is grote vooruitgang geboekt in de invasieve behandeling van patiënten 
met ernstig en complex coronarialijden dankzij verbeteringen in het ontwerp 
en de functie van stents, nieuwe invasieve technieken en behandelstrategieën. 
Dit proefschrift beschrijft de resultaten van ons onderzoek met een tweede 
generatie EES in een ‘all-comer’ populatie met een groot aantal hoog risico 
patiënten.
Achtereenvolgens zullen de resultaten, de klinische relevantie en nieuwe 
ontwikkelingen worden besproken.
Hoofdstuk 2: In de COMPARE studie werd, door gebruik te maken van een 
tweede generatie EES in vergelijking met een PES, na 1 jaar follow-up een 
significante reductie van MACE gezien. Deze betere uitkomst bij het gebruik 
van EES was een gevolg van een reductie in de incidentie van niet-fataal myo-
cardinfarct en een reductie in nieuwe revascularisatie van het behandelde vat. 
Tussen de beide groepen werd echter geen verschil gezien in cardiale sterfte. 
De significante lagere incidentie van een niet-fataal myocardinfarct in de 
EES groep was al zichtbaar na een follow-up periode van 30 dagen, alsmede 
na  een follow-up van 1 jaar.
In het tweede artikel laten we zien dat in de dagelijkse praktijk het klinische 
voordeel van EES ten opzichte van PES in zowel veiligheid als in effectiviteit 
ook na een follow-up periode van  twee jaar blijft bestaan. Het voordeel van 
EES ten opzichte van PES neemt zelfs significant toe bij 2 jaar follow-up ten 
opzichte van 1 jaar. Het voordeel door het gebruik van EES, bij 2 jaar follow up 
was met name te danken aan de reductie in MI en TVR. Een verdere toename 
in de reductie van stent trombose na 2 jaar follow-up ten opzichte van 1 jaar 
follow-up leidde uiteindelijk tot een significante reductie van stent trombose 
op 2 jaar.
Eveneens wordt de veiligheid van de EES in de groep patiënten met een 
acuut myocardinfarct vastgesteld waarvan de resultaten in het derde artikel 
van dit hoofdstuk worden beschreven. In dit onderzoek tonen we aan dat er 
een lagere incidentie is van zowel het primaire als het secundaire eindpunt 
in patiënten met een myocardinfarct die werden behandeld met een EES in 
vergelijking met PES. Dit werd voornamelijk veroorzaakt door een afname 
van het aantal re-TVR/TLR en van het aantal niet-fatale myocardinfarcten, een 
veiligheidsmaat voor de primaire en secundaire eindpunten. Er was in beide 
groepen geen verschil aantoonbaar in cardiale en niet-cardiale mortaliteit.
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Een andere belangrijke uitkomst van dit onderzoek is dat het gebruik van 
EES geassocieerd is met een reductie van het aantal stent tromboses in ver-
gelijking met PES. De incidentie van stent trombose bij patiënten met een 
acuut myocardinfarct die behandeld worden met een EES is te vergelijken met 
historische data over de incidentie van stent trombose bij BMS. Het klinische 
voordeel in effectiviteit en veiligheid van EES ten opzichte van PES was zowel 
in de NSTEMI als in de STEMI patiënten aantoonbaar.
Hoofdstuk 3: De SPIRIT IV en COMPARE studie, beiden besproken in het eerste 
artikel, hebben laten zien dat groot opgezette onderzoeken in patiënten 
met complexe laesies nodig zijn om belangrijke klinische verschillen tussen 
coronaire stents aan te tonen.
Op basis van deze twee onderzoeken kan de tot voor kort geldende ge-
dachte dat er geen werkelijke klinische verschillen zouden bestaan tussen de 
verschillende typen DES, of dat er sprake zou zijn van een zogenaamde DES 
klasse effect, worden ontkracht. In de toekomst zal een beter mechanistisch 
inzicht in hoe het ontwerp van EES leidt tot verbeterde veiligheid en effectivi-
teit ongetwijfeld leiden tot ontwikkeling van nog beter presterende coronaire 
stents. Ook hebben deze onderzoeken aangetoond dat het mogelijk is om in 
een type coronaire stent gelijktijdig zowel de veiligheid als ook de effectiviteit 
te verbeteren.
Beide onderzoeken hebben dezelfde mate van reductie in trombotische events 
met EES aangetoond vergeleken met PES na 30 dagen en 1 jaar follow-up, 
waarbij de meeste stent trombose werd gezien in de eerste 30 dagen. Tot 
voor kort was er onder interventiecardiologen en onderzoekers met name 
aandacht voor ‘very-late’ stent trombose (meer dan 1 jaar na implantatie). Met 
name eerste generatie drug-eluting stents toonden vrij veel stent trombose 
na 1 jaar in vergelijking met bare-metal stents. Vroege stent trombose vormt 
echter het grootste deel van de stent trombose events tijdens follow-up. Dit is 
nog meer uitgesproken in hoog risico patiënten met complexe laesies zoals in 
de COMPARE studie. Het is daarom belangrijk dat bij de toekomstige ontwik-
keling van nieuwe devices niet alleen gefocust moet zijn op reductie van erg 
late stent trombose, maar belangrijker nog, met name gericht moet zijn op 
het reduceren van vroege stent trombose zoals in EES.
Het tweede artikel beschrijft de grootste studie -op het moment van ver-
schijnen- die stent trombose incidentie vergelijkt tussen een eerste en tweede 
generatie DES. Deze studie had genoeg statistische ‘power’ om ‘time frame 
outcomes’ (landscape analyse) en voorspellers van stent trombose te bestu-
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deren. De belangrijkste uitkomst was dat EES het risico op stent trombose 
duidelijk verminderd in vergelijking met PES. Dit verschil was significant in alle 
geanalyseerde tijdsintervallen in de 2 jaars follow-up. Bij multivariate analyse 
was het type stent (PES vergeleken met EES) een onafhankelijke voorspeller 
van stent trombose. Lagere leeftijd, diabetes mellitus, meervats behandeling 
en lengte van de behandelde laesie waren ook onafhankelijke voorspellers 
voor stent trombose. Belangrijk is te vermelden dat een reductie in stent trom-
bose gepaard ging met een reductie in het gecombineerde eindpunt cardiale 
dood of myocardinfarct .
De gedachte dat patiënten die behandeld zijn met EES vanwege de toege-
nomen veiligheidsprofiel in vergelijking tot de eerste generatie DES mogelijk 
korter kunnen worden behandeld met DAPT wordt ondersteund door de 
uitkomsten van de huidige analyse. Het stoppen van DAPT op een willekeurig 
moment 1 maand na stent plaatsing had geen invloed op de incidentie van 
stent trombose tot 2 jaar follow-up in het EES cohort. Na exclusie van events 
in de eerste zes maanden werd er geen verschil gevonden in de incidentie van 
stent trombose onafhankelijk van de compliantie van DAPT. Dit suggereert 
dat patiënten die zijn behandeld met een EES mogelijk al na 6 maanden het 
gebruik van DAPT veilig kunnen staken.
Hoofdstuk 4: In het eerste hoofdstuk wordt een analyse beschreven uitge-
voerd op  een uit verschillende studies samengesteld patiëntenbestand, waarbij 
naar de relatieve veiligheid en effectiviteit van verschillende type DES is geke-
ken en de groep is gestratificeerd naar het hebben van diabetes (suikerziekte). 
De belangrijkste bevindingen in deze studie waren: 1) er is een significante 
interactie tussen het hebben van diabetes en de mate van veiligheid en ef-
fectiviteit van de stent op 2 jaar als er een vergelijking wordt gemaakt tussen 
EES en PES, 2) indien de patiënt geen diabetes heeft, reduceert behandeling 
met een EES de kans op dood, myocardinfarct, stenttrombose, de noodzaak 
tot reinterventie van het letsel en MACE op 2 jaar, vergeleken met PES, echter 
wanneer de patiënt wel diabetes heeft is er geen verschil in effectiviteit tus-
sen de verschillende stent types op 2 jaar; 3) binnen de groep met diabetes 
verlaagd EES t.o.v. PES de 2-jaar kans op de noodzaak tot reinterventie van 
het letsel in die groep van diabeten die geen insuline nodig hebben, terwijl 
het omgekeerde het geval was voor die diabeten die wel insuline-afhankelijk 
waren. In het tweede hoofdstuk wordt een grote retrospectieve register ana-
lyse beschreven die kijkt naar mogelijk effectiviteits verschillen tussen eerste 
en tweede generatie DES bij patiënten die met medicijnen worden behan-
deld voor diabetes. Hierbij is gebruik gemaakt van gegevens uit het Swedish 
Coronary Angiography and Angioplasty Register (SCAAR). De resultaten van 
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deze studie die keek naar de totale groep patiënten met diabetes in Zweden 
die een dotterbehandeling ondergingen, toonden aan dat: 1) de behandeling 
met een EES was geassocieerd met een significant lager voorkomen van dood 
vergeleken met SES en PES; 2) de behandeling met EES een significant lager 
aantal stenttromboses opleverde vergeleken met SES, en dat eenzelfde trend 
werd gezien voor de vergelijking met PES, echter dat deze verschillen geen 
significantie bereikten; 3) er geen verschil in de kans op restenose was tussen 
de verschillende stent types (EES, PES en SES) bij deze diabeten.
Ofschoon er nu voor het eerst belangrijke veiligheidsverbeteringen zijn 
aangetoond voor het gebruik van EES bij patiënten met diabetes, bestaande 
uit een lager aantal overlijdens, sluit deze studie aan bij de bevindingen uit de 
eerdere analyse dat er nog voldoende ruimte is voor verbetering, met name 
wat betreft effectiviteit. Voor patiënten met diabetes mellitus zijn daarom 
grotere studies nodig om te kijken naar: 1) of rapamycin-analogen of paclitaxel 
het voorkeursmedicijn moet worden bij patiënten met diabetes, 2) de rol van 
het afgifteprofiel en met name de afgifte tijd, 3) de rol van het ontwerp van 
de stent, het type metaal, de stentdikte en de rol van het gebruikte polymeer.
nIeuWe StuDIeS en tOeKOMStPerSPeCtIeVen
De studies die in dit proefschrift worden beschreven zetten nieuwe deuren 
open voor de interventiecardiologie. Reeds nu al zijn nieuwe hypothesen, 
ontstaan uit de ervaringen met EES uit onze eigen studies en uit de samenge-
stelde database van de SPIRIT II, III, IV en COMPARE trials, omgezet in nieuwe 
reeds lopende onderzoeken. Gebaseerd op de betere uitkomsten met EES bij 
patiënten met acuut myocardinfarct (STEMI en non-STEMI) met betrekking 
tot effectiviteits -en vooral veiligheidseindpunten, worden er op dit moment 
al nieuwe strategieën voor de behandeling van STEMI getest. De COMPARE-
ACUTE studie is een prospectief, gerandomiseerde, multicenter studie die de 
klinische uitkomsten tussen twee behandelstrategieën vergelijkt (superiority) 
in bijna 900 STEMI patiënten. In deze studie wordt een nieuwe revascularisatie 
strategie bij STEMI, opgeleide van fractional flow reserve, voor de behandeling 
van “non-culprit” vaten in dezelfde sessie versus gestadieerd en opgeleide van 
non-invasief gemeten ischemie, getest, hetgeen overeenkomt met de stan-
daard guidelines behandeling. Een andere prospectieve, gerandomiseerde, 
multicenter studie (DAPT-STEMI) onderzoekt (gericht op non-inferiority m.b.t. 
netto klinisch majeure cardiovasculaire voorvallen, inclusief TIMI majeure bloe-
dingen) de duur van DAPT na het gebruikt van een DES in patiënten met een 
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STEMI. In deze studie zullen ongeveer 1000 patienten worden geincludeerd 
en de mensen die geen ernstig voorval hebben gehad in de eerste 6 maanden 
na behandeling (ongeveer 1000) zullen worden gerandomiseerd naar enkele 
(alleen aspirine) versus duale antiplaatjestherapie (aspirine en P2Y12 remmer) 
en zij zullen gedurende 18 maanden worden vervolgd.
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COnCluSIeS
Dit proefschrift heeft laten zien dat:
a. De tweede generatie everolimus-afgevende stents zijn geassocieerd met 
een significante verbetering in zowel effectiviteit en veiligheid vergeleken 
met de eerste generatie paclitaxel-afgevende stents op 1 en 2 jaar bij een 
gemengde groep patienten. Hiermee is voor de eerste keer aangetoond 
dat verschil in stenttechnologie binnen DES ook daadwerkelijk kunnen 
leiden tot verschil in klinische uitkomsten.
b. De resultaten bestendigen zich ook op 2 jaar voor de subgroep van pa-
tienten die zich presenteren met een myocardinfarct, of STEMI of NSTEMI, 
en helpen hiermee de zorg voor DES veiligheid in deze populatie weg te 
nemen.
c. Door het verlagen van de kans op stenttrombose tot 2 jaar, hebben de 
EES een nieuwe standaard gezet m.b.t. DES veiligheid. Dit gunstige profiel 
zet de deur open naar korte duale antiplaatjesremming, hetgeen op zijn 
beurt belangrijke klinische voordelen op kan leveren door het verlagen van 
bloedingscomplicaties.
d. De verbeterde veiligheid van de everolimus-afgevende stents vergeleken 
met de meest gebruikte eerste generatie DES zich mogelijk strekt tot de 
subgroep van patiënten met diabetes. Ofschoon dit nog niet het geval is 
voor de effectiviteitseindpunten, is hiervoor verder onderzoek noodzake-
lijk.
e. Als laatste, de verbetering in klinische uitkomsten met deze stent de deur 
heeft opengezet voor nieuwe klinische studies die de toekomst van de 
interventiecardiologie verder vorm kunnen geven.
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